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STRENGTH OF PATIENT COHORTS AND 
BIOBANKS FOR CARDIOMYOPATHY RESEARCH
R.A. de Boer, L.L.A.M. Nijenkamp, H.H.W. Silljé, T.R. Eijgenraam, R. Parbhudayal, B. van 
Driel, R. Huurman, M. Michels, J. Pei, M. Harakalova, F.H.M. van Lint, M. Jansen, A.F. 
Baas, F.W. Asselbergs, J.P. van Tintelen, B.J.J.M. Brundel, L.M. Dorsch, M. Schuldt, 
D.W.D. Kuster, J. van der Velden (DOSIS consortium)





In 2011 the Netherlands Heart Foundation initiated consortium funding (CVON, 
Cardiovasculair Onderzoek Nederland) to stimulate collaboration between clinical and 
basic (preclinical) researchers on specific areas of research. One of those areas involves 
genetic heart diseases, which are frequently caused by pathogenic variants in genes 
that encode sarcomere proteins. In 2014, the DOSIS (Determinants of susceptibility 
in inherited cardiomyopathy: towards novel therapeutic approaches) consortium was 
initiated, focusing their research on secondary disease hits involved in the initiation 
and progression of cardiomyopathies. Here we highlight several recent observations 
from our consortium and collaborators which may ultimately be relevant for clinical 
practice.
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Inherited cardiomyopathies, caused by pathogenic variants in genes encoding 
proteins that regulate cardiomyocyte contractility, are a major cause of morbidity 
and mortality. In 50-60% of familial hypertrophic (HCM) and 30-40% of dilated (DCM) 
cardiomyopathy, a pathogenic gene variant can be identified. The most common 
genes that are affected in HCM are MYH7, MYBPC3 and TNNT2, which encode the thick 
filament proteins myosin heavy chain, cardiac myosin-binding protein-C (cMyBP-C), 
and the thin filament protein troponin T. In DCM the titin (TTN) gene, which encodes 
the giant myofilament protein titin, is the most frequently affected gene (~15-20% 
of all gene variants)[1]; in particular gene variants that lead to TTN truncation have 
been shown to be pathogenic [2]. In addition, in the Netherlands, a founder mutation 
in the PLN gene, which encodes the calcium-handling protein phospholamban, 
was identified in 2012 as a now well-known cause of DCM and arrhythmogenic 
cardiomyopathy [3,4]. Figure 1 depicts a cardiomyocyte to illustrate the affected 
proteins involved in cardiomyopathies. Upon activation of a cardiomyocyte, calcium 
enters the cell via the L-type calcium channel, which subsequently releases calcium 
from the intracellular calcium store, the sarcoplasmic reticulum. Calcium binds to the 
troponin complex, which induced a conformational change of troponin-tropomyosin, 
and thereby releases binding sites for myosin heads on the thin actin filament. Binding 
of myosin to actin (so-called cross-bridge) results in force development. The kinetics 
of cross-bridge cycling is regulated by cMyBP-C, and the giant protein titin, encoded 
by TTN and linked with DCM, underlies passive stiffness of sarcomeres [5].
In past years the number of genes in genetic diagnostic panels increased with the 
hope to identify a disease-causing variant in a larger group of patients and their 
family members. However, recent studies conclude that the additional benefit of 
screening large numbers of genes is disappointingly low and of marginal clinical 
utility [6,7]. Numerous new TTN gene variants have been identified mainly because 
of its large size. A study in 3 European cardiogenic centers showed that missense and 
non-frameshifting insertions/deletions variants are most likely benign, as reference 
populations showed comparable frequencies of these rare TTN variants [8]. The 
current panels thus rather increase the number of variants with unknown significance 
(VUS), which are likely benign, though they may have a modifier role in disease. 
Cardiomyopathy patients with a suspected genetic etiology should be referred for 
genetic screening. For HCM this includes patients with (usually asymmetric) left 
ventricular hypertrophy, not (fully) explained by abnormal loading conditions, with 
or without a clear family history. For DCM this includes patients with non-ischemic 
DCM, not (fully) explained by other etiological factors. Young age of onset and familial 
occurrence are important parameters that hint towards a genetic etiology. However, 
late onset in seemingly sporadic cases does not exclude a genetic origin due to the 
reduced penetrance and variable disease expression. All HCM and DCM patients in 
whom genetic screening was performed can be added to the biobanks, including their 




FIGURE 1. Activation of a cardiomyocyte triggers calcium entry and release of calcium from the 
sarcoplasmic reticulum (SR), which results in contraction of the cardiac myofibrils. To relax the 
cardiomyocyte, calcium is pumped back into the SR, and out of the cell via the sodium-calcium 
exchanger (NCX ). Myofibrils consist of sarcomeres composed of the thin actin and thick myosin 
filament, and the third filament titin. Sarcomeres consist of sub-regions (depicted by the different 
bands), which underlie the striated pattern of cardiac muscle. Gene variants that cause cardio-
myopathies are frequently found in myosin heavy chain, troponin T, cardiac myosin-binding 
protein-C (located in the Z-zone) and titin. (Figure is adapted from Sequeira at al. [30]).
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Since cardiomyopathies remain to constitute one of the most common causes of sudden 
cardiac death in the young and still represent major causes for cardiac transplantation, 
adequate identification of additional disease triggers and understanding the 
pathomechanisms is of utmost importance. The clinical approach is furthermore 
complicated since inherited cardiomyopathies are clinically heterogeneous: age-
dependent penetrance and disease-severity differ greatly between patients with 
the identical genetic variant. The mechanisms that underlie the variation in disease 
expression are still largely unknown. By combining cellular, genetic and clinical data 
from well-phenotyped national patient cohorts, DOSIS strived to define disease 
factors (i.e. secondary hits) that in addition to the pathogenic gene variant cause and 
aggravate cardiac disease in cardiomyopathy patients (Table 1; Figure 2). Several 
recent observations are highlighted below.
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Indexation for body size to set the diagnostic threshold for left ventricular thickening
Using a large collection of myectomy samples from patients with obstructive HCM, 
we have shown that there is a sex-specific difference in diastolic function at the time 
of myectomy in HCM patients carrying pathogenic variants in MYH7 and MYBPC3 [9]. 
Women showed more diastolic dysfunction evident from significantly higher E/e’ ratios, 
impaired left ventricular filling patterns, and higher tricuspid regurgitation velocities. 
Of the female patients, 50% showed grade III diastolic dysfunction, while the majority 
of male patients (56%) had only mild (grade I) diastolic dysfunction. Correction of 
maximal septal thickness and left atrial diameter for body surface area (BSA) resulted 
in significantly higher values in female compared to male patients. Histological and 
protein analyses revealed more advanced remodeling of the heart in female compared 
to male HCM patients evident from higher levels of fibrosis and activation of the 
cardiac fetal gene program, which is characteristic of heart failure. In addition to 
genetic screening, the current diagnostic criterion of hypertrophy is a maximal LV wall 
thickness of ≥15mm, or ≥13mm in first-degree relatives of HCM patients. As the heart 
of women, and in general relatively small persons, is smaller compared to the heart of 
men, this threshold for the diagnosis of HCM probably should be corrected for body 
size [10]. The current diagnostic threshold, which does not take into account body size, 
19
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may likely explain the male predominance in HCM patient cohorts, simply because 
males in general have larger hearts. A recent study in a Dutch cohort of 199 genotype-
positive subjects, family members of HCM patients, who were referred for cardiac 
screening between 1995 and 2018, indexation of wall thickness by BSA decreased the 
number of HCM diagnoses [11]. Moreover, predictive accuracy for HCM-related events 
(mortality, cardiac transplantation, implantable cardioverter-defibrillator implantation 
and septal reduction therapy) improved significantly after indexation by BSA. These 
studies indicate that correcting LV thickness for body size should be considered for 
the diagnosis of HCM and longitudinal follow-up studies in larger cohorts of preclinical 
genotype-positive individuals are needed to confirm this.
Altered metabolism as key driver of disease in cardiomyopathies
Several studies suggest an important role for secondary disease-modifiers such as 
additional (epi)genetic variations and environmental disease triggers. Compelling 
data have accumulated that obesity is an overarching risk factor, also for age-of-onset 
and severity of cardiomyopathies. Proof that obesity contributes to disease onset and 
severity comes from cohort studies. The international HCM Share registry showed that 
patients with a high body mass index have a significantly increased risk of heart failure, 
more advanced left ventricular outflow tract obstruction and arrhythmias (i.e. HCM-
related outcomes)[12]. Moreover, a prospective study in adolescent men demonstrated 
that even mildly elevated body weight in late adolescence significantly increased 
the risk to develop dilated cardiomyopathy in adulthood [13]. At the heart level, a 
recent proteomics study in human HCM tissue samples showed reduced levels of 
energy metabolism proteins [14].This observation is in line with studies in human HCM 
showing energy deficiency of the heart [15,16]. Energy deficiency has been proposed 
as the primary variant-induced pathomechanism of HCM [17], which is supported by 
studies showing reduced cardiac efficiency in preclinical asymptomatic carriers of 
sarcomere gene variants in the absence of cardiac hypertrophy [16,18]. Accordingly, 
DCM caused by TTN gene variants has been linked with mitochondrial dysfunction and 
metabolic perturbations as cause of disease progression [19]. Overall, these studies 
indicate that timely (disease stage-specific) treatment of metabolic perturbations may 
slow down disease progression in cardiomyopathy patients [20]. An observational 
cohort to determine the predictive value of metabolic biomarkers (BIO FOr CARe: 
identification of biomarkers for development and progression of HCM in carriers of 
the Dutch MYBPC3 founder carriers) and a clinical trial using metabolic drug therapy 
aimed to improve energetics of the heart at preclinical stage in HCM gene variant 
carriers are currently performed by several DOSIS PIs (ENERGY trial)[21].
Altered protein quality control as disease modifier in cardiomyopathy
An age-related decline in protein quality control (PQC) has been proposed as 
contributor to disease progression in cardiomyopathy. As sarcomere proteins are the 




depends on PQC mechanisms. Pathogenic gene variants result in poison polypeptides 
or reduced protein levels (haploinsufficiency) and may trigger PQC and/or stress cellular 
protein homeostasis. DCM patients with truncating TTN variants show a relatively mild 
disease course, though with significant excess mortality in elderly patients. The latter 
may be explained by an age-related deterioration of the PQC mechanisms. As life 
expectancy increases, TTN-associated morbidity and mortality will likely become 
more prevalent [22]. Also in PLN-associated cardiomyopathy protein aggregation 
and activation of PQC pathways has been observed in end-stage disease [23].
Terminally misfolded and aggregation-prone (mutant) proteins are cleared by the two 
degradation systems, UPS and autophagy. Furthermore, pathways of PQC are strongly 
linked to cell architecture, such as the microtubules network. DOSIS studies in a large 
set of cardiac tissues from a well-characterized HCM patient group showed altered 
PQC with several specific changes in gene-variant positive patients (genotype-positive) 
compared to genotype-negative patients and non-failing controls. An introduction to 
the role of PCQ control in the heart is given in Chapter 3, and DOSIS results on PQC 
in HCM patient samples are described in Chapters 4 and 7.
Cell-to-cell mRNA/protein variability as pathomechanism in cardiomyopathy
As familial cardiomyopathies represent an autosomal dominant genetic disorder, most 
patients are heterozygous for the mutation and carry one variant and one normal (wild-
type) allele. In cardiomyopathy patients, the heart of a genotype-positive individual 
produces the variant protein in addition to the normal protein. As indicated above, 
the homeostasis of cellular proteins is tightly regulated by the PQC system, but 
it is also regulated at the mRNA level by non-sense mediated mRNA decay. Both 
systems are needed to suppress the accumulation of variant protein while keeping 
the normal protein at sufficient levels in cardiac muscle cells. It was recently shown 
that transcription of both alleles occurs independently and in a stochastic manner, 
where one cell favors one allele and the next cell favors the other allele [24]. This 
burst-like, stochastic on/off-switching of allele transcription does not affect mRNA 
and protein levels in case of homozygous wild-type alleles. However, heterozygosity of 
alleles as present in genotype-positive individuals may introduce cell-to-cell variation 
with one cardiomyocyte expressing high levels of variant protein, while variant levels 
may be low in another cardiomyocyte [25]. Indeed, Kraft and colleagues showed that 
MYH7 gene variants cause a variable variant to wild-type ratio of mRNA expression 
in cardiomyocytes from the same heart [24,26]. The DOSIS consortium showed 
intercellular variation of cMyBP-C myofilament protein expression due to truncating 
MYBPC3 variants in the myocardium of HCM patients [27]. The functional consequences 
of the variable protein expression, which results in a mosaic pattern of cardiomyocytes 
with low and high variant/wild-type expression remain to be determined. Loss of 
cMyBP-C causes severe dysfunction in mouse studies and engineered heart tissue 
[28,29]. We propose that the intercellular variation of cMyBP-C protein levels cause 
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inhomogeneous contraction and relaxation and underlies the formation of myofibrillar 
disarray, a currently unexplained disease characteristics of HCM. As aging reduces 
the quality of PQC, an age-dependent progression of the degree of allelic imbalance 
and cell-to-cell variation may contribute to cardiomyopathy development.
In conclusion, monogenetic cardiomyopathies have been intensely studied in the last 
3 decades, and this has resulted in major progress in understanding what genes are 
involved. On the other hand, the striking heterogeneity, the highly variable age of 
onset, and the presence of gene variant carriers that never develop disease is as of 
yet largely unexplained. Given the profound repercussion for carriers, patients and 
family members we must improve to better understand the individual’s response to 
the presence of a pathogenic gene variant.
DOSIS aims for hitherto unexplored mechanisms that probably will modify the pathogenic 
gene variant (Figure 3). We have set up important initiatives and collaborations and 
have generated preliminary results showing that environmental and genetic modifiers 
indeed are important in our understanding. In the future we will step up our initiatives 
and projects and have identified an agenda, that contains - what we feel - important 
additional factors that when fully understood will guide clinicians in proper diagnosis, 
risk prediction, prognostication and, ultimately, cause-specific novel treatments.
FIGURE 3. By combining cellular, genetic and clinical data from well-phenotyped national pa-
tient cohorts, DOSIS strives to define disease factors that in addition to the pathogenic gene 
variant cause and aggravate cardiac disease in cardiomyopathy patients.
Sources of funding: CVON-DOSIS consortium 2014-40 Netherlands Heart Foundation





AIM AND OUTLINE OF THIS THESIS
As described above, HCM is clinically heterogeneous and disease penetrance 
and severity differs greatly even between individuals carrying the same sarcomere 
gene mutation. Within the scope of the DOSIS consortium (Figure 2), we explored 
disease modifiers of HCM in this thesis, that may influence disease onset and disease 
phenotype. Therefore, we performed functional studies in isolated cardiomyocytes 
of myectomy tissue from the Erasmus MC myectomy cohort and determined protein 
levels of modifiers in these tissues. We pursued a targeted approach exploring known 
or hypothesized modifiers (part 1) as well as an unbiased approach using different 
omics techniques to identify novel modifiers (part 2).
Part 1: Targeted analysis of known and hypothesized disease modifiers
In part 1 of this thesis we explored disease modifiers in myectomy tissue of HCM 
patients for which we already had evidence from studies in animal models or other 
cardiac pathologies.
The DOSIS consortium has shown intercellular variability in cMyBP-C protein expression 
due to truncating MYBPC3 mutations in the myocardium of HCM patients [27], but the 
functional consequences still remain to be elucidated. In line with variable levels (dose) 
of healthy and mutant protein in the myocardium, we defined the functional impact of 
mutant protein dose and mutation location in Chapter 2. Therefore, we assessed the 
mutant protein dose effect of the pathogenic TNNT2 variants I79N, R94C and R278C on 
contractile function of cardiomyocytes in functional single cell studies. We performed 
troponin exchange experiments to introduce defined levels of mutant protein into 
healthy cardiomyocytes. Furthermore, we determined levels of mutant cardiac troponin 
T in patient tissues with the TNNT2 R278C mutation and combined it with functional data.
The following two chapters focus on the role of the cellular protein quality control 
(PQC) system in disease progression. As mutant proteins are often misfolded 
and aggregation-prone, they likely trigger the PQC to maintain a healthy protein 
homeostasis. Chapter 3 gives an overview about the different components of the 
cellular protein quality control system and summarizes the current knowledge of its 
involvement in inherited cardiomyopathies. It further highlights pharmacological 
targeting of the PQC as potential novel therapeutic strategy in cardiomyopathies.
In Chapter 4 we determined the expression levels of different heat shock proteins 
involved in protein stabilization (HSPB1, HSPB5, HSPB7) and refolding (HSPD1, HSPA1, 
HSPA2) in myectomy tissue of HCM patients. Thereby we also looked at differences 
between genotype-positive and genotype-negative HCM patients. As PQC function 
is also linked to the microtubule network, we also assessed levels of α-tubulin and 
acetylated α-tubulin.
23
STRENGTH OF PATIENT COHORTS AND BIOBANKS FOR CARDIOMYOPATHY RESEARCH
Part 2: Omics-studies to identify novel disease modifiers
In part 2 we used proteomics, transcriptomics and metabolomics to identify novel 
disease modifiers and biomarkers, that may represent potential novel treatment 
targets and may be used for early diagnosis of cardiac dysfunction.
In Chapter 5 we performed a proteomics screen on a large and clinically well-
characterized set of myectomy tissues from the Erasmus MC myectomy cohort. By 
comparing to non-failing controls, we defined major HCM disease-specific changes 
on the protein level. As genotype-specific differences were low, we compared in 
particular genotype-positive and genotype-negative samples. We validated our top 
candidate in a novel MYBPC32373insG mouse model to demonstrate functional relevance.
In Chapter 6 we applied a multi-omics approach on a set of myectomy samples 
harboring a MYBPC3 mutation by integrating the proteomics data with the histone 
acetylome and transcriptomics data in close collaboration with colleagues from 
Utrecht. In this study we aimed to identify disease markers that are consistently 
changed on three levels of regulation, the chromatin level, the RNA level and the 
protein level.
As the DOSIS consortium has shown that there is a sex-specific difference in diastolic 
function at the time of myectomy, with women having more severe diastolic dysfunction 
[9], we analyzed sex differences in the proteomics data set in Chapter 7. Thereby we 
aimed to identify changes on the protein level that may underlie the sex-specific 
differences in clinical presentation of male and female HCM patients.
In Chapter 8 we performed a metabolomics screen in serum of healthy controls, 
asymptomatic mutation carriers and symptomatic obstructive HCM patients, that were 
part of the ENGINE study [15]. As advanced imaging techniques have shown disease 
stage-dependent differences in myocardial oxygen consumption and efficiency, we 
aimed to identify serum biomarker panels that are able to distinguish healthy controls, 
asymptomatic mutation carriers and symptomatic patients.
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TARGETED ANALYSIS OF KNOWN 
AND HYPOTHESIZED DISEASE MODIFIERS

2
MUTATION LOCATION OF HCM-CAUSING 
TROPONIN T MUTATIONS DEFINES THE DEGREE 
OF MYOFILAMENT DYSFUNCTION IN HUMAN 
CARDIOMYOCYTES
Maike Schuldt, Jamie R. Johnston, Huan He, Roy Huurman, Jiayi Pei, Magdalena 
Harakalova, Corrado Poggesi, Michelle Michels, Diederik W.D. Kuster, Jose R. Pinto, 
Jolanda van der Velden




Background: The clinical outcome of hypertrophic cardiomyopathy patients is not only 
determined by the disease-causing mutation but influenced by a variety of disease 
modifiers. Here, we defined the role of the mutation location and the mutant protein 
dose of the troponin T mutations I79N, R94C and R278C.
Methods and results: We determined myofilament function after troponin exchange 
in permeabilized single human cardiomyocytes as well as in cardiac patient samples 
harboring the R278C mutation. Notably, we found that a small dose of mutant protein is 
sufficient for the maximal effect on myofilament Ca2+-sensitivity for the I79N and R94C 
mutation while the mutation location determines the magnitude of this effect. While 
incorporation of I79N and R94C increased myofilament Ca2+-sensitivity, incorporation 
of R278C increased Ca2+- sensitivity at low and intermediate dose, while it decreased 
Ca2+-sensitivity at high dose. All three cTnT mutants showed reduced thin filament 
binding affinity, which coincided with a relatively low maximal exchange (50.5 ± 5.2%) 
of mutant troponin complex in cardiomyocytes. In accordance, 32.2 ± 4.0% mutant 
R278C was found in two patient samples which showed 50.0 ± 3.7% mutant mRNA. 
In accordance with studies that showed clinical variability in patients with the exact 
same mutation, we observed variability on the functional single cell level in patients 
with the R278C mutation. These differences in myofilament properties could not be 
explained by differences in the amount of mutant protein.
Conclusions: Using troponin exchange in single human cardiomyocytes, we show that 
TNNT2 mutation-induced changes in myofilament Ca2+-sensitivity depend on mutation 
location, while all mutants show reduced thin filament binding affinity. The specific 
mutation-effect observed for R278C could not be translated to myofilament function of 
cardiomyocytes from patients, and is most likely explained by other (post)-translational 
troponin modifications. Overall, our studies illustrate that mutation location underlies 
variability in myofilament Ca2+-sensitivity, while only the R278C mutation shows a highly 
dose-dependent effect on myofilament function.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited heart disease 
affecting 1:500 to 1:200 individuals in the general population [1,2]. Current genetic 
screening identifies a pathogenic gene variant (further referred to as mutation) in ~50–
60% of all patients [3]. Despite improved genotyping, prediction of disease based on 
genotype is challenging as the HCM population shows large clinical variability. This is 
evident from large differences in disease onset and severity, even in individuals carrying 
the exact same mutation. There is thus no clear frequent affected sarcomere genes [4]. 
As the majority of genotype-positive individuals are heterozygous for a gene mutation, 
carrying one normal and one mutant allele, clinical heterogeneity may be explained by 
the abundance (dose) of the mutant protein. Although 50% of healthy and 50% of mutant 
protein would be expected with a heterozygous mutation, this ratio can change due to 
allelic expression being stochastic, which can result in variable expression levels of healthy 
and mutant protein [5,6]. Accordingly, 43% of mutant protein has been shown in human 
induced pluripotent stem cell-derived cardiomyocytes carrying the I79N mutation in the 
gene (TNNT2) encoding cardiac troponin T (cTnT) [7], whereas heterozygous Tnnc1-A8V 
mice only showed 21% of mutant protein [8]. Furthermore, mutant protein dose can be 
influenced by changes in protein stability and/or degradation. A mutant protein dose-
dependent increase in myofilament Ca2+-sensitivity was reported in a transgene (Tg) 
mouse model with a α-tropomyosin mutation [9]. Another study showed a dose-dependent 
effect of the Tnnt2 mutation R92Q on morphological and structural abnormalities as well 
as hypertrophy markers in Tg mice [10]. In addition to mutant protein dose, location of the 
mutation in the gene may explain the degree of cardiac muscle dysfunction. A mutation 
location effect has been observed in a study comparing two mouse models with different 
Tnnt2 mutations, a missense and a truncation mutation, that differ in their degree of 
hypertrophy and fibrosis development [11]. Furthermore, studies in transgenic mice found 
that the Tnnt2 mutation I79N increased Ca2+-sensitivity [12], whereas the R278C mutation 
did not [13]. Differences in Ca2+-sensitivity and Ca2+- binding affinity have also been 
demonstrated in a study comparing the mouse models for Tnnt2 I79N, F110I and R278C [14]. 
Similarly, in vitro studies using recombinant proteins have shown that the HCM-associated 
increase in Ca2+-sensitivity differs for different human TNNT2 mutations incorporated 
into porcine fibers [15], strengthening the concept of mutation location as a disease 
modifier. Based on these previous studies, we hypothesize that the degree of myofilament 
dysfunction depends on both the mutant protein dose and mutation location. To test 
our hypothesis we make use of the troponin exchange method in human cardiomyocytes, 
which enables us to control the dose of mutant protein in single cardiac muscle cells and 
study the effects on myofilament Ca2+-sensitivity. We compared three pathogenic TNNT2 
mutations I79N, R94C and R278C. Furthermore, we were able to characterize myofilament 
function in three human myectomy samples of patients carrying the R278C mutation, which 
enabled us to compare the effects of this specific mutation in the absence (exchange 






Exchange experiments were performed in the human sample 2.114 which had a high 
endogenous phosphorylation background and was obtained from the Sydney Heart 
Bank. HCM tissue samples from the interventricular septum of patients harboring the 
TNNT2 R278C mutation were obtained during myectomy surgery to relieve LV outflow 
tract obstruction and collected by the Erasmus University Medical Center Rotterdam 
and the University of Florence. HCM samples from patients with other mutations and 
without a sarcomere mutation (sarcomere mutation-negative) were used as controls 
in our protein analyses studies (samples from Erasmus Medical Center and Sydney 
Heart Bank). Table 1 provides an overview, including clinical characteristics, of all 
HCM samples used in this study. The samples 4.021, 5.033, 6.034, 7.012 and 7.040 were 
used as non-failing controls for single cardiomyocyte measurements and/or western 
blot analysis. They originate from the LV free wall of donor hearts without history of 
cardiac disease and were obtained from the Sydney Heart Bank. Written informed 
consent was obtained from each patient prior to myectomy and the study protocol 
was approved by the local medical ethics review committees. All samples were stored 
in liquid nitrogen until use.
Cardiomyocyte force measurements
Single cardiomyocytes were mechanically isolated from frozen cardiac tissue and 
functional myofilament measurements performed as described previously [16]. Briefly, 
the membrane of isolated cardiomyocytes was permeabilized with 0.5% Triton X-100 
and single cardiomyocytes were attached to a force transducer and a motor needle. To 
determine the force-calcium relation, the force development of the cell was measured 
at different calcium concentrations. Ca2+-sensitivity of myofilaments was determined as 
the [Ca2+] needed to achieve half-maximal force (EC50). The protocol was performed at 
1.8 and 2.2 μm sarcomere length of the cell to determine length-dependent activation 
(LDA), which was measured as the difference in EC50 at both sarcomere lengths. Only 
cells with a maximal force >10 kN/m2 were included in the analysis to ensure good 
quality of the cells.
33











































































































































































































































































































































































































































































































































































































































































































































Troponin exchange in cardiomyocytes
Troponin exchange in permeabilized cardiomyocytes was performed as described 
previously [17]. The recombinant troponin complex was expressed and assembled as 
reported before [18]. The membrane-permeabilized cells of a highly phosphorylated 
human sample were incubated with non-phosphorylated recombinant troponin 
complex at the concentrations 0.01, 0.1 and 1.5 mg/ml, resembling a low, intermediate 
and high mutant protein concentration, respectively. Functional measurements after 
exchange were performed after incubation with protein kinase A (PKA) because the 
incorporated recombinant troponin complex was non-phosphorylated. The amount of 
troponin replacement was determined by phos-tag analysis of cardiac troponin I (cTnI) 
using the phosphorylation difference between the endogenous and the recombinant 
troponin complex, the former being highly phosphorylated and the latter being 
non-phosphorylated (example shown in Fig. 1B for the TNNT2 I79N mutation). The 
percentage of troponin replacement after exchange was quantified as the percentage 
of non-phosphorylated cardiac troponin I (cTnI) of the total non-, mono- and bis-
phosphorylated cTnI levels.
Co-sedimentation assay
Thin filament co-sedimentation assays were carried out using rabbit skeletal muscle 
filamentous actin (F-actin), recombinant human tropomyosin (Tm), and recombinant 
human troponin complexes as previously described [19,20] with a few modifications. 
Recombinant human cardiac tropomyosin was expressed with the N-terminal tag 
alanine-serine after the initiatior methione to mimic N-terminal acetylation [21]. 
Prior remove potential precipitates and the resultant supernatants were resolved 
on a denaturing gel to assess purity. Protein concentrations were determined using 
Pierce Coomassie Plus/Bradford assay (Thermo Fisher Scientific). F-actin, Tm, and 
troponin complexes were combined at a molar ratio of 7:1:1, respectively, into a final 
volume of 100 μl co-sed buffer (25 mM HEPES, 60 mM NaCl, 3 mM MgCl2, 0.5 mM 
EGTA, 1 mM DTT, 0.5 mM CaCl2, 2 mM β-mercaptoethanol, pH 7.0) resulting in a final 
concentration of 20 μmol/l F-actin, 2.86 μmol/l Tm and 2.86 μmol/l troponin complex. 
The samples were centrifuged for 30 min at 120,000 × g in a TLA-100 rotor (Beckman 
Coulter) at 21 ◦C. The pellets (P) and supernatants (S) were subsequently diluted with 
reducing Laemmli buffer, boiled, and resolved on 12% SDS-PAGE gels. The proteins 
were stained with Coomassie, destained, and imaged on an Odyssey IR system (LI-
COR Biosciences) followed by densitometric quantification using Image Studio V5.2 
(LI-COR Biosciences).
Phosphorylation assays
Tissue samples were homogenized to a concentration of 2.5 μg/μl, and 100 μl of the 
homogenate was incubated with 10 units of protein kinase A (PKA; Sigma, P5511) and 
0.006 mM cAMP for 40 min at 25 ◦C. The phosphorylation level before and after PKA 
incubation was assessed with ProQ phosphostaining and phos-tag gel analysis of 
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cTnI. Troponin complexes were incubated with 0.5 units of PKA/μg and incubated at 
room temperature for 1, 5, 10, 20, 40 and 60 min. The phosphorylation level of cTnI 
was determined with phos-tag gel analysis.
FIGURE 1. (A) Exchange of endogenous troponin complex with different concentrations of re-
combinant WT and mutant complex harboring the mutations I79N, R94C and R278C. Exchange 
percentage was analyzed by phos-tag gel analysis. (B) Representative image of phos-tag gel 
analysis for exchange curves in (A). (C) Ymax and k represent parameters of the exponential 
plateau curve fit with the 95% confidence interval (please note that an upper limit of Ymax and 
a lower limit of k for R278C could not be determined), n = 2. (D-E) Co-sedimentation assay. (D) 
Quantification of thin filament co-sedimentation assay results. Vertical axis is the band intensity 
ratio of cardiac troponin I to tropomyosin. (E) Representative image of an SDS-PAGE gel (12%) 
containing thin filament co-sedimentation products for WT and mutant troponin complexes. 
Abbreviations: S, supernatant; P, pellet; WT, wild-type; Tm, tropomyosin; cTnT, cardiac troponin 
T; cTnI, cardiac troponin I; cTnC, cardiac troponin C; one-way ANOVA with Dunnett’s multiple 






Non-, mono- and bis-phosphorylated forms of cTnI (Pierce, MA1- 22700) were 
quantified by phos-tag gel analysis as described previously [22]. It was used to assess 
the percentage of troponin replacement after exchange and to assess the cTnI 
phosphorylation level of human cardiac tissue samples.
Protein levels
Whole tissue lysates were prepared to determine troponin protein levels. Therefore, 
pulverized frozen tissue was homogenized in 40 μl/mg tissue 1× reducing sample 
buffer (106 mM Tris-HCl, 141 mM Tris-base, 2% lithium dodecyl sulfate (LDS), 10% 
glycerol, 0.51 mM EDTA, 0.22 mM SERVA Blue G250, 0.18 mM Phenol Red, 100 mM 
DTT) using a glass tissue grinder. Proteins were denatured by heating to 99 ◦C for 
5 min and debris was removed by centrifugation at maximum speed for 10 min in a 
microcentrifuge (Sigma, 1–15 K). For analysis of troponin protein levels by Western blot, 
5 μg of protein were separated on a 4–15% TGX gradient-gel (Biorad) and transferred 
to a polyvinylidene difluoride membrane. Site-specific antibodies directed to cTnT 
(ab10214, Abcam), cTnT (T6277, Sigma-Aldrich), cTnT (ab8295, Abcam), cTnI (ab10231, 
Abcam), cardiac Troponin C (cTnC, sc48347, Santa Cruz) and α-actinin (A7811, Sigma-
Aldrich) were used to detect the proteins which were visualized with an enhanced 
chemiluminescence detection kit (Amersham) and scanned with Amersham Imager 
600. Protein levels were determined by densitometric analysis. Protein levels were 
normalized to α-actinin or cTnI when appropriate. Equal loading of troponin complexes 
was verified with Imperial protein stain (Thermo Scientific).
Mass spectrometry to determine mutant protein dose in human tissue samples
Whole tissue lysates were run on 13% SDS gels to achieve a good separation of the 
cTnT and the actin band. Thereto approximately 15 μg of protein were loaded for each 
sample. The gel was stained with coomassie to visualize the protein bands and the cTnT 
band was cut out of the gel. Subsequently, a wash buffer (50% aqueous acetonitrile with 
50 mM ammonium bicarbonate) was used to de-stain cut gel bands. De-stained gel 
bands were then cut into ~1 mm pieces and shrunk by incubation with acetonitrile at 
37 ◦C for 10 min. Gel pieces were further dried in SpeedVac (Thermo Fisher Scientific, 
Waltham, MA). A digestion buffer (10% aqueous acetonitrile with 50 mM ammonium 
bicarbonate) was added to rehydrate the gel pieces. Reductive alkylation of cysteine was 
carried out by mixing with 1,4-dithiothreitol (DTT, Sigma-Aldrich, catalog #: 11583786001, 
St. Louis, MO) at 37 ◦C for 10 min followed by mixing with iodoacetamide (IAA, Sigma-
Aldrich, catalog #: I1149, St. Louis, MO) at room temperature for 10 min. Afterwards, 
endoproteinase Glu-C (catalog number 90054, Thermo Fisher Scientific, Waltham, MA) 
was added and the mixture was incubated at 37 ◦C overnight. The supernatant was 
collected and the digestion was quenched by addition of a 0.5% formic acid aqueous 
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solution. After incubation at 37 ◦C for 10 min, the supernatant was collected. The gel 
pieces were dried by incubation with acetonitrile at 37 ◦C for 15 min and the supernatant 
was collected. The combined supernatant was dried in the SpeedVac. A series of 
calibration curve standards of varying mutant/wild-type (WT) cTnT ratios (0.05, 0.1, 0.2 
and 1), but of a fixed total concentration of 20 μM cTnT, was reductively alkylated with 
DTT and IAA with the same procedure as the in-gel digestion. After mixing with Glu-C 
and incubation at 37 ◦C overnight, the digestion reaction was quenched by addition of 
a 0.5% formic acid aqueous solution. The mixture was then dried in the SpeedVac. The 
dried peptides mixture was dissolved in a 0.1% formic acid aqueous solution and the 
mixture was injected to an Easy Nano-Liquid Chromatography (nLC) II system (Thermo 
Fisher Scientific, Waltham, MA) equipped with a 75 μm × 10 cm C18AQ analytical 
column (catalog # SC003, Thermo Fisher Scientific, Waltham, MA) and a 100 μm × 2 cm 
trap column (catalog # SC001, Thermo Fisher Scientific, Waltham, MA). Mobile phase 
composition is as follows – A: H2O with 0.1% formic acid; B: acetonitrile with 0.1% formic 
acid. The gradient profile is linear from 1% B to 35% B in 90 min at 0.3 μl/min. The nLC 
was online coupled with a Hybrid Velos LTQ-Orbitrap Mass Spectrometer (Thermo 
Fisher Scientific, Waltham, MA). Eluates from nLC were electrospray-ionized with a 2.2 
kV spray voltage. For the initial peptide identification, precursor full mass scans (m/z 
350–2000, mass resolution of 60,000 at m/z 400, automatic gain control – AGC target 
1 × 106 ions and maximum ionization time 500 ms) were followed by data-dependent 
collisional-induced-dissociation (CID) MS2 of the top 9 most abundant precursor ions 
(AGC target 1 × 105 ions, maximum ionization time 100 ms, isolation window of 2 m/z, 
normalized collision energy NCE 35 and dynamic exclusion of 60 s). For quantification 
of percentage of mutant proteins, targeted FT scan (m/z 390–440, mass resolution of 
60,000 at m/z 400, AGC target 1 × 106 ions, maximum ionization time 200 ms) were 
carried out in triplicates for each gel band samples and calibration curve standards. For 
initial peptide identification, the acquired Xcalibur. raw files were analyzed by Proteome 
Discoverer 1.4 with Sequest HT (Thermo Fisher Scientific) against a modified human 
proteome database with troponin T R278C mutant sequence. Variable modification of 
methionine oxidation and cysteine carboxymethylation were included. Mass tolerance 
was set with a precursor mass error of less than 5 ppm and MS2 fragment ion mass 
error of less than 0.8 Da. Peptides with sequence of NQKVSKTRGKAKVTGRWK (TnT 
WT 271–288, [M + 5H]5+ m/z 415.2498) and NQKVSKTCGKAKVTGRWK (TnT R278C 
MT 271–288, C278 is carboxylated, [M + 5H]5+ m/z 416.0357) were identified as the 
R/C278 containing peptides with the highest S/N best suited for quantification. For 
quantification, the acquired Xcalibur.raw files with the targeted FT scan of m/z 390–440 
were manually analyzed in the Xcalibur Qual Browser. Since the retention time (RT) of 
WT or mutant TnT 271–288 peptides overlaps, the MS signal over the RT with those 
MS (WT: m/z 415.2498; mutant: m/z 416.0357) signals were averaged and the ratio of 
mutant/WT MS signals calculated. A calibration curve was established with the above 
mentioned mutant/WT MS signals ratio and the actual mutant/WT concentration 





RNA was isolated using ISOLATE II RNA Mini Kit (Bioline) according to the 
manufacturer’s instructions with minor adjustments (10 min digestion using 20 μg 
proteinase K and a subsequent washing step using 100% ethanol were added after 
the lysis step). Sample quality and quantity was assessed using the 2100 Bioanalyzer 
with a RNA 6000 Pico Kit (Agilent), and Qubit Flourometer with a HS RNA Assay 
(Thermo Fisher). After selecting the polyadenylated fraction of RNA, libraries were 
prepared using the NEXTflexTM Rapid RNA-seq Kit (Bioo Scientific). Libraries were 
sequenced on the Nextseq500 Illumina platform, producing 75 bp long single end 
reads. Reads were aligned to the human reference genome GRCh37 using STAR v2.4.2a 
[23]. Picard’s AddOrReplaceReadGroups v1.98 (http://broadinstitute.github.io/picard/) 
was used to add read groups to the BAM files, which were sorted with Sambamba 
v0.4.5 [24] and transcript abundances were quantified with HTSeq-count v0.6.1p1 [25] 
using the union mode. Subsequently, reads per kilobase million reads sequenced 
(RPKMs) were calculated with edgeR’s RPKM function [26]. The secondary structure 
of mRNAs were predicted using the RNAfold software, with the minimum free energy 
(MFE) and partition function option selected (URL: http://rna.tbi.univi e.ac.at/cgi-
bin/RNAWebSuite/RNAfold.cgi) [27]. WT or mutant full-length human TNNT2 mRNA 
sequence corresponding to the adult-expressed isoform of cTnT (NCBI Reference 
Sequence: NM_001276347.2) was used for the prediction.
Immunofluorescence
Slides were thawed at RT for 20 min inside a closed a box. Tissue sections were 
washed with PBS-T, permeabilized with 0.25% PBS-Triton and blocked with 1% BSA 
and 10% donkey serum for 30 min. Primary antibodies for α-actinin (ACTN2, 14221-
1-AP, Proteintech, dilution 1:100) and cTnT (TNNT2 [1C11], ab8295, Abcam, dilution 
1:250) were incubated overnight at 4 ◦C. Afterwards tissue sections were washed and 
incubated with suitable secondary Alexa fluor antibodies for 30 min. The sections 
were washed in PBS and mounted with Mowiol. Images were acquired with a Nikon 
A1 confocal microscope and analysis and quantifications were performed with FIJI 
software.
Statistics
Graphpad Prism v8 software was used for statistical analysis. Data were statistically 
analyzed using unpaired t-test, one-way ANOVA with Dunnett’s or Tukey’s multiple 
comparisons post hoc test or 2way-ANOVA when appropriate. All values are shown 
as mean ± standard error of the mean. A p-value ≤0.05 was considered as significantly 
different.
39
MUTATION LOCATION EFFECT OF HCM-CAUSING CTNT MUTATIONS
RESULTS
Lower thin filament-binding affinity of mutant compared to WT troponin complex
We performed troponin exchange in permeabilized human cardiomyocytes to test the 
direct effect of mutation location and mutant protein dose on myofilament function. 
Therefore we used the HCM-causing troponin T mutations I79N, R94C and R278C. To 
analyze their ability to incorporate into the myofilaments and to determine the required 
complex concentration for a low, intermediate and high protein dose, we exchanged 
endogenous troponin with different concentrations of recombinant WT and mutant 
troponin complex. All complexes incorporated to a similar degree (Fig. 1A, C), with a 
maximum incorporation (Ymax) of 47% for WT, 49% for I79N, 45% for R94C and 50% 
for R278C. Dose dependency of incorporation appeared to be slightly different for the 
different complexes. WT and I79N showed almost maximal incorporation at very low 
concentrations, while R94C and R278C reached the maximal incorporation at higher 
concentrations (Fig. 1A), which is also illustrated by the difference in k representing 
the rate constant (kWT = 15.0, kI79N = 22.2, kR94C = 6.2 and kR278C = 3.1) (Fig. 1C). However, 
the variation is too large to assess whether the complexes exchange differently at low 
and intermediate dose. Additionally, we performed a co-sedimentation assay with 
the three complexes to determine their binding affinity to isolated thin filaments. 
While we observed reduced binding affinity of all three mutants compared to WT, no 
differences were observed in thin filament binding affinity between the three mutants 
(Fig. 1D, E, Table S1).
Mutation location determines degree of myofilament dysfunction
Based on the obtained percentage of exchange at different concentrations of 
recombinant troponin complex we selected 0.01 mg/ml, 0.1 mg/ml and 1.5 mg/ml 
for subsequent functional experiments, which are indicated as low, intermediate and 
high dose, respectively. Exchange of cTn complex containing the TNNT2 mutants 
were compared to cells exchanged with cTn complex containing WT recombinant 
cTnT (1.5 mg/ml). To avoid that PKA-mediated cTnI phosphorylation differences may 
mask mutant-related changes in myofilament function, all functional measurements 
were performed in troponin-exchanged cells after treatment with exogenous PKA. A 
time-dependent PKA phosphorylation assay of the isolated recombinant complexes 
confirmed that the cTnI phosphorylation level of the recombinant complex after 40 
min of PKA incubation is comparable to that of non-failing donors (Fig. S1). There 
was no difference in PKA’s ability to phosphorylate the different troponin complexes 
(Fig. S1E). Moreover, to further minimalize an interfering effect of myofilament protein 
phosphorylation background, exchange with all 4 troponin complexes (WT and 3 
mutants) were performed in the same human sample (sample 2.114). Interestingly, we 
did not see a mutant protein dose effect for the I79N and R94C mutations (Fig. 2A, 
B, D, E; Table S2). For the R94C mutation, a significant increase in Ca2+-sensitivity was 




the dose (Fig. 2E), indicating that the maximal increase in myofilament Ca2+-sensitivity 
was already achieved at low dose. A similar pattern with a dose-independent 
trend to increased Ca2+-sensitivity (not significant) was observed for I79N (Fig. 2D). 
The magnitude of the increase in Ca2+-sensitivity is determined by the mutation 
location. We found that R94C increases Ca2+- sensitivity to a larger extent than I79N, 
depicted by the larger curve shift of R94C compared to I79N (Fig. 2G). Interestingly, 
we observed strikingly different results for the R278C complex. While the low and 
intermediate dose led to an increase in Ca2+-sensitivity to a similar level as R94C, we 
observed significantly decreased Ca2+-sensitivity for the high dose (Fig. 2C, F; Table 
S2). This is also demonstrated by the large difference in EC50 at low and high dose 
(Fig. 2F). In several exchange experiments we were able to determine the exchange 
efficiency in the remaining cell suspension after functional measurements of single 
cardiomyocytes. In Fig. 2I we plotted myofilament Ca2+-sensitivity data relative to the 
troponin exchange efficiency obtained in experiments in which we collected both 
data sets. This figure illustrates the mutation location-specific effects on EC50. LDA, 
the cellular analogue for the Frank-Starling mechanism of the heart, was assessed for 
all three mutations at low, intermediate and high dose of mutant protein (Fig. 3A-C, 
Table S3). The variability between cells was large and we did not observe differences 
in LDA for all three mutations compared to cardiomyocytes exchanged with wild-type 
troponin complex. Maximal force did not differ between the different mutations and 
mutant protein dosages (Fig. 3D-F, Table S4).
Expression of R278C at mRNA and protein level in human patient samples
In patients, the percentage of mutant protein in the cell and its contribution to disease 
variability is unknown. We collected myocardial tissue from the interventricular septum 
of three obstructive HCM patients carrying the R278C mutation during myectomy 
surgery (HCM 173, HCM 175 and HCM 234). In these tissues we performed protein 
analysis and functional measurements to investigate the variability in patients with the 
exact same mutation. Western blot analysis revealed a 5.20 ± 0.37 fold increase in total 
cTnT protein levels in the three human TNNT2-R278C mutant samples compared to 
donor tissue, sarcomere mutation-negative (SMN) samples, samples with a truncating 
MYBPC3 mutation and samples with missense mutations in genes other than TNNT2, 
when analyzed with the ab10214 antibody (abcam) (Fig. 4A, B). Levels of cTnI and cTnC 
were not changed in the TNNT2-R278C samples compared to all other groups (Fig. 
4C, D), implying that the presence of mutation R278C in TNNT2 leads to elevated 
cTnT levels only.
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FIGURE 2. (A-C) Force-calcium relations after exchange with cTnT I79N (A), R94C (B) and R278C (C) 
complex at low, intermediate and high dose. (D-F) EC50 values after exchange with I79N (D), R94C 
(E) and R278C (F) at low, intermediate and high mutant protein dose. (G) Comparison of force-cal-
cium relation of the different mutants at high dose. (H) Change in EC50 (ΔEC50) of mutants at high 
dose compared to WT. (I) Relation of EC50 and exchange percentage defined in the same exchange 
experiments. In (I) n(I79N) = 2/2/2, n(R94C) = 2/1/1, n(R278C) = 3/1/1 for low/intermediate/high 
dose, respectively. *p < 0.05, **p < 0.01 compared to WT in (D-F); ****p < 0.0001 compared to I79N 




FIGURE 3. (A), (B) and (C) show length-dependent activation after exchange with cTnT I79N, 
R94C and R278C, respectively. (D), (E) and (F) show maximal force development after exchange 
with cTnT I79N, R94C and R278C, respectively. Low, intermediate and high mutant protein dose 
are depicted for each mutation compared to WT. n(WT) = 11, n(I79N) = 7/6/9, n(R94C) = 7/3/5, 
n(R278C) = 6/5/4 for low/intermediate/high dose, respectively.
This deviation from the expected troponin stoichiometry of 1:1:1 for cTnT, cTnI and 
cTnC would be an unexpected unique finding. Therefore, we also determined the cTnT 
protein levels with the T6277 (Sigma) and the ab8295 (abcam) antibodies to validate the 
results. Interestingly, the analysis revealed elevated levels of cTnT but with a smaller 
fold change of 2.09 ± 0.13 for the T6277 antibody (Fig. 4E) and unchanged levels of cTnT 
with the ab8295 antibody (Fig. 4F). Because of these divergent results, we determined 
whether the antibodies have the same affinity to recombinant WT and R278C cTnT 
protein, or whether the mutation affects antibody binding. To do so, we performed 
western blot analysis on different amounts of recombinant WT and R278C troponin 
complex. For the two antibodies ab10214 and T6277 we found an approximately 2- fold 
increase of the cTnT/cTnI signal for the R278C compared to WT, whereas the ab8295 
antibody showed an increased cTnT/cTnI signal only at low protein concentrations 
(Fig. S2A-B).
This indicates that the R278C mutation influences antibody binding of all three 
antibodies, in a possibly protein concentration-dependent manner. We obtained 3 
more human TNNT2-R278C samples from an Italian patient cohort and compared all 
available TNNT2-R278C samples to two patient samples with other TNNT2 mutations 
(Gln272* and K280N) and could show that the increased cTnT signal is specific for 
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tissue samples harboring the R278C mutation (Fig. S2C). Based on these western blot 
analyses we cannot make a confident statement about troponin stoichiometry in the 
TNNT2 R278C samples. Consequently, we performed immunofluorescence (IF) for cTnT 
and α-actinin on a selection of the human samples (3 TNNT2 R278C, 1 Donor, 2 SMN, 2 
MYBPC32373insG and 2 missense mutation samples) to determine cTnT protein levels with 
a different method. Due to the poor performance of the ab10214 and T6277 antibodies 
in IF, we only used the ab8295 (abcam) antibody for the stainings. In contrast to the 
western blot analysis of the ab10214 and T6277 antibodies but in line with the results 
from the ab8295 antibody, IF did not show a significant difference in cTnT protein 
levels compared to the non-failing donor sample (p = 0.0777, Fig. 5A-B). Overall, our 
data show that the R278C mutation alters cTnT antibody-binding, and cannot be used 
to determine cTnT protein levels. We further performed RNA sequencing and mass 
spectrometry on two HCM tissue samples with the R278C mutation to assess the 
percentage of the mutant cTnT-R278C mRNA and protein levels in the samples. While 
TNNT2-R278C mRNA levels were close to 50%, the levels of mutant protein were 36% 
in HCM 173 and 28% in HCM 175 (please note that we were not able to define levels in 
HCM 234 upon several attempts) (Fig. 5C and Fig. S3). This supports the results from 




FIGURE 4. (A) shows representative western blot images of troponin protein levels in the three 
human samples harboring the TNNT2 R278C mutation compared to control and other HCM 
patient samples with the cardiac troponin T (cTnT) antibodies ab10214, T6277 and ab8295. cTnT 
protein levels with the ab10214 antibody are quantified in (B). (C) shows quantified protein levels 
of cardiac troponin I (cTnI) and (D) of cardiac troponin C (cTnC). (E) displays quantified cTnT 
protein levels with the antibody T6277 and (F) with the antibody ab8295. Every dot represents 
the average of 2 data points per sample in (B), (E) and (F) and the average of 4 data points in (C) 
and (D). Data is normalized to Donor which is set to 1. ****p < 0.0001 compared to WT, one-way 
ANOVA with Dunnett’s multiple comparisons test.
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FIGURE 5. (A) Representative immunofluorescence images of human cardiac tissue stained for 
cardiac troponin T (cTnT), α-actinin and nuclei. (B) Quantified intensity of cTnT staining normal-
ized to α-actinin staining. Every dot represents one sample and is an average of 3 images. (C) 
shows the content of mutant cTnT mRNA and protein in the human tissue samples determined 




R278C mutant human samples differ on a functional level
We compared myofilament function of the three patient samples in isolated membrane-
permeabilized cardiomyocytes. While the difference in percentage of mutant protein 
was only slightly different between HCM 173 (36%) and HCM 175 (28%), the direction 
of the change in Ca2+-sensitivity compared to non-failing donors was opposite in 
these samples, showing a trend to an increase and a decrease, respectively (Figs. 
6A-B, Table S5). HCM 234 shows a significant increase in Ca2+-sensitivity compared to 
donor samples (Fig. 6C, Table S5). Analysis of cTnI phosphorylation revealed reduced 
levels of phosphorylation in all three patient samples compared to donors, shown by 
lower levels of the highly phosphorylated 2P band and increased levels of the 1P and 
0P bands (Fig. 6G-H). The lowest level of cTnI phosphorylation was observed in HCM 
234. Since it is well-known that reduced cTnI phosphorylation increases myofilament 
Ca2+-sensitivity [16], we repeated the functional measurements after incubation with 
PKA to increase cTnI phosphorylation in HCM samples to levels observed in non-failing 
donor samples. First of all we determined with a phosphorylation assay if cTnI is still 
PKA responsive in these patients. As seen in Fig. 6G-H, cTnI phosphorylation increases 
after treatment with PKA in the TNNT2 mutant samples, indicating that PKA-mediated 
phosphorylation of cTnI is not hampered by the presence of the TNNT2 mutation.
Accordingly, PKA treatment of isolated cardiomyocytes decreases myofilament 
calcium sensitivity significantly in HCM 173 and with a strong trend in HCM 234 (Fig. 
6D-F, Table S5). In line with these results, we observed a blunted LDA in all three 
patient samples compared to donor, but detected a statistically significant difference 
only for HCM 173 (Fig. 6I-K, Table S6). LDA was enhanced only in HCM 173 after PKA-
mediated phosphorylation of cTnI (Fig. 6L-N, Table S6). Overall, our data suggest that 
perturbations in myofilament function in samples harboring the R278C mutation can 
be corrected to values that are seen in non-failing samples by PKA treatment.
DISCUSSION
In this study we investigated the mutation location and mutant protein dose effect 
of three HCM-causing TNNT2 mutations. We proposed that the mutation location 
and mutant protein dose are potential disease modifiers via specific changes in 
myofilament function. While our exchange experiments show a more important role 
for the mutation location than for the mutant protein dose for mutations I79N and 
R94C, the functional consequences of R278C are highly dose-dependent.
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FIGURE 6. (A-C) show myofilament Ca2+-sensitivity measured as EC50 for the human samples 
HCM 173, HCM 175 and HCM 234 carrying the TNNT2 R278C mutation compared to donor 
tissue. (D-F) show Ca2+-sensitivity measured as EC50 for the human samples HCM 173, HCM 
175 and HCM 234 carrying the TNNT2 R278C mutation before and after normalizing cTnI phos-
phorylation by incubation with protein kinase A (PKA). (G) and (H) display the phosphorylation 
status of cardiac troponin I determined by phos-tag gel analysis before and after incubation 
with PKA. 0P represents non-phosphorylated cTnI, 1P single-phosphorylated cTnI and 2P dou-
ble-phosphorylated cTnI. (G) shows the phos-tag gel image for the quantified data in (H). (I-K) 
Length-dependent activation of the human samples HCM 173, HCM 175 and HCM 234 compared 
to donor. (L-N) Length-dependent activation of the human samples HCM 173, HCM 175 and HCM 
234 before and after PKA treatment. *p < 0.05, **p < 0.01, unpaired t-test. n(Donor) = 4, n(HCM 




Mutant protein dose effect is mutation-specific
HCM mutations in thin filament proteins such as cTnT have been associated with 
an increase in myofilament Ca2+-sensitivity [28,29] and blunted length-dependent 
myofilament activation [28]. Impaired LDA was normalized to values in non-failing 
donor cardiomyocytes by reducing the percentage of mutant cTnT to 22% [28]. In the 
present study, we show that a relatively low dose of mutant cTnT protein is sufficient 
to increase myofilament Ca2+-sensitivity, which was significant for R94C, though the 
magnitude is dependent on mutation location (Fig. 2). At low, intermediate and high 
dose of mutant protein we did not observe differences in LDA (Fig. 3). R94C led to an 
increase in myofilament Ca2+-sensitivity independent of dose and also I79N showed a 
strong trend to increased dose-independent myofilament Ca2+-sensitivity, with R94C 
having an even stronger effect than I79N. The Ca2+- sensitizing effect of I79N has 
been described previously [12,29,30], and also for R94C a Ca2+-sensitizing effect and 
hypercontractility has been predicted [31].
In our study, a very low dose of mutant protein results already in the maximal shift in 
myofilament Ca2+-sensitivity (Fig. 2I). In contrast to our study in human cardiomyocytes, 
the R92Q mutation showed a dose-dependent effect on atrial mass, hypertrophic 
markers and structural abnormalities in a Tg mouse model [10]. Unlike the direct 
mutation effects that we studied in single permeabilized cardiomyocyte, the dose-
dependent changes in cardiac remodeling described in the Tg-mice may represent 
secondary changes and may not be solely due to the direct mutation dose effect. 
Several studies in animal models and patients have also described that individuals with 
two disease-causing mutations show earlier disease onset, more severe hypertrophy 
and a higher risk of sudden cardiac death [32–34]. Double mutations in the same 
gene, dependent on their location, might have an additive effect as described for two 
MYBPC3 mutations [35]. Compound heterozygous or homozygous MYBPC3 mutations 
have also been shown to cause severe cardiomyopathy which was lethal in the first 
few weeks after birth [36,37]. An additive mutation dose effect has also been shown 
for double heterozygous mutations in two different genes like MYH7 and CSRP3 [38]. 
These studies indicate that the mutation dose effect might not always be in the dose of 
one gene, but rather in the combination of mutations in different genes that increase 
the cellular burden resulting in a more severe clinical outcome. In contrast to the 
findings with the I79N and R94C mutations, R278C shows a trend to increased Ca2+-
sensitivity at low and a significant increase at intermediate dose, while a high dose 
significantly decreased Ca2+-sensitivity (Fig. 2C, F, I). Conflicting results regarding 
this mutation have been reported in literature, showing either a Ca2+-sensitization 
or no effect on Ca2+-sensitivity [13,29]. Considering the findings of our study, the 
different reported effects on myofilament function could be explained by differences 
in mutant protein dose. The different behavior of the N-terminal TNNT2 mutations 
(I79N and R94C) and the C-terminal mutation R278C may also be explained by their 
interactions with other thin filament proteins, e.g. tropomyosin and cTnC as calcium 
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binding to cTnC triggers conformational changes in troponin and tropomyosin that 
subsequently allow interactions between actin and myosin heads. The stoichiometry 
of 7:1:1 for actin, tropomyosin and troponin underlies the tight regulation of calcium-
induced cross-bridge formation and myofilament force development. Molecular 
models based on crystal structures showed that the N-terminal region of cTnT 
(residues 87–150) is extremely elongated and interacts with both tropomyosin and 
3 out of 7 actin subunits [39], and stabilizes tropomyosin-troponin binding to actin. 
As the cTnT N-terminus bridges over two tropomyosin strands [39], small amounts 
of mutant TNNT2 in this region may already exert a maximal effect on myofilament 
Ca2+-sensitivity via propagation of the calcium-binding signal over the thin actin-
filament. Furthermore, it has recently been shown that the C-terminus of cTnT, at which 
the R278C mutation is located, can directly interact with cTnC [19]. This cTnT-cTnC 
interaction may be altered by the presence of mutant R278C in a dose-dependent 
manner, and thereby differentially alter cTnC sensitivity to calcium. Interestingly, a 
divergent effect of a TNNT2 mutation has been reported before. The introduction of 
the dilated cardiomyopathy (DCM)- causing TNNT2 mutation ΔK210 in reconstituted 
thin filaments led to decreased Ca2+-sensitivity when using WT and ΔK210 cTnT in a 
50:50 ratio, whereas it resulted in increased Ca2+-sensitivity when using 100% ΔK210 
[40]. These findings indicate that dose-dependency of the functional defect might 
not be a common disease mechanism for all TNNT2 mutations but might depend on 
mutation location. Moreover, based on the elegant work by Davis and colleagues, who 
build proof for tension-mediated cardiomyocyte remodeling [41], the R278C mutation 
may trigger concentric remodeling (i.e. HCM phenotype) at low dose, and eccentric 
remodeling (i.e. DCM phenotype) at high protein dose.
Mutation location determines myofilament alterations
The differences between the mutations in this study could be due to mutation-specific 
changes in protein properties like structure or charge, that have differential effects 
on protein function by e.g. influencing their interaction with binding partners. In a 
study with MYH7 mutations, differences in disease severity have been proposed to 
depend on the mutation location due to their effect on different protein domains 
that might be of more or less importance for proper protein function [42]. Some of 
these mutations could be associated with either mild or severe disease phenotype 
[43,44]. Also for ACTC1 it has been described that the subdomain location of the 
mutation determines the alterations in protein properties. Mutations in one subdomain 
predominantly affected protein stability or polymerization, whereas mutations in other 
subdomains caused alterations in protein-protein interactions [45]. Vang et al. have 
shown in in vitro experiments that different HCM- and DCM-causing mutations in 
ACTC1 impair protein folding by the TRiC chaperonin complex resulting in inefficient 
incorporation into the myofilament and aggregation of actin [46]. A similar mechanism 
could potentially explain the lower thin filament binding affinity of the TNNT2 




residue, together with other charged residues, forms stable salt bridges that border 
hydrophobic patches leading to a very tight interaction of the cTnT fragment with 
residues 89–151 and tropomyosin [47]. Having an uncharged cysteine (C) instead of 
the positively charged arginine (R) at residue 94 may weaken the interaction of cTnT 
with tropomyosin and explain the reduced binding affinity of R94C to the thin filament. 
A similar mechanism may be true for the R278C mutation, which shows the same 
amino acid change. Accordingly, also the change from a non-polar isoleucine (I) to 
a polar asparagine (N) for the I79N mutation may potentially alter the interaction of 
cTnT with tropomyosin. Differences in exchangeability into porcine skinned fibers of 
different mutant cTnT proteins was shown in a previous study, in which R92W, R94L 
or R130C showed reduced exchangeability compared to WT and other cTnT mutant 
proteins (A104V, E163R, S179F, E244D) [15]. This is in line with findings by Palm et al., 
who have shown that mutations within the residues 92–110 alter the interaction of 
cTnT with tropomyosin [48]. Furthermore, studies in Tg mice showed less efficient 
incorporation of mutant compared to WT cTnT. Tg-I79N lines expressed 52% and 35% 
Tg-cTnT compared to 71% Tg-cTnT in the Tg-WT line [12]. Similar results have been 
reported for the Tg-cTnI mouse lines R145G and R145W that only showed 36% and 11% 
of mutant Tg-cTnI compared to 66% of Tg-cTnI in the Tg-WT line [49,50]. Overall, our 
study strengthens the notion that the degree of myofilament dysfunction depends on 
mutation location, and that mutant cTnT protein reduces thin filament binding affinity 
of the troponin complex.
Altered antibody binding affinity to cTnT-R278C
Troponins function as part of a complex, which is closely linked with tropomyosin. It has 
been shown that mutations in one of the troponin units can affect the composition of 
the entire troponin complex. In a study of different DCM-causing troponin mutations 
it has been shown for a truncating mutation in TNNI3 and an amino acid deletion 
in TNNT2 that the stoichiometry of the troponin complex was altered. In these 
DCM patient samples the mutation also affected the protein levels of its binding 
partners [51]. Although part of our western blot data suggests elevated cTnT levels 
in the TNNT2-R278C samples, we have shown in Fig. S2 that all cTnT antibodies show 
increased binding specifically to the mutant R278C compared to WT protein. Although 
the cTnT antibody epitope is more than 100 amino acids away from the mutation site, 
the amino acid change in the mutant protein is influencing antibody binding in western 
blot analysis. This, in combination with the ab8295 western blot and IF results, which 
did not show higher cTnT protein levels compared to donor (Fig. 5), suggest that 
there is no change in troponin stoichiometry in the HCM patient samples carrying 
the TNNT2-R278C mutation. This study shows that special care has to be taken when 
analyzing mutant proteins as antibody binding can be affected even under denaturing 
conditions. Our RNA analyses showed a ~50/50% ratio of WT and mutant mRNA in 
the TNNT2 R278C cardiac patient samples, while mass spectrometry revealed that 
the amount of mutant protein was less than 50%. This finding is in line with our in vitro 
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data that show reduced binding of the mutant protein to the thin filament compared 
to WT and may explain the lower percentage of mutant protein in the human tissue. 
The predicted mRNA structures for WT and R278C mRNA differ, suggesting that 
R278C mRNA may indeed have different characteristics than WT mRNA (Fig. S4), 
which may affect its translation efficiency, resulting in lower protein levels of cTnT-
R278C. Alternatively, it may be speculated that the turnover of WT cTnT protein is 
reduced, a mechanism which was recently proposed for MYBPC3 truncating mutations 
to maintain normal cMyBP-C levels and prevent haploinsufficiency [52]. Future research 
is warranted to investigate mechanisms underlying protein translation and turnover in 
order to define the role of both WT and mutant proteins in sarcomere homeostasis.
Differences in myofilament function between human TNNT2 R278C samples do 
not correspond with mutant protein dose
Interestingly, our human samples with the R278C mutation showed differences in 
myofilament Ca2+-sensitivity, while their clinical characteristics were very similar (Table 
1) and samples were all collected at the time of myectomy. HCM 173 showed a strong 
trend to increased myofilament Ca2+-sensitivity and HCM 234 showed a significant 
increase in myofilament Ca2+-sensitivity compared to donor, whereas HCM 175 was 
not different. Based on the dose-dependent effect observed for the R278C mutation 
in our exchange experiments, i.e. high myofilament Ca2+-sensitivity at low dose, 
and low myofilament Ca2+- sensitivity at high mutant dose, mutant protein levels 
should be higher in the HCM 175 than in the HCM 173 sample. However, our mass 
spectrometry data showed a slightly lower mutant protein level in HCM 175 (28%) 
than in HCM 173 (36%). A well-known modifier of Ca2+-sensitivity is PKA-mediated 
phosphorylation of cTnI [16]. While the level of cTnI phosphorylation was lower in 
all three samples compared to non-failing donor tissue, only HCM 173 and HCM 
234 displayed increased Ca2+-sensitivity. Restoring phosphorylation of cTnI indeed 
decreased Ca2+-sensitivity significantly in HCM 173 and with a strong trend in HCM 234. 
Although PKA phosphorylation of cTnI is a major regulatory mechanism of myofilament 
Ca2+-sensitivity, there are many more post-translational protein modifications that 
could potentially alter myofilament function. Also protein kinase C (PKC)-mediated 
phosphorylation can influence myofilament Ca2+-sensitivity and has been shown to 
decrease it [53]. Therefore, enhanced PKC activity may explain why Ca2+-sensitivity 
is not reduced in HCM 175 while the sample does show reduced phosphorylation of 
cTnI. Additionally, myofilament Ca2+-sensitivity could be influenced by a range of other 
factors, that are beyond the scope of this study. We can speculate that the extent 
of fibrosis, medication and the presence of comorbidities can influence myofilament 
function by altering post-translational modifications of myofilament proteins. Overall, 
our data illustrate that myofilament Ca2+-sensitivity measured at the time of myectomy 
in HCM samples harboring TNNT2 mutations is highly diverse, and most likely reflect 
a complicated mix of translational and post-translational protein modifications. The 




filament gene mutations [28,51], and also matches previously reported conflicting 
results on the R278C mutation. One study showed dramatically increased Ca2+-
sensitivity [29], whereas another one described R278C as a rather benign mutation 
with no effect on Ca2+- sensitivity [13].
STUDY LIMITATIONS
This study gives new insight into the effect of mutant protein dose and location of 
TNNT2 mutations on human myofilament function. It is a limitation of the study that 
we only assessed two N-terminal mutations and one C-terminal mutation, which all 
show differences on a functional level. To make a more general statement on the 
effect of mutations in certain cTnT domains, additional mutation locations have to 
be investigated. Furthermore, our study shows that isolated mutation effects are not 
directly translatable to the human situation, since several other disease modifying 
factors can influence the impact of the mutant protein on the cell and lead to differences 
in the functional state of the cardiomyocytes between patients with the same mutation.
CONCLUSION
From our exchange experiments we can conclude that mutant protein dose-dependency 
may be relevant only for certain TNNT2 mutations. Based on our experiments, this may 
be true for mutations located in the C-terminal domain that interacts with other troponin 
subunits. Our studies show that a relatively small dose of mutant protein is sufficient 
to exert the maximal effect on myofilament Ca2+-sensitivity for the I79N and R94C 
mutation, while the mutation location determines the magnitude of this effect. This 
could be explained by the interaction of troponin with tropomyosin which is involved 
in the regulation of cooperativity of thin filament activation. Our study emphasizes 
that care has to be taken when analyzing mutant proteins as single amino acid changes 
can alter antibody binding even under denaturing conditions. The ‘classical’ view 
of the HCM-related myofilament Ca2+-sensitization clearly is too simplified, as our 
study shows that thin filament-based HCM pathology involves additional levels 
of complexity including sarcomere homeostasis and mutation-specific effects.
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Mutations in genes encoding sarcomeric proteins are the most important cause 
of inherited cardiomyopathies, which are a major cause of mortality and morbidity 
worldwide. Although genetic screening procedures for early disease detection have 
been improved significantly, treatment to prevent or delay mutation-induced cardiac 
disease onset is lacking.
Recent findings indicate that loss of protein quality control (PQC) is a central factor in 
the disease pathology leading to derailment of cellular protein homeostasis. Loss of 
PQC includes impairment of heat shock proteins, the ubiquitin-proteasome system 
and autophagy. This may result in accumulation of misfolded and aggregation-prone 
mutant proteins, loss of sarcomeric and cytoskeletal proteins, and, ultimately, loss 
of cardiac function. PQC derailment can be a direct effect of the mutation-induced 
activation, a compensatory mechanism due to mutation-induced cellular dysfunction 
or a consequence of the simultaneous occurrence of the mutation and a secondary 
hit. In this review, we discuss recent mechanistic findings on the role of proteostasis 
derailment in inherited cardiomyopathies, with special focus on sarcomeric gene 
mutations and possible therapeutic applications.
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CLASSIFICATION OF CARDIOMYOPATHIES
Cardiomyopathies (CM) constitute one of the most common causes of sudden cardiac 
death in young adults and represent major causes for cardiac transplantation [88]. 
Disease onset generally ranges between 20-50 years of age. CMs are defined by 
abnormal myocardial structure and function in the absence of any other diseases 
sufficient to cause these abnormalities [24]. These can be sub-classified based on their 
functional phenotype and their specific morphological changes. The most common 
types are hypertrophic CM (HCM), characterized by increased left ventricular (LV) wall 
thickness often occurring asymmetrically, and dilated CM (DCM), in which the presence 
of LV dilatation is accompanied by contractile dysfunction [24]. Besides HCM and 
DCM, there are less frequent forms such as restrictive CM (RCM) and desmin-related 
cardiomyopathy [24]. All these cardiomyopathies can be familial and are typically 
inherited in an autosomal dominant manner. Mutations in genes encoding sarcomeric 
proteins are the most common cause of these types of CMs [3]. However, the 
genotype-phenotype relationship is far from clear. The variations in age of CM onset 
and disease phenotype suggest that additional factors play a role in CM pathogenesis.
Accumulating evidence indicates the presence of derailed proteostasis in CMs as 
well as its contribution to CM onset and progression. This derailment could either be 
caused directly by the mutation or indirectly due to a compensatory mechanism. In 
the former case, the mutant protein might be instable or improperly folded leading to 
direct activation of the protein quality control (PQC). In the latter case, the mutation 
does not interfere with protein folding or stability but causes functional impairment 
which in turn leads to cellular stress and indirect activation of the PQC. Furthermore, 
the “secondary-hit” model may apply in CMs, in which a primary sarcomere mutation 
enhances vulnerability to secondary stressors which increases cellular burden resulting 
in PQC derailment. This review summarizes the current knowledge about perturbations 
in the different components of the PQC in CMs that are caused by mutations in 
sarcomeric proteins.
PROTEOSTASIS NETWORK ENSURES CARDIAC HEALTH
The heart has a very limited regenerative capacity and therefore requires surveillance 
by a system that maintains protein homeostasis to ensure cardiac health [106]. The PQC 
system sustains proteostasis by refolding misfolded proteins or removing them if refolding 
is impossible. It is composed of heat shock proteins (HSPs), the ubiquitin-proteasome 
system (UPS) and autophagy. PQC is only then functional when all three components are 
operative and interact with each other. This means that derailment of one of the parts 
might impair the function of the others in a direct or indirect manner. In a physiological 




misfolded and aggregation-prone proteins are cleared by the two degradation 
systems, i.e. the UPS and autophagy, that work in collaboration with the HSPs (Fig.1).
First, the different parts of the PQC in normal physiology are described, before 
addressing their role in CMs.
Heat shock proteins
HSPs, originally identified as heat responsive proteins, are constitutively expressed 
in the cell to serve as molecular chaperones to ensure correct folding and assembly 
of proteins. HSPs are classified in two categories: the small HSPs with a low molecular 
weight (15-30 kDa) and the chaperones with a high molecular weight (>30 kDa).
One functional group of HSPs are chaperonin complexes, which are ATP-dependent 
chaperones with a barrel-like structure, that provide correct folding of nascent proteins 
after translation. Besides their folding function during protein translation, HSPs are 
also induced in response to cellular and environmental stressors to maintain a healthy 
cellular proteostasis by clearance of misfolded proteins [66, 111].
As reviewed by Garrido et al, small HSPs show an ATP-independent holdase activity. This 
means that they bind to misfolded proteins, keep them in a state competent for either 
refolding or degradation, and thereby prevent or attenuate their aggregation. Due to 
the association of small HSPs with the HSPs that have an ATP-dependent folding activity, 
the misfolded proteins can be refolded into their native and functional conformation [28]. 
The binding affinity of HSPs to the misfolded protein is dependent on the chaperone 
cofactors bound to the HSPs. Furthermore, this binding of chaperone cofactors 
determines the processing of the misfolded protein for either refolding or degradation. 
Chaperone cofactors involved in degradation pathways can switch off the refolding 
activity of HSPs by inhibiting their ATPase activity and assist the HSPs and the UPS or 
autophagy in the breakdown of misfolded proteins (Fig.2) [13, 25]. The degradation of 
the thick filament protein myosin-binding protein-C (MyBP-C), for instance, is mediated 
via the chaperone cofactor HSC70 playing a major role in regulating MyBP-C protein 
turnover [32]. These degradation pathways are addressed in the following sections.
To maintain the structure and function of the highly dynamic cardiac sarcomeres, 
HSPs play an important role. The molecular chaperones GimC (Prefoldin), chaperonin 
TCP-1 Ring Complex (TRiC), αB-crystallin and HSP27 ensure correct folding and 
assembly of proteins, maturation of actin and prevent aggregate formation [10, 14, 
34, 36]. HSP27 is mostly found as high–molecular weight oligomers in the cytosol of 
unstressed cells [23]. Upon stress, HSP27 deoligomerizes and translocates to F-actin 
and thereby stabilizes the F-actin network [16]. To assemble the myosin thick filament, 
the chaperones UNC-45, HSP90 and HSP70 are required, whereas the actin filament 
is self-assembled [7, 8, 94]. Several members of the small HSPs family are expressed 
in the heart and associate with cytoskeletal proteins [33, 103]. These HSPBs stabilize 
cytoskeletal structures and improve coping with stress situations [33, 48, 49].
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FIGURE 1. Collaboration of the protein quality control components. Stress leads to misfolding 
of proteins, which may result in abnormal interaction and subsequent aggregation. Small HSPs 
(white/gray rectangle) and HSPs with ATPase activity (blue moon shape with black rectangle) 
prevent aggregation formation by binding to the hydrophobic surfaces of misfolded proteins. 
They either refold the misfolded proteins to its native structure or initiate its polyubiquitination 
(Ub, orange hexagon). Misfolded proteins with polyubiquitin chains linked to lysine 48 (K48) 
are mainly degraded by the proteasome. Misfolded proteins carrying K63-linked polyubiquitin 
chains and aggregated proteins enter the autophagic pathway.
Ubiquitin-proteasome system
In case of terminally misfolded proteins, that failed be refolded, HSPs and their 
chaperone cofactors recruit enzymes to mediate polyubiquitination of the target 
substrate and thereby mark them for the appropriate degradation pathway. Short-
lived proteins are typically degraded by the UPS, whereas autophagy is mainly used 
for degrading long-lived proteins and entire organelles [17, 39].
The polyubiquitination of the target substrate requires the sequential action of 




then transferred to a ubiquitin-conjugating enzyme (E2). In the last step, a ubiquitin 
ligase (E3) links ubiquitin from the E2 enzyme to a lysine residue of the target protein. 
There are only two E1 enzymes, several E2 enzymes and many E3 ligases, each of 
which recognizes one or several specific protein motifs. Therefore, the substrate 
specificity is achieved by the selectivity of the different E3 ligases [26, 80]. Dependent 
on the combination of E2 enzyme and E3 ligase, polyubiquitin chains are linked to 
the preceding ubiquitin molecule either via lysine 48 (K48) or via lysine 63 (K63) 
which marks the protein for degradation. Therefore, the polyubiquitination process 
determines the degradation pathways: Proteins carrying K48-linked polyubiquitin 
chains are predominantly targeted to proteasomal degradation, and proteins carrying 
K63-linked polyubiquitin chains enter the autophagic pathways as discussed in the 
following paragraph [1].
K48-linked polyubiquitinated proteins are transferred to the proteasome, which is 
almost exclusively the 26S proteasome in eukaryotic cells. This protein complex consist 
of one 20S core- and two 19S regulatory subunits forming a barrel-like structure. 
The regulatory subunits have ubiquitin-binding sites to recognize polyubiquitinated 
proteins and unfold them using their ATPase activity. The unfolded proteins are 
transferred to the catalytic core and proteolytically cleaved [104].
Sarcomeric proteins have an average turnover rate of 5-10 days [12, 112]. Therefore, 
they rely on a proper functioning UPS to regulate their clearance. Once dissociated 
from the myofibrils, ubiquitin-conjugating enzymes mark the proteins for proteasomal 
degradation by adding K48-linked polyubiquitin chains [91, 112]. In cardiomyocytes, 
this step is mediated by the MuRF family of E3 ligases [59, 93].
Autophagy
Autophagy cleans up aggregates or proteins via lysosomal breakdown that cannot 
be refolded by chaperones or processed by the UPS [46]. During macroautophagy, 
herein referred to as autophagy, membrane enclosed vesicles are formed containing 
the targeted cellular components. First, an isolation membrane is formed engulfing 
the cytoplasmic material. The membrane expands until the edges fuse to form the 
autophagosome [118]. Fusion of the autophagosome with a lysosome leads to an 
autolysosome which breaks down the cargo [5]. During selective autophagy, proteins 
carrying a K63-linked polyubiquitin chain are degraded. In the case the proteasome is 
overwhelmed with proteins carrying a K48-linked ubiquitin chain, such as aggregated 
proteins, they can also be cleared via autophagy. Their polyubiquitin chain docks 
to the adaptor protein p62/SQSTM1 which enables the translocation into the 
autophagosome [45]. Acidic lysosomal hydrolases degrade the captured material 
together with the inner membrane and the resulting macromolecules are recycled 
into ATP, amino acids and fatty acids.
Autophagy is found to be upregulated in response to starvation, growth factor 
withdrawal or high bioenergetic demands [50, 56, 65, 86]. The ability to sequester 
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and break down entire organelles, such as mitochondria, peroxisomes, endoplasmic 
reticulum and intact intracellular microorganisms, makes autophagy a unique and 
essential process in the cell. Especially in post-mitotic cells like cardiomyocytes, 
basal activation of autophagy is important to maintain a balanced proteostasis by 
degradation of long-lived proteins, lipid droplets and dysfunctional organelles [17].
Cardiomyocytes have a low basal autophagic activity under normal conditions. Upon 
stress, the formation of protein aggregates is facilitated and triggers activation of 
autophagy [96]. Furthermore, cardiac autophagy is initiated in response to energy 
stress during periods of nutrient deprivation or high metabolic demand [35].
FIGURE 2. Chaperone cofactor binding determines the heat shock protein (HSP) function. Small 
HSPs (white/gray rectangle) and HSPs with ATPase activity (blue moon shape with black rectan-
gle) bind to the misfolded protein to stabilize it. Dependent on the chaperone cofactors (green 
circles or turquoise squares), the misfolded protein gets either refolded or ubiquitinated for 
subsequent degradation. If refolding is impossible, the chaperone cofactors can be exchanged 
to promote degradation. In case of ubiquitination, the chaperone cofactors can switch off the 
HSP refolding activity by blocking the ATPase activity and, together with HSPs, assist in clearance 




PROTEOSTASIS DERAILMENT IN INHERITED CARDIOMYOPATHIES
The PQC is of great importance in many cardiac diseases caused by ‘wear and tear’, 
including cardiac amyloidosis, myocardial infarction and atrial fibrillation [37, 60, 73, 115]. 
The activation of PQC in a variety of cardiac stress conditions can be considered as a 
positive compensatory response to maintain proteostasis. This might be especially true 
in the case of inherited CMs, where mutant protein expression is the disease-causing 
mechanism. Recent studies provide evidence for a causative role of the PQC in CM. 
On one hand, mutations in components of the PQC itself can cause CM. This has been 
described for the R120G mutation in CRYAB encoding for the chaperone αB-crystallin, 
causing desmin-related CM, and the P209L mutation in the chaperone cofactor BAG3, 
leading to juvenile DCM [87, 105]. Mutations in PQC components as causes of inherited 
CM are rare, but PQC impairment can also occur as a result of CM-causing sarcomeric 
mutations. In this case, mutant sarcomeric proteins may impair the function of the PQC 
through overload of its components including HSPs, UPS and autophagy. This could 
lead to increased levels of mutant protein, exacerbating CM disease progression.
So far, the role of PQC has been investigated only in a limited number of studies on CM 
caused by sarcomeric gene mutations. In vitro information is available for HCM- and 
DCM-causing mutations in ACTC1. Furthermore, it has been studied in vivo with HCM-
causing mutations in MYBPC3, MYH7 and MYOZ2, DCM-causing NEBL mutations and 
RCM-causing TNNI3 mutations (Table 1). In the following sections, the interaction 
between CM and derailments of the different parts of the PQC are described in detail.
Diverse abnormalities in heat shock protein function
HSP impairment or activation contribute to disease pathology in CMs. Desmin-related 
CM displays HSP impairment and is either caused by mutant desmin itself or mutant 
chaperone αB-crystallin. In a normal state, αB-crystallin binds to desmin and thereby 
prevents its aggregation [10]. Mutant desmin, however, impairs the interaction with 
αB-crystallin leading to desmin accumulation and cardiomyocyte dysfunction [54]. This 
suggests aberrant protein aggregation can cause CM. Correspondingly, the R120G 
mutation in CRYAB results in desmin-related-CM as well and also presents with aggregates 
containing desmin and mutant αB-crystallin [105]. Sanbe et al. showed that upregulation 
of HSPB8 due to geranylgeranylacetone treatment reduces the amount of mutant αB-
crystallin-containing aggregates [83]. This implies that other HSPs can compensate 
for the loss of function to remove aggregates. Furthermore, in vitro experiments 
have shown that HCM- or DCM-causing mutations in ACTC1, encoding cardiac actin, 
can interfere with its folding by the TRiC chaperonin complex resulting in inefficient 
incorporation of actin into the myofilament and its subsequent aggregation [102]. 
Mutations in one specific subdomain of actin affect protein stability or polymerization, 
making actin more prone for degradation. Whereas mutations in other subdomains 
of actin cause alterations in protein-protein interactions [67]. A gene co-expression 
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analysis of human controls and HCM samples identified the TRiC chaperonin complex 
as the most differential pathway thereby further highlighting its importance in HCM [19].
By contrast, various studies on the role of PQC in CMs report on increased levels of 
HSPs due to PQC activation. However, it still remains unresolved whether the increased 
levels of HSPs are a direct effect of the mutant protein or a compensatory secondary 
effect due to increased cellular stress. Therefore, the direct interaction of mutant 
protein and HSPs needs to be studied. In mice with a truncating MYBPC3 mutation and 
an HCM phenotype, increased levels of αB-crystallin have been found [116]. In other CM 
mouse models, independent of a sarcomeric mutation, increased levels of HSP70 have 
been observed [62]. A study in patients with chronic heart failure due to DCM revealed 
a correlation of serum HSP60 levels with disease severity [69]. Since increased levels of 
HSP27 and HSP70 are associated with a protective effect in models for atrial fibrillation, 
by maintaining cardiomyocyte function, one can speculate that increased expression 
of these HSPs might be part of a compensatory protective mechanism in CM [15, 62].
In general, research findings indicate that HSP impairment is detrimental for 
cardiomyocyte function due to a higher risk of impaired protein folding and aggregate 
formation. By contrast, HSP activation in CM is considered as a beneficial effect and 
is most likely a compensatory mechanism of the cell.
Derailment of the ubiquitin-proteasome system
Derailed UPS function in CM affects the degradation of terminally misfolded proteins. 
MYBPC3 mutations often lead to expression of truncated protein, which is not 
incorporated into the sarcomere because the most C-terminal domain needed for 
incorporation is missing [64]. Truncated MyBP-C has not been detected in cardiac 
samples of HCM patients [101]. In addition, very low levels (<4%) of truncated MyBP-
C, which were not incorporated into the sarcomeres, were found in engineered 
heart tissue made of MYBPC3 knock-out mouse cardiomyocytes transfected with a 
truncating MYBPC3 mutation [110]. Therefore, it is likely that either the mutant mRNA 
is degraded via nonsense-mediated mRNA decay and/or the truncated MyBP-C forms 
a substrate for immediate degradation by the UPS or autophagy. Since MyBP-C is 
highly expressed in cardiomyocytes, high levels of truncated protein may lead to 
an increased UPS burden and competitive inhibition of the proteasome [84, 85]. In 
this case, the UPS is overwhelmed by the amount of truncated protein that needs to 
be degraded. In line with this hypothesis are analyses of myectomy samples from 
HCM patients with sarcomeric mutations which show a decrease in proteolytic activity 
(Table 1) [77, 85]. Decreased processing through the UPS system is also indicated by 
the increase in overall levels of protein ubiquitination in HCM patients and animal 
models which is already detectable at an early postnatal phase prior to any other 
symptom development [6, 30, 77, 85]. Consistent with the studies in MYBPC3-mutant 




mutations [30]. Patient samples with a sarcomeric mutation showed higher levels of 
polyubiquitination and decreased proteolytic activity compared to healthy controls [77].
In addition to overload of the UPS by mutant protein, increased oxidative stress can 
also impair the function of the proteasome. In this case, the proteasomal dysfunction 
would not be a direct effect of the mutant protein but a consequence of secondary 
cellular changes. In CM samples, an increase in oxidation of cytosolic protein content 
as well as the 19S proteasome, thereby decreasing the overall proteolytic function of 
the 26S proteasome subunit, has been identified [21, 30, 77].
In addition to the proteasome itself, the expression of ubiquitin ligases can be altered. 
In an HCM mouse model with mutant Mybpc3, the muscle specific E3 ligase Asb2β 
showed decreased mRNA levels compared to wild-type mice [99]. Since one of its 
targets is desmin, accumulation of desmin could contribute to the HCM phenotype, 
as observed for desmin-related CMs.
A large HCM patient cohort and matched healthy controls were screened for genetic 
variants in all three members of the MuRF family, since mutations in the gene encoding 
MuRF1 were reported to cause HCM [18]. In this study, a higher prevalence of rare 
variants of the cardiac-specific E3 ligases MuRF1 and MuRF2 was found in HCM 
patients [95]. These were associated with earlier disease onset and higher penetrance 
implying that disturbances of the UPS might act as a disease modifier contributing 
to HCM.
In contrast to HCM, in DCM the reported UPS derailments could not yet be linked 
to sarcomeric mutations. A likely reason for this is that the DCM patient samples did 
not carry a sarcomeric mutation and/or the underlying disease cause was not known. 
Tissue analysis from explanted DCM hearts revealed increased expression of both 
E1 and/or E2 enzymes [47, 108]. Further evidence of increased ubiquitin-conjugating 
enzyme activity was detected in end-stage DCM. Here, increased levels of MuRF1 
and MAFbx were associated with increased UPS degradation activity, which might 
be the cause of ventricle wall thinning as observed in end-stage DCM patients [9]. 
In line with the increased ubiquitin-conjugating enzyme levels, increased levels of 
polyubiquitinated proteins have been detected in DCM samples [11, 47, 72, 108]. This 
finding is further supported by a 2.3-fold reduced expression of the deubiquitinating 
enzyme isopeptidase-T in DCM patients [47]. Furthermore, increased proteolytic 
activity of the 26S proteasome as well as the 20S subunit peptidase activity have 
been found [9, 11, 72].
In contrast to HSPs, the answer to the question whether UPS activation or inhibition 
would be beneficial in HCM and DCM, is not as straight forward. In an HCM phenotype, 
proteasome activation might improve the hypertrophic phenotype due to increased 
mutant protein degradation. However, in DCM, increased proteasome function might 
augment wall thinning and therefore DCM might benefit from proteasome inhibition.
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Unresolved role of the autophagic response in cardiomyopathies
Autophagy is a crucial mechanism in CMs that only fulfills its cytoprotective mechanisms 
when it is in balance [50]. Moderate activation of autophagy has beneficial effects in 
CM patients by removing aggregates and supplying the cell with energy.
However, protein degradation due to excessive autophagy has been associated 
with different types of CM, including HCM, DCM, ischemic CM and chemotherapy-
induced CM [22, 44, 55, 58, 71, 89]. This could lead to loss of myofibrils, as observed 
in end-stage HCM and DCM patients [40, 70]. In a recent study, the expression of 
vacuolar protein sorting 34 (Vps34), an important autophagy regulator, was shown to 
be decreased in the myocardium of HCM patients and deletion of Vsp34 resulted in an 
HCM-like phenotype in mice. Furthermore, decreased expression of Vsp34 impaired 
the HSP-autophagy axis, as indicated by αB-crystallin-positive aggregates [44]. HCM 
patients with mutations in MYBPC3 or MYH7 revealed an upregulation of autophagic 
vacuoles and markers, indicating increased autophagic activity [92]. In a homozygous 
Mybpc3-mutant HCM mouse model, levels of autophagy markers were increased 
at the protein level implying autophagic activation. However, mRNA levels of these 
markers were not increased. This rather suggests an accumulation of autophagic 
proteins due to defective autophagic-lysosomal degradation instead of activation 
on transcriptional level [85]. In explanted hearts from DCM patients, the imbalance of 
high uibiquitination rate and insufficient degradation may contribute to autophagic 
cell death [47]. Vacuolization in CMs has been reported with mutations in ACTN2, 
MYBPC3 and NEBL [31, 75, 109]. This observation suggests that the accumulation of 
autophagic vacuoles implies cardiomyocyte stress. However, the interpretation of 
vacuole accumulation remains unclear since it could reflect an increase in autophagic 
activity or an impairment of autophagosome-lysome fusion.
For a correct interpretation of the role of autophagy in CM, autophagic flux in combination 
with gene and protein expression data have to be studied in the future.
Environmental stressors influencing the proteostasis network
Besides the above mentioned effects of the sarcomeric gene mutations on the PQC, 
other environmental stressors, including physiological stress, genetic and epigenetic 
pathways and inflammation, can also impair its function [82, 120]. In CM patients with 
a sarcomeric mutation, these stressors can act as second hit and thereby determine 
disease severity. Since most of CM patients become symptomatic only in a later stage 
of their life, the influence of drugs directed at the PQC system as treatment modality 
for co-morbidities and the age-related decline of the PQC are discussed below.
Several anti-cancer agents block the PQC to cause a lethal proteotoxicity in 
cancer cells. Anthracyclines, for example, directly impair its function by enhancing 




proteasome activity as well as inhibition of autophagy in cardiomyocytes [2, 27, 51, 63]. 
Furthermore, they disturb Ca2+ homeostasis, leading to endoplasmic reticulum stress, 
which derails protein folding [27]. In CM patients, dealing already with a sarcomeric 
mutation, treatment of another non-cardiac disease can trigger the onset of CM or 
worsen the clinical outcome. Cardiotoxic side effects of anthracyclines can lead to 
anthracycline-associated cardiomyopathy (AACM) which presents as LV dysfunction 
and DCM in adults and RCM in children [53, 61]. Treatment with a low dose of anti-
cancer agents induced CM in cancer patients without a history of cardiac disease. 
Genetic screening of these patients revealed truncating titin variants which are known 
as a genetic cause of DCM. These variants may increase the susceptibility for anti-
cancer agents-induced CM [52]. In general, patients having a genetic predisposition 
for DCM are more prone to develop AACM after anthracycline treatment [100, 107]. It 
can be speculated that the impairment of the PQC due to the anti-cancer treatment is 
an additional burden to the cardiomyocyte. The clinical cardiac phenotype is caused 
by insufficient clearance of the mutant protein via UPS and/or autophagy. Therefore, 
these findings suggest that PQC impairment by anthracyclines can act as catalysts in 
the development of CM in patients with underlying sarcomeric gene mutation.
Ageing represents another cellular stressor leading to toxic mutation effects because 
of the late disease onset and development of symptoms in inherited CMs. Clinical 
characteristics, such as wall thickness and diastolic function, worsen with increasing 
age [57]. This could be related to an age-associated decline in proteostatic function, 
which is supported by the presence of damaged macromolecules and mitochondria in 
aged cardiomyocytes [98]. Dysfunctional mitochondria generate high levels of reactive 
oxygen species, which promote proteotoxic stress and accelerate detrimental effects 
on the cardiomyocyte [90]. Also, the activity of the 26S proteasome is decreased 
during ageing which is possibly caused by oxidation of its components [21, 29, 30, 
42]. The age-dependent decline in proteasome function increases the burden for the 
autophagic pathway. However, not only the proteasome, but also the autophagy-
lysosomal system declines during ageing [81]. As an example, mTOR, a negative 
regulator of autophagy, was upregulated during ageing in a mouse study which 
indicates decreased autophagic activity [4]. As a result, the activity of the autophagic 
response might not be sufficient. However, similar to findings related to the UPS, 
autophagy was enhanced during ageing in some animal models, suggesting an 
increased need for autophagy in aged cells [113]. Further research is warranted to 
investigate whether the age-related decline of the PQC is causative for CM onset 
and/or progression.
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FUTURE THERAPEUTIC IMPLICATIONS
To improve the clinical outcome of CM patients, modulation of PQC components 
might serve as a novel therapeutic strategy. Figure 3 summarizes the three different 
ways and illustrates how a sarcomeric gene mutation can lead to PQC derailment. In 
case of a direct mutation effect on the PQC as well as in combination with secondary 
hits, targeting of the PQC would be most beneficial and the most direct way to prevent 
cardiomyocyte dysfunction. In case where the PQC derailment is a consequence of 
mutation-induced cellular disturbances, it is important to also target the cellular 
dysfunction to prevent further worsening of the PQC.
FIGURE 3. Effects of sarcomeric gene mutations on the protein quality control (PQC) system. 
Sarcomeric gene mutations can directly derail PQC function leading to cardiomyocyte dys-
function. PQC derailments in cardiomyopathies (CMs) can also be a compensatory mechanism 
to counteract cardiomyocyte dysfunction caused by the sarcomeric gene mutation. The sec-
ondary-hit hypothesis suggests that the PQC of cardiomyocytes carrying a sarcomeric gene 
mutation is more prone to derail in response to additional cellular stressors, thereby resulting 
in cardiomyocyte dysfunction.
As extensively discussed in this review, PQC alterations in CMs are disease- and 
mutation-specific leading to either increased or reduced function in one or several of 
its components. Therefore, personalized treatment strategies are required to restore 
a balanced proteostasis. Potentially, all three PQC components can be therapeutically 




HSP expression can be induced by the drug geranylgeranylacetone. In animal models 
of desmin-related CM, the induction of HSP expression by geranylgeranylacetone 
resulted in a beneficial effect on heart function because desmin-aggregate formation 
was reduced [83]. This example suggests that activation of HSPs might also be 
beneficial in other types of inherited CMs since HSPs play a crucial role in coping 
with the mutant protein.
The derailment of the UPS is context dependent: proteasomal function is decreased in 
HCM, RCM and desmin-related CM and increased in DCM [9]. Decreased proteasomal 
function suggest that the misfolded proteins hamper the UPS by overwhelming it due 
to permanent degradation of misfolded proteins. As a consequence, the activity of the 
UPS is reduced. Therefore, UPS activation might be a beneficial therapeutic strategy 
in HCM and desmin-related CM [9]. In line with this, in HCM patients with a TNNT2 
mutation increased proteasomal activity was correlated with a better clinical outcome 
[30]. In contrast, over-activation of the UPS indicates a direct response of the UPS to 
the misfolded proteins to ensure optimal clearance. However, excessive activation of 
the UPS transforms the initially beneficial effects into a detrimental maladaptation 
that possibly contribute to loss of myofibrils [9]. Nevertheless, complete proteasome 
inhibition itself triggered cardiac dysfunction and a CM-like phenotype in healthy 
pigs [38]. Therefore, it is important to achieve a moderate UPS response in DCM to 
prevent the detrimental effects of complete proteasome inhibition.
The altered autophagic flux in CMs can be caused on the one hand directly by the 
misfolded protein itself or on the other hand indirectly by compensating for the impaired 
functionality of the UPS. To optimize the degradation response, the autophagic activity 
needs to be pharmacologically titrated into its proteostasis promoting range [114].
CONCLUSION
The PQC is crucial for cardiac health and requires the collaboration of all its 
components to be functional. Key modulators of the PQC are disease- and mutation-
specifically altered and derailed in CM. Pharmacological targeting of PQC components 
represents a novel therapeutic strategy to treat CMs. Since most of the described 
findings are retrieved from single CM patients or experimental animal models, 
systematic studies in larger CM patient populations are warranted to untie the knot 
of disease- and mutation-specific derailments of the PQC.
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Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder. 
It is mainly caused by mutations in genes encoding sarcomere proteins. Mutant forms 
of these highly abundant proteins likely stress the protein quality control (PQC) 
system of cardiomyocytes. The PQC system, together with a functional microtubule 
network, maintains proteostasis. We compared left ventricular (LV) tissue of nine 
donors (controls) with 38 sarcomere mutation-positive (HCMSMP) and 14 sarcomere 
mutation-negative (HCMSMN) patients to define HCM and mutation-specific changes 
in PQC. Mutations in HCMSMP result in poison polypeptides or reduced protein 
levels (haploinsufficiency, HI). The main findings were 1) several key PQC players 
were more abundant in HCM compared to controls, 2) after correction for sex and 
age, stabilizing heat shock protein (HSP)B1, and refolding, HSPD1 and HSPA2 were 
increased in HCMSMP compared to controls, 3) α-tubulin and acetylated α-tubulin 
levels were higher in HCM compared to controls, especially in HCMHI, 4) myosin-
binding protein-C (cMyBP-C) levels were inversely correlated with α-tubulin, and 5) 
α-tubulin levels correlated with acetylated α-tubulin and HSPs. Overall, carrying a 
mutation affects PQC and α-tubulin acetylation. The haploinsufficiency of cMyBP-C 
may trigger HSPs and α-tubulin acetylation. Our study indicates that proliferation 
of the microtubular network may represent a novel pathomechanism in cMyBP-C 
haploinsufficiency-mediated HCM.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a common familial cardiac disease with 
an estimated prevalence of 1:200 [1]. It is characterized by an asymmetrically 
hypertrophied, non-dilated left ventricle and an impaired diastolic function [2]. 
More than 1500 pathogenic mutations that most frequently encode proteins in 
the sarcomere have been identified. Previous studies have shown that sarcomere 
mutations alter myofilament function (reviewed recently in [3]). However, while the 
same sarcomere mutation is present in members of one family, the age of onset and 
disease severity vary greatly between patients, spanning from asymptomatic mutation 
carriers to symptomatic patients with severe cardiac remodeling [4]. This large clinical 
heterogeneity implies that HCM pathophysiology is more complex than the functional 
defects triggered by the gene mutation. Furthermore, pathogenic mutations were only 
found in ~50% of all HCM patients [4]. Moreover, a recent large international clinical 
HCM study showed that patients with a mutation in a sarcomere gene had a 2-fold 
higher risk of adverse outcomes (e.g., heart failure and atrial fibrillation) compared to 
patients with no known mutations [5]. The exact mechanisms underlying the difference 
in disease severity between sarcomere mutation-positive (HCMSMP) and mutation-
negative (HCMSMN) patients are currently unknown.
A mechanism implicated in HCM progression is perturbed protein quality control 
(PQC) [6,7]. Cardiomyocytes contain a multilayered PQC system for maintaining proper 
protein conformation and for reorganizing and removing misfolded or aggregated 
(mutant) proteins [8]. The PQC system comprises heat shock proteins (HSPs), the 
ubiquitin-proteasome system (UPS), and autophagy [9]. HSPs are involved at all stages 
of sustaining protein homeostasis: during protein biosynthesis and maturation, in 
chaperoning the folding, in protection from environmental stress, in rearrangements 
of cellular macromolecules during the functional cycles of assembly and disassembly, 
and finally, in targeting proteins for degradation [10]. Terminally misfolded and 
aggregation-prone proteins are cleared by the two degradation systems, UPS and 
autophagy [11]. Furthermore, pathways of PQC are strongly linked to cell architecture, 
such as the microtubules network [12]. As sarcomere proteins are the most abundant 
proteins in the heart, maintenance of sarcomere structure and functions depends on 
functioning PQC mechanisms.
Perturbations in PQC mechanisms may be aggravated by the presence of sarcomere 
gene mutations that may explain the difference in disease severity between HCMSMP 
and HCMSMN patient groups. Moreover, the proteotoxic burden on PQC may depend 
on the type of mutation: in HCM, gene mutations either result in a ‘poison polypeptide’ 
(an expressed protein containing a mutated sequence) or haploinsufficiency, where 





Here, we identified and quantified key PQC players, such as HSPs and degradation 
markers (ubiquitinated proteins, p62, LC3BII) and microtubule network markers (for 
example acetylation of α-tubulin) in a large set of myectomy samples from HCMSMP and 
HCMSMN patients to define if the presence of a sarcomere mutation differentially affects 
PQC. In addition, mutation-specific PQC changes were assessed by comparing HCM 




Cardiac tissue from the interventricular septum was obtained during myectomy 
surgery to relieve left ventricular (LV) outflow tract obstruction. Patients were selected 
for surgery at our HCM center on the basis of the following indications: (1) peak left 
ventricular outflow tract (LVOT) gradient ≥ 50 mmHg at rest or on provocation and 
(2) presence of unacceptable symptoms, despite maximally tolerated medications 
consisting of β-blocking agents and/or calcium channel blockers. The decision 
to perform surgery was made after the consensus of a heart team consisting of a 
cardiothoracic surgeon, an interventional cardiologist, and a cardiologist specialized 
in HCM care [15]. Hypertrophic obstructive cardiomyopathy was evident from the 
increased septal thickness with a mean (± SD) of 21 (± 6) mm and high LV outflow tract 
pressure gradient with a mean (± SD) of 66 (± 37) mmHg. Next-generation-sequencing 
was used to check 48 different HCM-associated genes for variants [16].
This study included 52 septal myectomy patients, as summarized in Table 1. A total 
of 38 HCM patients were tested positive for carrying a gene variant in one of the 
genes encoding for the sarcomeric protein. The ages of all 38 HCMSMP patients ranged 
between 15 and 72, with a mean (± SD) of 49 (± 16) years, and 68% of these were 
males. Depending on the reported pathomechanism, this group was subdivided into 
haploinsufficiency (HI) and poison polypeptide (PP) subgroups.
Seven patients of the HCMHI group were identified as carrying the Dutch founder 
mutation (c.2373dupG) in MYBPC3, the gene encoding the A band protein, cardiac 
myosin-binding protein-C (cMyBP-C) and twelve patients carried other mutations in 
MYBPC3, of which three were missense and the remainder were truncations. Patient 
ages ranged between 21 and 71 years, with a mean (± SD) of 43 (± 15) years, and 
79% of these were males. We collected 19 myectomy samples from HCMPP patients 
carrying a missense mutation. Nine patients presented with mutations in the gene for 
the cardiac myosin heavy chain (MYH7), the second most commonly mutated gene in 
HCM patients. Four patients carried mutations in the gene for troponin I (TNNI3), three 
patients carried troponin T (TNNT2) mutations and two patients carried myosin light 
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chain 2 (MYL2) mutations. The HCMPP patients were aged between 15 and 72 years, 
with a mean (± SD) of 55 (± 15) years, and 58% of these were males.
Our study included 14 patients with no known sarcomere gene mutation. HCMSMN 
patient ages ranged between 22 to 74, with a mean (± SD) of age 57 (± 14), and 64% 
of these were males. Not all the myectomy samples were sufficiently large to perform 
all the analyses.
Finally, the 52 HCM samples were compared with nine samples of healthy donor 
hearts that were not used for heart transplantation, mostly because of poor tissue 
matching against patients in the heart failure clinic of St Vincent’s Hospital. While these 
controls had no history of cardiac disease, their validity as “controls” was based on 
their extensive use as such in publications from a wide range of other laboratories. 
We therefore assumed that these donors are representative of the diverse human 
population. Consistent with the HCM patients, these donors were 67% male, with 
a mean age (± SD) of 43 (± 14) years, ranging from 19 to 65. All donor hearts were 
perfused with ice-cold cardioplegia and transported on ice to the Sydney Heart Bank 
where ~1 g samples were snap frozen and stored in liquid nitrogen. The average values 
of the control cardiac samples (n = 9) are indicated by the dotted lines in Figures 1 to 4 
and Figure 6. The distribution of the controls is shown in the Supplementary Materials 
(Figure S1), as well as uncropped full-width images of the membranes (Figure S2). The 
patients study protocol was approved by the local ethics committees and the donor 
hearts were approved by the University of Sydney (HREC #7326). All the collections 
were made with written informed consent obtained from each patient prior to surgery 
and from the donors’ next of kin.
Whole Protein Isolation
Frozen tissue was dissected on dry ice and homogenized with RIPA buffer (0.05 M 
C4H11NO3·HCl pH 8.0, 0.15 M NaCl, 1% IGEPAL CA-630, 0.5% sodium deoxycholate, 1% 
sodium dodecyl sulfate) using a Tissuelyser II (Qiagen). The lysates were centrifuged 
and the supernatant was collected and passed through an insulin syringe (Becton 
Dickinson Microlance needle, 25 gauge). Whole protein lysate was mixed with the 4× 
Laemmli sample buffer (8% sodium dodecyl sulfate, 40% glycerol, 0.04% bromophenol 
blue, 0.240 M C4H11NO3·HCl pH 6.8, 10 mM β-mercaptoethanol, 0.01 M NaF, 0.001 
M Na3VO4, cOmplete mini protease inhibitor cocktail (Roche)), boiled for 5 min and 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Electrophoresis and Western Blots
Equal amounts of protein (10 µg) were separated on pre-cast SDS-PAGE 4–12% 
criterion gels (Bio-Rad) and transferred onto nitrocellulose membranes (Bio-Rad). 
The membranes were blocked in 5% skim milk/1× TBST for 1 h at room temperature 
and incubated overnight at 4 °C with the following primary antibodies in 3% BSA/1× 
TBST: mouse anti-acetylated α-tubulin (T7451, Sigma-Aldrich, Saint Louis, MO, USA, 
mouse anti-α-actinin (A7811, Merck KGaA, Darmstadt, Germany), mouse anti-HSPA1 
(ADI-SPA-810, Enzo Life Sciences, Zandhoven, Belgium), mouse anti-HSPA2 (66291-1, 
Proteintech Group, Rosemont, IL, USA), mouse anti-HSPB1 (ADI-SPA-800, Enzo Life 
Sciences, Zandhoven, Belgium), rabbit anti-HSPB5 (ADI-SPA-223, Enzo Life Sciences, 
Zandhoven, Belgium), rabbit anti-HSPB7 (ab150390, Abcam, Cambridge, UK), rabbit 
anti-HSPD1 (ADI-SPA-805, Enzo Life Sciences, Zandhoven, Belgium), mouse anti-
GAPDH (10R-G109a, Fitzgerald Industries International, Acton, MA, USA), mouse anti-
LC3B (#2775, Cell Signaling Technology, Danvers, MA, USA), rabbit anti-p62 (#5114, 
Cell Signaling Technology), mouse anti-α-tubulin (T9026, Sigma-Aldrich), and rabbit 
anti-ubiquitin (#3933, Cell Signaling Technology). The membranes were incubated for 
1 h at room temperature with horseradish peroxidase-conjugated secondary antibody 
(DakoCytomation, Santa Clara, CA, USA), raised in goat, in 3% BSA/1x TBST. Signals 
were detected by Amersham Imager 600 (GE Healthcare, Chicago, IL, USA) and 
quantified by densitometry (ImageQuant TL, GE Healthcare). To correct for loading 
differences, protein amounts were expressed relative to GAPDH.
Statistical Analyses
Data were analyzed with SPSS Statistics version 22.0 for Windows (IBM Corporation, 
Armonk, NY, United States of America) and GraphPad Prism version 7.0 (GraphPad 
Software Inc., San Diego, CA., United States of America). Data in figures are presented 
as means ± standard errors of the mean (SEM) per group and in the text, data are 
presented as means ± standard deviations (SD). The distribution of each data set was 
determined by Q-Q plots and then double checked by Kolmogorov-Smirnov and 
Shapiro Wilk tests after data collection was completed. Normally distributed data 
were analyzed with unpaired t-test (comparing 2 groups) and ordinary one-way ANOVA 
(comparing > 2 groups) with Tukey’s multiple comparisons post-hoc test (comparing ≤ 
3 groups) and Dunnett’s multiple comparisons post-hoc test (comparing > 3 groups). 
To analyze non-parametric data, the Mann-Whitney U test (comparing 2 groups) and 
the Kruskal-Wallis test with Dunn’s multiple comparisons post-hoc test (comparing 
> 2 groups) were used. A two-sided p < 0.05 was considered to indicate statistical 
significance. Multivariate generalized linear model testing (detailed description in 
the Supplementary Materials) was performed to study the main effects of different 
mutation groupings, sex, and age at operation on PQC proteins, which were used as 
dependent variables.
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RESULTS
Changes of Protein Quality Control in HCMSMP and HCMSMN
We investigated the expression levels of key PQC proteins to determine if they were altered 
in patients with HCM at the time of myectomy compared with the levels in LV samples from 
healthy controls. As the mutant sarcomere proteins may directly affect PQC, we used Western 
blots to compare myectomy samples from 38 HCMSMP and 14 HCMSMN patients with LV tissue 
from nine healthy controls that were age- and sex-matched to the HCM samples (Table 1).
HSPs that Stabilize Target Proteins
Dependent on their function, HSPs were classified in two categories: stabilizing HSPs 
and HSPs with refolding capacity. Stabilizing HSPs (HSPB1 (also known as HSP27), 
HSPB5 (αB-crystallin), HSPB7 (cardiovascular HSP)) have relatively low molecular 
weights (15–30 kDa). They stabilize misfolded proteins using an ATP-independent 
holdase activity, thereby preventing their aggregation (Figure 1A). Compared to 
controls, the HCMSMP samples expressed significantly higher levels of HSPB1 and 
HSPB7, while HSPB5 appeared to be unaltered (Figure 1C; Table 2).
We then quantified the protein levels of these stabilizing HSPs (HSPB1, HSPB5 and 
HSPB7) in HCMSMN samples. Only HSPB7 was significantly higher in HCMSMN compared 
to controls (Figure 1C; Table 2). Despite this, there were no significant differences in 
stabilizing HSPs levels between HCMSMP and HCMSMN.
TABLE 2. Overview of results on statistical testing for differences between controls, HCMSMP and HCMSMN
Adjusted p Value after Post-Hoc Testing






HSPB1 Kruskal-Wallis 0.0019 0.0018 0.2113 0.3302
HSPB5 Ordinary one-way ANOVA 0.1297 0.1090 0.3807 0.8174
HSPB7 Kruskal-Wallis 0.0060 0.0048 0.0341 >0.9999
Refolding HSPs
HSPD1 Ordinary one-way ANOVA 0.0004 0.0003 0.0530 0.2123
HSPA1 Kruskal-Wallis 0.3636 0.6382 >0.9999 >0.9999
HSPA2 Ordinary one-way ANOVA 0.0101 0.0071 0.1008 0.7334
Protein degradation
Ubiquitin Kruskal-Wallis 0.2159 0.3094 >0.9999 0.9890
p62 Ordinary one-way ANOVA 0.1087 0.5822 0.7531 0.1046
LC3BII Kruskal-Wallis 0.0451 0.0384 0.2455 >0.9999
Tubulin network
α-tubulin Ordinary one-way ANOVA <0.0001 <0.0001 0.0119 0.0019
Acetylated
α-tubulin
Kruskal-Wallis <0.0001 <0.0001 0.0451 0.0516




FIGURE 1. Stabilizing HSPs. (a) Under stress conditions when native proteins are destabilized 
and begin to unfold, stabilizing HSPs dissociate from homo- and/or heterogeneous oligomeric 
complexes into dimers to bind these partially misfolded proteins. Thereby, stabilizing HSPs 
prevent the aggregation of misfolded proteins. Figure reproduced and adapted with permission 
from Dorsch, L.M. et al., Pflügers Archiv–European Journal of Physiology; published by Springer 
Berlin Heidelberg, 2018. (b) Representative blot images for HSPB1, HSPB5, and HSPB7 expres-
sion. (c) Higher levels of HSPB1 and HSPB7 in HCMSMP (n = 38) compared to controls. Higher 
HSPB7 levels in HCMSMN (n = 12) compared to controls (n = 9; average is shown as dotted line). 
HSPB1 and HSPB5 protein levels were not different in HCMSMP (n = 14) compared to controls. 
There were no significant differences between HCMSMP and HCMSMN. Each dot in the scatter 
plots represents an individual sample. *p < 0.05 and **p < 0.01 versus controls.
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HSPs that Refold Target Proteins
Next we investigated the expression levels of HSPD1 (HSP60), HSPA1 (HSP70 and 
HSP72) and HSPA2 (HSP70-2) that have an ATP-dependent folding activity. These HSPs 
have molecular weights >30 kDa and either refold misfolded proteins or assist in their 
degradation. HSPD1 is mainly located in mitochondria while HSPA1 and HSPA2 are 
cytosolic, but when they are exposed to heat stress, both translocate to the nucleus 
[60,61]. Compared to controls, significantly higher levels of HSPD1 and HSPA2 were 
observed in HCMSMP samples, while HSPA1 levels were not significantly changed. Levels 
of HSPs with a refolding capacity were not significantly different in HCMSMN compared 
to controls, although HSPD1 and HSPA2 showed a trend to higher levels. There were 
no significant differences in HSPs with a refolding capacity between the two HCM 
groups (Figure 2; Table 2).
Degradation of Proteins
PQC is also involved in the degradation of proteins and therefore levels of 
ubiquitination, p62 and LC3BII were assessed. The antibody used for ubiquitin 
recognizes polyubiquitinated proteins without distinguishing between K48-linked 
polyubiquitin chains (predominantly targeted by proteasomal degradation) and 
K63-linked polyubiquitin chains (targeted by autophagic degradation) [62]. Levels of 
ubiquitin and the ubiquitin-binding autophagic adaptor protein p62 were unaltered in 
both HCM groups compared to controls. Levels of the autophagosome marker LC3BII 
were significantly higher in HCMSMP compared to controls, while only some samples 
of the HCMSMN group had higher levels of LC3BII (Figure 3, Table 2).
To ensure that the significant differences detected by ANOVA testing were not related 
to differences in age and/or sex of the myectomy patients, we performed multivariate 
testing (Wilks’ Lambda test). This test uses age, sex and the HCM grouping (controls, 
HCMSMP and HCMSMN) as the effects and the HSPs, ubiquitination, p62, and LC3BII as 
dependent variables. We found an overall significant difference in the levels of key 
PQC players based on the different mutation groups (Table 3), while sex and age at 
operation had no significant effect on levels of key PQC players. To determine which 
of the individual key PQC players differed among groups when taking into account 
sex and age, we performed tests for between-subjects effects. This test revealed 




FIGURE 2. HSPs with a refolding capacity. (a) HSPs with ATPase activity and stabilizing HSPs 
bind to the misfolded protein to stabilize and further process it. HSPs with a refolding capac-
ity either refold the misfolded protein to its native structure or, if refolding is impossible, the 
HSPs assist in the degradation pathways to degrade the misfolded protein. Figure reproduced 
and adapted with permission from Dorsch, L.M. et al., Pflügers Archiv—European Journal of 
Physiology, published by Springer Berlin Heidelberg, 2018. (b) Representative blot images for 
HSPD1, HSPA1, and HSPA2 expression. (c) Higher levels of HSPD1 and HSPA2 in HCMSMP (n = 38) 
compared to controls. HSPs with refolding capacity were unaltered in HCMSMN (HSPD1, HSPA1: 
n = 14; HSPA2: n = 12) compared to controls. There were no significant differences between 
HCMSMP and HCMSMN. Each dot in the scatter plots represents an individual sample. **p < 0.01 
and ***p < 0.001 versus controls.
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FIGURE 3. Degradation pathways. (a) Misfolded proteins with polyubiquitin chains linked via 
lysine 48 (K48) are mainly degraded by the proteasome. Misfolded proteins carrying K63-linked 
polyubiquitin chains and aggregated proteins enter the autophagic pathway. Figure reproduced 
and adapted with permission from Dorsch, L.M. et al., Pflügers Archiv‒European Journal of Phys-
iology; published by Springer Berlin Heidelberg, 2018. (b) Representative blot images for ubiqui-
tin, p62, and LC3BII expression. (c) Protein levels of ubiquitin and p62 did not differ between HCM 
and controls samples. Higher levels of LC3BII in HCMSMP (n = 38) compared to controls. There 
were no significant differences between HCMSMP and HCMSMN (ubiquitin, p62: n = 12; LC3BII: 
n = 13). Each dot in the scatter plots represents an individual sample. *p < 0.05 versus controls.
TABLE 3. Multivariate Tests a: HCM grouping (controls, HCMSMP, and HCMSMN), sex and age at 
operation.
Effect Value F Hypothesis df Error df Significance Partial eta Squared
Intercept 0.260 14.561 b 9.000 46.000 <0.001 0.740
HCM 
grouping
0.479 2.278 b 18.000 92.000 0.006 0.308
Sex 0.754 1.664 b 9.000 46.000 0.126 0.246
Age at 
operation
0.717 2.016 b 9.000 46.000 0.059 0.283
a Design: Intercept and HCM grouping and sex and age at operation; b exact statistic; F: F statistic 
for the given effect and test statistic; Hypothesis df: Number of degrees of freedom in the model; 
Error df: Number of degrees of freedom associated with the model errors; Partial eta squared: 




TABLE 4. Tests for between-subjects: HCM grouping (controls, HCMSMP, HCMSMN) as an effect and 
correction for differences in sex and age at operation.









HSPB1 23.286 2 11.643 6.0313 0.004 0.182 0.261
HSPB5 1.777 2 0.889 2.495 0.092 0.085 0.088
HSPB7 9.725 2 4.863 3.319 0.044 0.109 0.162
Refolding HSPs
HSPD1 11.104 2 5.552 10.543 <0.001 0.281 0.323
HSPA1 0.258 2 0.129 0.981 0.381 0.035 0.055
HSPA2 1.724 2 0.862 5.114 0.009 0.159 0.171
Protein degradation
Ubiquitin 1.433 2 0.716 2.101 0.132 0.072 0.097
p62 0.733 2 0.367 2.498 0.092 0.085 0.122
LC3BII 12.839 2 6.420 2.276 0.112 0.078 0.111
df: Number of degrees of freedom in the model; F: F statistic for the given effect and test statistic; 
Partial eta squared: estimate of effect size; R squared: proportion of the variance in the dependent 
variable that is predictable from the independent variable; Bonferroni correction: statistical 
significance at p < 0.0056 (α/9 = 0.05/9 = 0.0056).
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Since we found between-subjects main effects, we performed a contrast analysis to 
determine significant pairwise differences between controls and the two HCM patient 
groups corrected for age and sex. A simple main effects analysis revealed significantly 
higher levels of HSPB1, HSPD1 and HSPA2 in HCMSMP compared to controls (Table 5), 
while a trend to higher levels of HSPD1 was observed in HCMSMN.
Overall, our analyses showed increased levels of several HSPs in HCMSMP and HCMSMN 
compared to controls, while no significant differences between HCMSMP and HCMSMN 
were observed.
Changes of Protein Quality Control: HCM Disease Mechanism
All the studied HCMSMP patients were heterozygous for the mutation, implying the 
potential to produce either or both the mutant and wild-type protein [14]. Either the 
expression of the mutant protein, which above a threshold (the ‘poison polypeptide’ 
mechanism) level might become toxic or have an inability to upregulate the haplotype 
protein levels to meet the needs of the heart (the ‘haploinsufficiency’ mechanism) 
might underlie HCM [14]. Truncation and missense MYBPC3 mutations usually involve 
haploinsufficiency as the disease mechanism since total cMyBP-C protein level is lower 
and the mutant protein has not been detected in human myectomy samples [13,63].
We determined whether key PQC players were differently changed in samples with 
haploinsufficiency (HI) and poison polypeptide (PP) by comparing 19 MYBPC3 mutation 
samples (HCMHI) with 19 HCMSMP samples carrying a missense mutation (HCMPP). 
Proteomics analysis using mass spectrometry revealed significantly lower cMyBP-C 
protein levels in the HCMHI samples compared to the HCMPP patients, consistent with 
a protein haploinsufficiency mechanism (Figure 4) [64]. No significant differences in 
PQC components were observed between HCMHI and HCMPP (Figure 5, Table 6).
FIGURE 4. cMyBP-C haploinsufficiency. Mass spectrometry-based proteomics analysis revealed 
lower levels of cMyBP-C in HCMHI (n = 19) compared to controls (n = 5) and HCMPP (n = 18). Each 
dot on the scatter plot represents an individual sample. ***p < 0.001 versus controls and ###p 
< 0.001 versus HCMPP.
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FIGURE 5. Pathomechanism of HCM and key PQC players. (a) Stabilizing HSPs (HSPB1, HSPB5, 
HSPB7), (b) HSPs with refolding capacity (HSPD1, HSPA1 HSPA2) and (c) degradation mark-
ers (ubiquitin, p62, LC3BII) were not significantly different between HCMHI (n = 19) and HCMPP 
(n = 19). Each dot in the scatter plots represents an individual sample. Figure reproduced and 
adapted with permission from Dorsch, L.M. et al., Pflügers Archiv‒European Journal of Physiol-
ogy; published by Springer Berlin Heidelberg, 2018.
Microtubule Network
Microtubule-based transport of proteins is required for autophagy and is thus an 
essential part of PQC. Acetylation of α-tubulin is associated with stable microtubules 
and is used as a marker of their stability [65,66]. Mouse models of familial HCM showed 
higher levels of acetylated α-tubulin [67]. Compared to controls, α-tubulin expression 
levels were significantly higher in both HCMSMP and HCMSMN (Figure 6A,B; Table 2). 
In addition, acetylation of α-tubulin was significantly higher in both HCM patient 
groups compared to controls (Figure 6A,B). The increases in the levels of α-tubulin 
and acetylated α-tubulin were significantly higher in HCMSMP compared to HCMSMN.
When comparing mutation types, significantly higher levels of α-tubulin and acetylated 
α-tubulin were observed in HCMHI compared to HCMPP (Figure 6C, Table 6). The levels 
of acetylated α-tubulin significantly correlated with α-tubulin (Figure 6D), which is in 
line with the observation that acetylation of α-tubulin compartmentalized on the stable 
microtubules. Moreover, a significant inverse linear correlation was present between 
the cMyBP-C protein level and α-tubulin in HCM with a sarcomere gene mutation 
(Figure 6E). Overall, these data show that the presence of a sarcomere mutation 




TABLE 6. Overview of results on statistical testing for differences between HCMHI and HCMPP.
Proteins Statistical Test p Value
Stabilizing HSPs
HSPB1 Unpaired t-test 0.4040
HSPB5 Unpaired t-test 0.6236
HSPB7 Mann-Whitney U test 0.4181
Refolding HSPs
HSPD1 Unpaired t-test 0.1712
HSPA1 Unpaired t-test 0.8044
HSPA2 Unpaired t-test 0.2096
Protein degradation
Ubiquitin Unpaired t-test 0.6099
p62 Unpaired t-test 0.5868
LC3BII Unpaired t-test 0.4297
Tubulin network
α-tubulin Unpaired t-test 0.0074
Acetylated α-tubulin Unpaired t-test 0.0079
Acetylated α-tubulin/α-tubulin Mann-Whitney U test 0.1629
p < 0.05 is considered to be significant.
Strong Correlation of HSPs with α-tubulin
Since the PQC is strongly linked to the microtubules network, we performed 
multivariate testing (Wilks’ Lambda test) using levels of α-tubulin, sex, and age at 
operation as effects and the HSPs, ubiquitination, p62, and LC3BII as dependent 
variables. There was an overall statistically significant difference in the levels of key 
PQC players based on the α-tubulin levels (Table 7).
To determine which of the key PQC players differed when α-tubulin levels changed, we 
performed tests for between-subjects effects. This test revealed that α-tubulin had a 
significant effect on all the measured HSPs, but not on the degradation markers (Table 
8). The correlation of HSPs and α-tubulin levels is visualized in Figure S3.
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FIGURE 6. Pathomechanism of HCM and acetylation of α-tubulin. (a) Representative blot images 
for α-tubulin and acetylated α-tubulin. (b) Higher levels of α-tubulin and acetylated α-tubulin 
in HCMSMP (n = 38) and HCMSMN (α-tubulin: n = 14; acetylated α-tubulin: n = 12) compared to 
controls. Significant difference of α-tubulin levels between HCMSMP and HCMSMN (##p < 0.01). (c) 
Higher levels of α-tubulin and acetylated α-tubulin in HCMHI (n = 19) than HCMPP (n = 19). (d) The 
levels of α-tubulin correlated well with acetylated α-tubulin (e) Significant inverse linear correla-
tion of α-tubulin with cMyBP-C. Controls = open squares, HCMSMP = filled circles, HCMSMN = open 
circles, HCMHI = filled triangles, HCMPP = filled rhomboids. Each dot in the scatter plots and the 
correlation analyses represents an individual sample. *p < 0.05 and ***p < 0.001 versus controls 




TABLE 7. Multivariate Tests a: α-tubulin (all samples), sex, and age at operation.
Effect Value F Hypothesis df Error df Significance Partial eta Squared
Intercept 0.389 8.186 b 9.000 47.000 <0.001 0.611
α-tubulin 0.427 7.009 b 9.000 47.000 <0.001 0.573
Sex 0.774 1.523 b 9.000 47.000 0.168 0.226
Age at 
operation
0.791 1.384 b 9.000 47.000 0.223 0.209
a Design: Intercept and α-tubulin and sex and age at operation; b exact statistic; F: F statistic for the 
given effect and test statistic; Hypothesis df: Number of degrees of freedom in the model; Error 
df: Number of degrees of freedom associated with the model errors; Partial eta squared: estimate 
of effect size; p < 0.05 is considered to be significant.
TABLE 8. Tests for between-subjects: α-tubulin as an effect and correction for differences in sex 
and age at operation.









HSPB1 38.460 1 38.460 23.663 >0.001 0.301 0.368
HSPB5 3.630 1 3.630 11.485 0.001 0.173 0.176
HSPB7 14.246 1 14.246 10.504 0.002 0.160 0.209
Refolding HSPs
HSPD1 10.273 1 10.273 19.305 >0.001 0.260 0.303
HSPA1 1.370 1 1.370 12.580 0.001 0.186 0.203
HSPA2 1.723 1 1.723 10.410 0.002 0.159 0.171
Protein degradation
Ubiquitin 0.419 1 0.419 1.187 0.281 0.021 0.047
p62 0.418 1 0.418 2.792 0.100 0.048 0.087
LC3BII 3.849 1 3.849 1.312 0.257 0.023 0.058
df: Number of degrees of freedom in the model; F: F statistic for the given effect and test statistic; 
Partial eta squared: estimate of effect size; R squared: proportion of the variance in the dependent 
variable that is predictable from the independent variable; Bonferroni correction: statistical 
significance at p < 0.0056 (α/9 = 0.05/9 = 0.0056).
DISCUSSION
The incomplete penetrance, age-related onset and the large clinical variability in 
disease severity imply a complex HCM pathophysiology mechanism. Patients with 
a sarcomere mutation have a particularly higher risk for adverse outcomes. The 
underlying causes for the difference in disease between HCMSMP and HCMSMN remain 
unclear.
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Here, we determined the protein levels of key PQC players, including HSPs and 
degradation markers, and the acetylation of α-tubulin by Western blot analysis in 
a large set of cardiac samples from HCMSMP and HCMSMN patients to define PQC 
changes in HCM at the time of myectomy, and identified if the presence of a sarcomere 
mutation mediates changes in PQC mechanisms and tubulin network. One of the 
limitations of the current study was that patients had a severe phenotype with LVOT 
obstruction. Therefore, this group may not be representative for all patients with HCM.
The main findings of our PQC assessment were that: 1) several HSPs and autophagy 
markers were higher in HCM compared to controls, but there are no major differences 
between HCMSMP and HCMSMN or mutation type (haploinsufficiency versus poison 
polypeptide) at the time of myectomy, 2) after correction for sex and age at operation, 
the major increases in HCMSMP compared to controls were observed in the stabilizing 
HSPB1 and the refolding HSPD1 and HSPA2, 3) the most significant increase compared 
to control samples was observed in the levels of α-tubulin and acetylated α-tubulin, 
with significant differences between the mutation groups: HCMHI > HCMPP > HCMSMN, 
and 4) the levels of α-tubulin significantly correlated with the levels of acetylated 
α-tubulin and all the HSPs (Figure 7).
Overall, our analyses indicate that carrying a HCM-causing mutation affects PQC and 
α-tubulin acetylation. We propose that reduced levels of cMyBP-C caused by MYBPC3 
mutations trigger HSPs and α-tubulin acetylation, and may present a pathomechanism 
in cMyBP-C haploinsufficiency-mediated HCM. The possible impact of the observed 
PQC changes is discussed below.
Elevated Levels of HSPs in Human HCM
We identified higher levels of HSPB1, HSPD1, and HSPA2 in HCMSMP compared to 
controls, which could not be explained by differences in sex and age at operation 
(Table 5). Our findings are in line with studies in human end-stage heart failure studies 
samples, which showed increases in HSPD1 and HSPB1 compared to controls [68].
HSPB1 is implicated in different cardio-protective processes involving interception 
of misfolded proteins, cytoskeletal organization, anti-apoptotic and anti-oxidant 
properties [69]. Therefore, its expression may improve the resistance of tissue exposed 
to stress and injuries [70]. While moderate cardiac expression of HSPB1 protects 
against doxorubicin-induced cardiac dysfunction through anti-oxidative stress, reports 
on the effects of HSPB1 overexpression have been inconsistent [71]. Overexpression 
of HSPB1 conferred protection against myocardial ischemia-reperfusion injury [72], 
whereas overexpression of HSPB1 caused reductive stress and cardiomyopathy in 
another study [73]. Further experiments are needed to clarify if the observed increase 




FIGURE 7. Schematic representation of PQC and microtubular system assessment in HCM. Our 
analyses show that HSPB1, HSPD1 HSPA2, α-tubulin and acetylated α-tubulin were increased in 
HCM, especially when a sarcomere mutation is present, while HSPB5, HSPB7, HSPA1 and degra-
dation markers are not changed in HCM compared to controls. Levels of α-tubulin (orange balls) 
and acetylated α-tubulin (small yellow balls attached to α-tubulin in the lumen of polymerized 
microtubules (blue and orange balls)) were more increased when haploinsufficiency (HI), char-
acterized by lower levels of cardiac myosin-binding protein-C (green lines), was the underlying 
pathomechanism instead of poison polypeptides (PP). =: similar to controls; ↑: significantly 
increased compared to controls; ↑↑: highly significantly increased compared to controls; ↓: 
significantly decreased compared to controls.
HSPD1 fulfills multiple tasks in a cell by refolding key proteins after their import into 
the mitochondria, transporting proteins between the mitochondrial matrix and the 
cytoplasm of the cell, and binding to cytosolic pro-apoptotic proteins to sequester 
them [74]. Upregulation of HSPD1 due to mitochondrial impairment is suggested to 
be an indicator of mitochondrial stress [75]. A total of 15–20% of HSPD1 is located at 
extra-mitochondrial sites, suggesting important physiological roles at other locations 
[61]. In human end-stage heart failure, HSPD1 localizes to the plasma membrane, 
thereby losing anti-apoptotic and protective effects and becoming detrimental to 
the cell [76]. Impairment of HSPD1-mediated anti-stress response has been reported 
in dilated cardiomyopathy (DCM) which progressed to end stage heart failure [77]. 
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Here, we identified higher levels of HSPD1, which may indicate mitochondrial stress, 
as has been reported in HCM [78].
The Western blot analysis showed higher levels of HSPA2 in HCMSMP compared to 
controls. In our mass-spectrometry-based proteomics study, HSPA2 was highly 
upregulated in cardiac disease (Figure 8A) [64]. HSPA2 has been reported in heart 
tissue and low expression was identified in fibroblasts [60,79]. Recently, HSPA-family 
chaperones have been suggested to interact with cMyBP-C to regulate its turnover 
[80]. Moreover, a significant inverse linear correlation was present between cMyBP-C 
protein levels and HSPA2 (Figure 8B). Therefore, HSPA2 may be an additional regulator 
of cMyBP-C. Further experiments are warranted to explain the role of HSPA2 in 
haploinsufficiency for cMyBP-C.
FIGURE 8. Upregulated HSPA2 in HCM in proteomics screen. (a) In a mass-spectrometry based 
proteomics study, HSPA2 levels were higher in HCMHI (n = 20) and HCMothers (n = 30) samples, 
including HCMPP and HCMSMN, compared to controls (n = 8). (b) Significant inverse correlation 
of HSPA2 levels, determined by Western blot analysis with cMyBP-C. Controls = open squares, 
HCMHI = filled triangles, HCMPP = filled rhomboids, HCMSMN = open circles, HCMothers = hexagons. 
Each dot in the scatter plots and correlation analysis represents an individual sample. ***p < 
0.001 versus controls.
In contrast, the levels of the HSPB5 and HSPA1 in HCM samples were not different 
compared to controls after adjusting for sex and age differences. Several studies 
have shown that HSPB5 and HSPA1 are both increased early in response to acute 
hypertrophic signaling, but with opposite functions. While HSPB5 is involved in 
counteracting acute cardiac remodeling by suppressing hypertrophic signaling 
pathways, HSPA1 supports pro-hypertrophic signaling pathways [81,82]. The increase 
of HSPA1 was transient and attenuated 14 days after isoproterenol-infusion in a 
mouse model for cardiac hypertrophy [82]. Consistent with our findings in myectomy 
samples from patient with advanced disease, HSPA1 levels were not changed in septal 
myectomy samples of HCM patients and end-stage heart failure patients compared 
to controls [68,80]. Increased HSPA1 in the heart protects against acute cardiac stress, 




Based on these studies, we propose that HSPB5 and HSPA1 levels were not changed 
in the HCM myectomy samples because of persistent chronic hypertrophic stimuli 
leading to their blunted response. Further research is warranted to investigate if the 
failure to increase HSPB5 implies a loss of responsiveness at advanced disease stage 
because HSPB5 seems to play a beneficial role in hypertrophic signaling.
Protein Degradation in HCM
Defects in the turnover of key sarcomere proteins may account for both hypertrophic 
and functional defects [9]. UPS dysfunction is characterized by the accumulation of 
ubiquitinated proteins, altered proteasome activity, and changes in expression of UPS 
proteins or E2 and E3 enzymes [84]. Upon correction for sex and age, no significant 
changes were observed in the levels of degradation-associated markers in HCM, such 
as HSPB7, ubiquitin, p62 and LC3BII. Compared to the protein folding-supportive 
HSPB1 and HSPB5, HSPB7 plays a critical role in preventing protein aggregation 
[85]. Genetic variants in HSPB7 have been associated with advanced heart failure 
and systolic dysfunction [86]. In a zebrafish model, HSPB7 was involved in early post-
damage processing of large cytoskeletal proteins and the loss of HSPB7 function was 
accompanied by an increased damaged protein load, protein aggregation and a risk 
of cardiomyopathy [87]. Due to the use of an antibody recognizing both K48- and 
K63-linked polyubiquitinated chains, we do not know if the ratio between K48- and 
K63-linked polyubiquitinated proteins was altered in HCM. Therefore, we cannot draw 
any conclusion about the functionality of the proteasome, which would be indicated 
by an increase in K48-linked polyubiquitinated proteins. LC3BII and p62 are both 
markers for autophagosomes because in selective autophagy, the cargo adapter 
protein p62 links polyubiquitinated proteins to the autophagic machinery via LC3 
[88]. We did not find a change in autophagosome markers, but this finding does not 
exclude the prospect that the autophagic flux might be impaired. Autophagy has 
been implicated in the pathogenesis of a wide range of cardiac pathologies [62,88]. 
Pre-clinical models of pressure overload-induced cardiac hypertrophy showed that the 
increase of autophagic flux correlated with the degree of hypertrophy and therapeutic 
inhibition of autophagy was accompanied by reduced amount of fibrosis [89].
Our analysis of protein degradation markers indicates that there is no enhancement 
of protein degradation pathways at the time of myectomy. This may indicate that 
boosting protein degradation may actually represent a treatment option to prevent 
cardiac dysfunction and remodeling.
Increased Mutation-dependent Proliferation and Acetylation of α-tubulin
Our protein analyses revealed significantly increased levels of α-tubulin in both HCM 
groups (Figure 6A), which correlated with an increase in α-tubulin acetylation and 
the levels of all HSPs. Changes of microtubules distribution occurred at the onset of 
hypertrophy [90]. In chronically hypertrophied hearts, the increase of microtubules 
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has been shown to be a major cause of contractile defects [91]. Two different 
hypotheses may explain microtubule densification: (1) microtubules may be involved 
in myofibrillogenesis and an increase in microtubules would be required when new 
myofibrils are formed in hypertrophied cardiomyocytes, and (2) microtubules may 
be intracellular compression-bearing elements needed to cope with increased 
contractile stress on cardiomyocytes [92,93]. In failing human hearts, the accumulation 
of microtubules impedes sarcomere motion and contributes to a decreased ventricular 
compliance [94]. Our results are in line with literature, showing an increase in α-tubulin 
in the HCM myocardial tissue [95]. The underlying pathomechanism seems to have an 
effect on extent of increase in α-tubulin and acetylated α-tubulin, since we observed 
the largest increase in samples with haploinsufficiency for cMyBP-C.
An intact microtubule-based cytoskeleton contributes to the stabilization of myofibril 
structure in the cardiomyocytes and HSPs may preserve this relationship [96]. Post-
chaperonin tubulin-folding cofactors, such as HSPs and other tubulin-associated proteins, 
regulate the synthesis, transport, and storage of α- and β-tubulin [97]. For instance, 
HSPA1 binds to native tubulin dimers and microtubules to assist in proper tubulin folding 
[98]. In addition, HSPB5 prevents the aggregation of tubulin and the chaperone activity 
is accompanied by the formation of large complexes between HSPB5 and tubulin [99]. 
We identified that α-tubulin level significantly correlates with all the investigated HSPs.
In addition to HSPs, acetylation of α-tubulin was higher in both HCM groups (Figure 
6B). Acetylation of α-tubulin directly tunes the compliance and resilience from 
mechanical breakage to ensure the persistence of long-lived microtubules [100]. 
Moreover, acetylation of α-tubulin most often compartmentalizes on the stable 
microtubules and is suggested to increase the assembly of autophagic cargo along 
microtubules, thereby initiating augmented autophagic degradation in the heart 
[101,102]. Interestingly, there is a strong linear relation between acetylated and total 
α-tubulin levels (Figure 6D). This may suggest hyperacetylation of α-tubulin, which is a 
common response to several cellular stresses. For example, acetyltransferase induction 
is triggered by the release of mitochondrial reactive oxygen species (ROS) and by AMP 
kinase [103,104]. Noteworthily, the underlying pathomechanism (HI versus PP) seems 
to have an effect on the extent of the increase in α-tubulin and the acetylation of 
α-tubulin, since we observed the largest increase in samples with haploinsufficiency 
for cMyBP-C. As such, our analyses suggest that proliferation of the microtubular 
network represents a pathomechanism in HI-mediated HCM. Based on previous 
studies [100–104], we propose that the increased tubulin network may function to 
maintain cellular stability and enhance autophagic flux of damaged proteins, while 
it may impair contractile function [95,105]. Future studies are warranted to establish 
this link (cause-consequence) between reduced cMyBP-C protein levels, increased 
α-tubulin acetylation and cardiomyocyte contractile function and hypertrophy that may 





We observed large inter-individual differences in various key PQC players and tubulin 
networks, especially in the presence of a sarcomere mutation. This variability may be 
explained by the large variability among HCM-causing mutations, which may all have 
a distinct effect on cellular PQC. Most of the mutation sites of proteins affect stability 
and aggregation but rarely its function [106]. This concept is supported by the fact 
that HCMHI mutations cause a rather heterogeneous cMyBP-C haploinsufficiency, with 
some samples having relatively low cMyBP-C, and others having still relatively high 
protein level. The loss of cMyBP-C levels correlates very well with α-tubulin, thereby 
supporting the diverse response to a change in sarcomere protein composition in the 
case of HCMHI. The microtubule response correlates significantly with the expression 
level of cMyBP-C, and may represent a direct compensation for the loss of cMyBP-C 
as cMyBP-C is known to have a central regulatory role in myofibril development 
and stability [107]. In line with this, reduced myofibril density was detected in septal 
myectomy samples from HCMSMP patients compared to HCMSMN patients [18]. While 
the excessive microtubular response to cMyBP-C haploinsufficiency may be an 
attempt to maintain myofibril stability, it may aggravate cardiac dysfunction by altering 
cytoskeletal mechanical properties [95,105].
CONCLUSIONS
In summary, our data show that the hypertrophied muscle of HCM patients is 
characterized by an increased and stabilized tubular network which may be an adaptive 
response to cardiomyocyte growth. While this compensatory response may aid to 
stabilize cardiomyocyte architecture, this structural adaption may contribute to a 
reduced function of the HCM myocardium.
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Background: Hypertrophic cardiomyopathy (HCM) is the most common genetic heart 
disease. While ~50% of HCM patients carry a sarcomere gene mutation (HCMSMP), the 
genetic background is unknown in the other half of the patients (sarcomere mutation-
negative, HCMSMN). Genotype-specific differences have been reported in cardiac 
function. Moreover, HCMSMN patients have later disease onset and better prognosis 
than HCMSMP patients. To define if genotype-specific derailments at the protein level 
may explain the heterogeneity in disease development, we performed a proteomic 
analysis in cardiac tissue from a clinically well-phenotyped HCM patient group.
Methods: A proteomics screen was performed in cardiac tissue from 39 HCMSMP, 
11 HCMSMN patients and 8 non-failing controls. HCM patients had obstructive 
cardiomyopathy with left ventricular outflow tract obstruction and diastolic 
dysfunction. A novel MYBPC32373insG mouse model was used to confirm functional 
relevance of our proteomic findings.
Results: In all HCM patient samples we found lower levels of metabolic pathway 
proteins and higher levels of extracellular matrix proteins. Levels of total and 
detyrosinated α-tubulin were markedly higher in HCMSMP than in HCMSMN and controls. 
Higher tubulin detyrosination was also found in two unrelated MYBPC3 mouse models 
and its inhibition with parthenolide normalized contraction and relaxation time of 
isolated cardiomyocytes.
Conclusion: Our findings indicate that microtubules and especially its detyrosination 
contribute to the pathomechanism of HCMSMP patients. This is of clinical importance 
since it represents a potential treatment target to improve cardiac function in HCMSMP 
patients, whereas a beneficial effect may be limited in HCMSMN patients.
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CLINICAL PERSPECTIVE
What is new?
This study shows that the most prominent derailment at the protein level in cardiac 
tissue obtained during myectomy of HCM patients in an advanced disease stage is 
reduced levels of proteins involved in metabolic pathways. This is common for all 
genotypes.
The study further demonstrates that increased levels of detyrosinated tubulin are 
specific for sarcomere mutation-positive HCM patients.
The increase in tubulin detyrosination is resembled in a mouse model with the Dutch 
founder mutation MYBPC32373insG. Pharmacological inhibition of tubulin detyrosination 
normalizes contractile function in isolated cardiomyocytes.
What are the clinical implications?
Recent and ongoing clinical trials investigate the therapeutic effect of targeting 
the energy metabolism in HCM patients which is supported by our proteomic data 
showing metabolic derailment.
Lowering tubulin detyrosination presents a potential novel treatment strategy that 
may improve contractile function in sarcomere-mutation positive HCM patients. Since 
HCM is characterized by diastolic dysfunction, enhancing cardiomyocyte relaxation 
by lowering detyrosination of microtubules is considered to be beneficial for HCM 
patients.
This study provides evidence that there is a need for genotype-specific treatment in 
HCM. Due to differences in pathomechanism, not every therapeutic strategy may be 





Hypertrophic cardiomyopathy (HCM) is characterized by diastolic dysfunction and 
asymmetric left ventricular (LV) hypertrophy, which lead to LV outflow tract obstruction 
(LVOTO) in the majority of cases1. Mutations in genes encoding sarcomere proteins 
cause HCM and are identified in more than half of the patients (sarcomere mutation-
positive, HCMSMP). The heterogeneity in genetic background of HCM is large with more 
than 1500 identified HCM-causing mutations2. Approximately 80% of mutations are 
located in MYH7 and MYBPC3. Less frequent are mutations in TNNT2 and TNNI33, 
4. Previous research in HCM mouse models and humans showed genotype-specific 
differences in cellular characteristics and cardiac remodeling and function. Gene-
specific differences in cellular redox and mitochondrial function were reported in mice 
harboring a MYH7 or TNNT2 mutation5. In accordance with studies in HCM mouse 
models, studies on patient myectomy samples reported gene-specific differences in 
the response to calcium, ADP, protein kinase A, and length-dependent activation of 
myofilaments compared to non-failing cardiomyocytes6, 7. Also, a comparison of two 
different patient-specific induced pluripotent stem cell-derived cardiomyocyte cell 
lines, carrying either a mutation in MYBPC3 or TPM1, showed differences in calcium 
handling and electrophysiological properties8. These in vitro studies are strengthened 
by clinical patient studies which revealed a more severe decline in myocardial efficiency 
in MYH7 than in MYBPC3 mutation carriers9, accompanied by a different response to 
therapy10. Notably, there is also a large patient population in which a disease-causing 
mutation cannot be identified, the so-called sarcomere mutation-negative patients 
(HCMSMN). While the cause of the disease in these patients is unknown, they present 
with the same clinical phenotype as HCMSMP patients albeit at older age
3. Moreover, 
recent data from the SHaRe registry indicate that HCMSMP have a 2-fold greater risk 
of adverse outcomes than HCMSMN
11. Whereas LVOTO can be invasively corrected 
by surgical myectomy, other symptoms can only be managed by pharmacological 
therapies, which do not halt or reverse cardiac disease1. Knowledge about the cellular 
changes that cause cardiac dysfunction and hypertrophy in HCM patients is needed 
to design new therapies.
The main goal of this study was to define HCM- and genotype-specific derailments 
at the protein level, which may explain the heterogeneity in cardiac characteristics 
and disease initiation and progression. Therefore, we used an unbiased proteomics 
approach in a large number of myectomy samples from a clinically well-characterized 
HCM patient group with (HCMSMP) and without (HCMSMN) sarcomere mutations. We show 
that lower levels of metabolic pathway proteins and higher levels of extracellular matrix 
(ECM) proteins are the most prominent genotype-independent HCM-specific disease 
characteristics at the time of myectomy. However, abundance and detyrosination of 
α-tubulin was significantly higher in HCMSMP than in non-failing (NF) controls, with 
intermediate levels in HCMSMN. Recent studies in human heart failure identified a 
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central role for detyrosinated microtubules in regulating cardiomyocyte function and 
demonstrated the functional benefit upon reversal of this modification12, 13. Our study 
in a European HCM patient cohort and genetic HCM mouse models strengthens the 
concept that targeting the microtubule network represents a therapeutic strategy to 
correct impaired function, and extends it to HCM caused by sarcomere mutations.
METHODS
The proteomics data have been deposited to the ProteomeXchange Consortium 
via the PRIDE partner repository with the dataset identifier PXD012467 and 
are publicly available (http://proteomecentral.proteomexchange.org/cgi/
GetDataset?ID=PXD012467).
Human cardiac samples
Tissue of the IVS of 50 HCM patients was obtained during myectomy surgery to relieve 
LVOTO or after heart transplantation (1 sample, HCM 164). Samples of IVS from 8 
healthy NF donors (5 males, 3 females; mean age 45.9 ± 9.7 years) with no history of 
cardiac abnormalities was obtained from the Sydney Heart Bank (HREC Univ Sydney 
2012/030) and served as controls. The parameters of all HCM and NF individuals 
are summarized in Table I. In this table we organized HCM patients based on their 
genotype into 5 sub-groups: Patients with the Dutch MYBPC3 founder mutation 
(2373insG), where the truncating mutation resulted in MYBPC3 haploinsufficiency14; 
Patients with MYBPC3 mutations other than the 2373insG mutation of which 81.8% were 
truncating mutations as well; Patients with MYH7 mutations; Patients with mutations 
in less frequently affected sarcomere genes (TNNT2, TNNI3 and MYL2); and HCMSMN 
patients. In line with studies in other cohorts15, almost all mutations in MYBPC3 were 
truncating mutations, whereas mutations in other sarcomeric proteins were missense 
except the truncating mutation c.814C>T in TNNT2.
Proteomics analysis
Tissue homogenization
Pulverized frozen tissue was homogenized in 40 μl/mg tissue 1x reducing sample buffer 
(106 mM Tris-HCl, 141 mM Tris-base, 2% lithium dodecyl sulfate (LDS), 10% glycerol, 
0.51 mM EDTA, 0.22 mM SERVA Blue G250, 0.18 mM Phenol Red, 100 mM DTT) using a 
glass tissue grinder. Proteins were denatured by heating to 99°C for 5 min, after which 
samples were sonicated and heated again. Debris was removed by centrifugation at 





Proteins were separated using 1D SDS-PAGE. Samples from each group were loaded 
alternating on the gels to avoid bias. Equal volumes of sample (30 μl protein homogenate 
per sample, containing approximately 20-30 μg of protein) were loaded on a precast 4-12% 
NuPAGE Novex Bis-Tris 1.5 mm mini gel (Invitrogen). Electrophoresis was performed 
at 200V in NuPAGE MES SDS running buffer until the dye front reached the bottom 
of the gel. Gels were fixed in a solution of 50% ethanol and 3% phosphoric acid, and 
stained with 0.1% Coomassie brilliant blue G-250 solution (containing 34% methanol, 3% 
phosphoric acid and 15% ammonium sulfate). Images of all gels are provided in Figure I.
In-gel digestion and nano-LC-MS/MS
Each gel lane was cut into 5 pieces and in-gel digestion was performed as described 
previously16. Samples were measured by LC-MS per gel band starting at the high 
molecular weight (MW) fraction for all samples, before continuing with the next gel 
band until the last (low MW fraction) band. Injections alternated between all different 
group samples to minimize experimental bias between groups. Analysis of the 
experiment was performed as described in Piersma et al17. Peptides were separated 
using an Ultimate 3000 Nano LC-MS/MS system (Dionex LC-Packings, Amsterdam, 
The Netherlands) equipped with a 40 cm x 75 μm ID fused silica column custom 
packed with 1.9 μm ,120 Å ReproSil Pur C18 aqua (Dr Maisch GMBH, Ammerbuch-
Entringen, Germany). Eluting peptides were ionized at a potential of + 2 kV into a Q 
Exactive mass spectrometer (Thermo Fisher, Bremen, Germany). MS/MS spectra were 
acquired at resolution 17,500 (at m/z 200) in the orbitrap using an AGC target value 
of 1x106 charges, a maxIT of 60 ms and an underfill ratio of 0.1%. Dynamic exclusion 
was applied with a repeat count of 1 and an exclusion time of 30 s (additional details 
to in-gel-digestion and nano-LC-MS/MS are provided in the Supplemental Methods).
Data analysis
MS/MS spectra were searched against a Uniprot human reference proteome FASTA 
file (Swissprot_2017_03_human_canonical_and_isoform.fasta, 42161 entries) using 
MaxQuant version 1.5.4.1 (details to search settings are provided in the Supplemental 
Methods). The mass spectrometry proteomics data are provided in Table V and the raw 
data have been deposited to the ProteomeXchange Consortium via the PRIDE18 partner 
repository with the dataset identifier PXD012467. Beta-binominal statistics were used 
to assess differential protein expression between groups, after normalization on the 
sum of the counts for each sample19. Proteins with a p value below 0.05 were considered 
significantly differentially expressed. Proteins which were present in less than 25% of 
the samples or had an average normalized count of less than 1.4 were excluded from 
further functional analysis. Principal component analysis was performed in R. Therefore 
quantile normalization and log2 transformation was performed on the normalized 
counts. The 95th Percentile was taken, the data median centered and the principal 
components calculated. Hierarchical clustering was performed after a statistical multi-
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group comparison. Proteins with a raw p-value <0.05 were selected for the pathway 
analysis. Protein networks were generated utilizing the STRING database (Search Tool 
for the Retrieval of Interacting Genes/Proteins) and visualized with Cytoscape software20. 
Protein interaction networks were generated with ClusterONE and gene ontology (GO) 
analysis was performed using the BiNGO application in cytoscape21, 22. Heatmaps for 
a specific GOs were created with ToppGene Suite23 and Graphpad Prism v7 software. 
Venn diagrams were created with InteractiVenn tool24 and the layout modified if needed.
Animal experiments
The MYBPC32373insG mouse model was engineered using CRISPR/Cas9 (details are 
provided in the Supplemental Methods). Echocardiographic phenotyping (Vevo 2100, 
Visualsonics) was performed on 7 homozygous MYBPC32373insG mice (3 females, 4 males) 
and 8 WT littermates (3 females, 5 males). The age of the mice ranged from 20-28 
weeks. Group size of 7 was determined by a power calculation to achieve a power 
of 0.8 and an alpha of 0.05 and to detect an effect size of 20% in echocardiography.
The MYBPC3772G>A mice were developed previously
25 and maintained on a blackswiss 
genetic background. Western blot analysis was performed of the cytosolic fraction of 
LV tissue in 6 homozygous MYBPC3772G>A mice (2 females, 4 males) and 6 WT littermates 
(2 females, 4 males). The age of these mice was 55-59 weeks.
Intact cardiomyocyte isolation and measurements
Intact adult cardiomyocytes were isolated from 4 WT and 6 homozygous MYBPC32373insG 
mice as described previously26. Cells were suspended in plating medium composed of 
Medium 199 (Lonza), 1% penicillin/streptomycin and 5% bovine serum and plated on a 
laminin coated dish (10 μg/ml, Sigma-Aldrich). The cells were incubated for 1 hour at 
37°C in humidified air with 5% CO2 to let them attach to the coated dish. Afterwards, 
non-attached cells were removed by washing cells with pre-heated culture medium 
(Medium 199 (Lonza), 1% penicillin/streptomycin, 1x ITS supplement (Sigma-Aldrich) 
and 0.5 μM cytochalasin D (Life technologies)). Cells were incubated with DMSO (0.1% 
v/v) or 10 µM parthenolide (Sigma) for 2 hours. Contractility measurements were 
performed in tyrode solution (HEPES 10 mM, NaCl 133.5 mM, KCl 5 mM, NaH2PO4 
1.2 mM, MgSO4 1.2 mM, glucose 11.1 mM, sodium pyruvate 5mM; pH 7.4 at 37°C) at 
37°C using the MultiCell system (CytoCypher, the Netherlands). The dish was field-
stimulated at 2 Hz, 25 V and a 4 ms pulse duration. Changes in sarcomere length 
were recorded with a high-speed camera and Ionoptix software (Ionoptix, Westwood 
MA, USA). The contractility profiles were analyzed with the automated batch analysis 
software CytoSolver (CytoCypher, Amsterdam, NL). An R² for peak and recovery fit 
>0.95 was selected as inclusion criteria for contraction data.
For protein analysis, cells were incubated with DMSO (0.1% v/v) or 10 µM parthenolide 





The study protocol for the human tissue samples was approved by the local medical 
ethics review committees and written informed consent was obtained from each 
patient prior to surgery.
Animal experiments were performed in accordance with the Guide for the Animal Care 
and Use Committee of the VU University Medical Center (VUmc) and with approval 
of the Animal Care Committee of the VUmc (CCD-number AVD114002016700) and 
conform the guidelines from Directive 2010/63/EU of the European Parliament on the 
protection of animals used for scientific purposes.
Extended methods section in the supplementary materials.
RESULTS
No major genotype-specific protein changes
We performed an unbiased proteomics approach to compare the protein expression 
profile of 50 interventricular septum (IVS) samples from HCM patients at the time 
of myectomy with 8 NFIVS samples (Table 1, Table I; patient characteristics). Patient 
characteristics are shown in Table 1. Echochardiographic parameters were assessed as 
described previously27. All HCM patients had obstructive HCM and showed impaired 
diastolic function evident from increased LV filling pressure indicated by an E/e’ ratio >15 
and atrial dilation indicated by increased left atrial diameter (LAD) compared to reference 
values28, 29. IVS thickness was higher in HCMSMP compared to HCMSMN. We identified 
3,811 proteins of which we included 2,127 into our analysis after applying our inclusion 
criteria of an average normalized count of >1.4 and the protein being detected in >25% 
of samples. This filtered out low-level proteins that could not be reliably quantified.
Samples were grouped based on their genotype and protein expression changes 
were analyzed in different group-wise comparisons. Table II lists all group-wise 
comparisons and the corresponding number of significantly deregulated proteins that 
contributed to the subsequent cluster and gene ontology (GO) analysis. An unbiased 
principal component analysis (PCA) of the protein expression data revealed separate 
clustering of the NFIVS and HCM samples, indicating different protein expression 
profiles between controls and patients (Figure 1A). Supervised hierarchical clustering 
of a multi-group comparison revealed separate clusters for NFIVS and HCM samples 
(Figure 1B). However, in both analysis the HCM samples did not cluster according to 
their genotypes, indicating that the protein profile at the time of myectomy surgery is 
relatively homogeneous with differences between genotypes that are not sufficiently 
large to distinguish them with cluster analysis.
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Sex, male 65.8% (25) 63.6% (7) >0.9999
Age at myectomy (years) 46.2 ± 17.4 53.6 ± 13.9 0.2084
Dimensions
IVS (mm) 21.0 [18.8-23.3] 16.0 [15.0-18.0] <0.0001*
LAD (mm) 46.0 ± 6.5 48.1 ± 5.4 0.3861
EDD (mm) 42.5 ± 5.2 44.3 ± 6.4 0.4466
ESD (mm) 21.7 ± 5.0 26.0 ± 2.8 0.2595
Diastolic parameters
E/A ratio 1.16 [0.81-1.54] 0.92 [0.67-1.15] 0.1795
E/e’ ratio 16.2 [13.1-20.1] 21.7 [16.0-33.4] 0.0226*
TR velocity (cm/s) 2.3 ± 0.5 NA
Stadium of diastolic dysfunction
1 46.9% (15) 40.0% (4) >0.9999
2 31.3% (10) 40.0% (4) 0.7071
3 21.9% (7) 20.0% (2) >0.9999
Systolic parameter
FS (%) 47.4 ± 11.7 47.5 ± 0.7 0.9942
LVOTg (mmHg) 54.9 ± 31.9 91.7 ± 40.9 0.0034*
Medication
beta blocker 79.5% (31) 63.6% (7) 0.4240
calcium channel blocker 33.3% (13) 45.5% (5) 0.4945
Statins 12.8% (5) 18.2% (2) 0.6407
Displayed are the mean±SD or the median with interquartile range when appropriate. EDD indicates 
end-diastolic diameter; ESD, end-systolic diameter; FS, fractional shortening; HCM, hypertrophic 
cardiomyopathy; IVS, interventricular septum; LAD, left atrial diameter; LVOTg, left ventricular 
outflow tract gradient; SMN, sarcomere mutation-negative; SMP, sarcomere mutation-positive; 




FIGURE 1. Clustering of proteome of controls and patient samples. A, Principal component 
(PC) analysis of the filtered protein expression data reveals separate clustering of the nonfail-
ing interventricular septum (NFIVS) samples (n=8) and the hypertrophic cardiomyopathy (HCM) 
samples (n=50) showing that the overall protein expression profile between NFIVS and HCM 
samples differs. HCM samples did not form separate clusters based on genotypes, indicating 
that genotype does not lead to major changes in protein expression profile. Also sarcomere 
mutation-positive (HCMSMP) and sarcomere mutation-negative (HCMSMN) samples do not show 
major differences at the overall protein expression profile as they cluster together. B, Hierarchical 
clustering of a multigroup comparison of all proteins that are differently expressed at P<0.05 
when comparing all HCM (HCMall) with NFIVS. Hierarchical clustering of all significantly different 
proteins between HCMall and NFIVS shows that the NFIVS samples cluster together and are most 
different from the HCM samples. Also among this selection of proteins, the HCM samples do not 
cluster based on genotype or based on presence or absence of mutation (HCMSMP and HCMSMN).
Sample HCM 83 did not cluster with any of the other HCM or NFIVS samples and 
turned out to have a very high serum albumin content. This implicated contamination 
with blood and therefore we excluded this sample from all further analyses. Sample 
HCM 164 also showed a unique protein expression pattern. It may reflect the infant 
proteome due to the young age (2 months), or the very severe disease stage since 
this is the only sample obtained from a heart transplantation. Since the variation in 
this sample is due to a biological reason, we did not exclude it.
To validate our experimental approach, we checked the expression of proteins 
involved in pathways that are known to be altered in HCM (Figure II, Table III). Fibrosis, 
characterized by an increase in ECM components, is a well-established feature of 
HCM as shown by data from myectomy biopsies and cardiac magnetic resonance 
imaging of patients27, 30. In line with the presence of fibrosis in patients, we found 
increased levels of fibronectin, thrombospondin 4 and periostin (Figures IIA-C). Since 
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hypertrophy is a morphological hallmark of HCM, we checked FHL2 expression as a 
negative regulator of hypertrophy31. In line with pro-hypertrophic signaling, reduced 
FHL2 protein expression was observed (Figure IID). The hypertrophic phenotype was 
also evident from reduced α-MHC encoded by MYH6, and increased CSRP3 expression 
in HCM samples (Figures IIE-F )32, 33. Finally, MYBPC3 haploinsufficiency was confirmed 
in samples with a mutation in MYBPC3 irrespective of whether the mutation is a 
truncation or missense mutation (Figures IIG-H, Table IV )14, 34.
Additionally, we performed RNA sequencing in a subset of samples. Similar to the 
proteomics data, the PCA plot of the RNA data did not show clustering based on 
genotype (Figure IIIA). The MA-plot depicts all genes with the differentially expressed 
genes in red (Figure IIIB).Gene set enrichment analysis of the proteomics and 
transcriptomics data revealed a significant correlation of upregulated proteins with 
genes that showed higher expression levels in HCM compared to NFIVS (FDR<0.001), 
while less expressed proteins are positively correlated with genes that showed lower 
expression levels in HCM (FDR=0.008). This observation suggested that protein 
expression changes were well correlated with the mRNA expression changes between 
HCM and NFIVS (Figure IIIC-D).
HCM-specific protein changes
To identify HCM disease-specific protein expression patterns at the time of myectomy 
we grouped all HCM samples (HCMall) and compared them to NFIVS. We identified 
clusters of interacting proteins for higher and lower expressed proteins separately.
Analysis of all significantly lower expressed proteins of HCMall compared to NFIVS 
uncovered the highest enrichment in oxidative phosphorylation, generation of 
precursor metabolites and energy, NAD metabolic process, translation, fatty acid 
catabolic process, regulated exocytosis and neutrophil degranulation (Figure 2A, 
more extensive list in Figure IV ). This shows that the major changes in tissue of HCM 
patients are in metabolic pathways related to energy metabolism including both 
glucose and fatty acid metabolism. We selected all significantly lower expressed 
proteins annotated to the pathways and created a heatmap displaying the log2-fold 
change for a detailed visualization of protein changes in the pathway. We included 
RNA expression data of the corresponding genes to check if the protein changes 
coincide with changes at the RNA level. Strikingly, most of these proteins are not 
changed on RNA level (Figure V ).
The top clusters of the higher expressed proteins are associated with the GO 
terms ECM organization, actin filament-based process, myofibril assembly, muscle 
contraction, post-translational protein modification, protein folding and microtubule 
cytoskeleton organization (Figure 2B, more extensive list in Figure VI). The biggest 




collagens that are components of fibrotic tissue. Interestingly, many of these genes 
showed unaltered RNA levels compared to NFIVS. The same was observed for the 
other top clusters of higher expressed proteins, namely actin filament-based process, 
myofibril assembly and muscle contraction, where RNA levels were unaltered or even 
lower than in NFIVS (Figure VII).
Since HCM at the time of myectomy is characterized by pronounced hypertrophy 
of the myocardium, we expected a protein cluster related to hypertrophy among 
the significantly increased proteins. Surprisingly, we did not find this. This could be 
because the myocardium is not in a state of active hypertrophic growth at the time of 
sample collection, or because we did not detect low abundant hypertrophy promoting 
signaling proteins. It is also known that several signaling proteins are regulated by 
post-translational modifications rather than by abundance on which our proteomics 
screen was based. Western blot analysis of the expression and phosphorylation of 
AKT and ERK, two well-known inducers of hypertrophy35, 36, showed higher AKT and 
ERK phosphorylation in HCMall samples, indicating activation of hypertrophic signaling 
(Figure VIII).
Subsequently, we repeated the cluster and GO analysis restricted to proteins that are 
higher and lower expressed if all 5 genotype HCM groups are compared individually 
to NFIVS to extract the most consistent and robust changes. Venn diagrams (Figure IX 
and X ) were made to identify overlapping protein changes (76 higher and 92 lower 
expressed), which were subsequently used as analysis input.
The results confirmed the findings from the initial analysis showing that the major HCM-
specific protein changes include reduced metabolism, increased ECM remodeling, 
and pathways including muscle related processes.
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FIGURE 2. Hypertrophic cardiomyopathy (HCM)-specific changes in biological processes. Pro-
tein interaction cluster of significantly different proteins between all HCM (HCMall) and nonfail-
ing interventricular septum (NFIVS) were identified and are displayed with the most significant 
corresponding gene ontology (GO) term. A, Top 10 downregulated protein interaction cluster 
based on cluster size with the most significant biological process related to this cluster. B, 
Top 10 upregulated protein interaction cluster based on cluster size with the most significant 
biological process related to this cluster. The color gradient from light to dark indicates an 




Specific changes for HCMSMP and HCMSMN
To study the pathways that are characteristic for HCMSMP or HCMSMN and might explain 
sarcomere mutation-specific changes in cardiac function, we created a Venn diagram 
of significantly different proteins in HCMSMP and HCMSMN compared to NFIVS. The Venn 
diagrams (Figures 3 and XI) illustrate that the majority of significantly different proteins 
are similar in HCMSMP and HCMSMN (191 lower and 121 higher expressed proteins). 
However, a substantial number of proteins is only changed in either HCMSMP or 
HCMSMN, when compared to NFIVS.
The 130 proteins that are specifically less abundant in HCMSMP overlap to a large 
degree with the biological processes of the 194 proteins that are significantly less 
abundant in both HCMSMP and HCMSMN when compared to NFIVS (Figure XII). Analysis of 
the 62 proteins that are specifically less expressed in HCMSMN results in clusters related 
to stress granule assembly, translational initiation and protein folding (Figure XI).
The majority of the shared higher expressed proteins involve ECM organization (Figure 
XIII). GO analysis of the 68 proteins that are specifically more abundant in HCMSMP 
identified amongst others a protein clusters related to microtubule cytoskeleton 
organization (Figure 3).
This cluster representing tubulin subunits is solely more abundant in HCMSMP when 
compared to NFIVS, and is also among the functional protein cluster of proteins that 
are significantly upregulated in HCMSMP when directly compared to HCMSMN (Figure 
XIV ). Since the tubulin network is highly regulated by post-translational modifications, 
we determined the levels of total α-tubulin, tyrosinated and detyrosinated tubulin 
by western blot (Figure 4, Figure XVA). In line with the proteomics data we found an 
increase in total α-tubulin which is more prominent in HCMSMP than in HCMSMN (Figure 
4A). We validated this with another primary antibody and obtained very comparable 
results (Figure XVA). A post-translational modification of tubulin that leads to increased 
stiffness of cardiomyocytes is detyrosination of α-tubulin12. We found markedly 
elevated detyrosinated tubulin only in HCMSMP samples (Figure 4C), while levels of 
tyrosinated tubulin were slightly increased in both HCMSMP and HCMSMN (Figure 4B). 
Within the HCMSMP group, levels of α-tubulin tend to be highest in the MYBPC3other 
group and lowest in the MYH7 group, whereas desmin levels tend to be highest in 
MYH7. Levels of tyrosinated and detyrosinated tubulin do not show any genotype-
specific differences. Levels of tyrosinated and detyrosinated tubulin normalized to 
total α-tubulin are depicted in Figure XVB-C. Our data show that high levels of tubulin 
in HCMSMP represent mostly the detyrosinated form. We also determined desmin 
protein levels by Western blot since this protein is associated with microtubules in 
cardiomyocytes. Accordingly, desmin levels were elevated in HCM with the largest 
increase in HCMSMP (Figure 4D).
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FIGURE 3. Differences in upregulated proteins between patients with hypertrophic cardio-
myopathy sarcomere mutation-positive (HCMSMP) and sarcomere mutation-negative (HCMSMN). 
Protein interaction cluster of proteins that are only significantly upregulated for the HCMSMP vs 
nonfailing interventricular septum (NFIVS) or the HCMSMN vs NFIVS comparison were identified 
and are displayed with the most significant corresponding gene ontology (GO) term. The top 5 
protein interaction clusters of upregulated proteins are displayed The color gradient from light 
to dark indicates an increase in fold change.
Inhibition of tubulin detyrosination corrects cardiomyocyte dysfunction in 
MYBPC32373insG mice
Based on previous studies in human heart failure13, our data in human myectomy 
samples indicate that microtubules may represent a treatment target to correct cardiac 
dysfunction in HCM. To provide proof for a role of tubulin in modulating cardiomyocyte 
function in HCM caused by a sarcomere gene mutation, we generated a HCM knock-
in (KI) mouse model of the Dutch founder mutation c.2373insG in MYBPC3 (Figures 
XVIA-B). This mutation introduces a new splice donor site in exon 25 leading to a 
frameshift and premature stop codon resulting in an expected truncated protein of 
95 kDa37. As no truncated protein is found in HCM patients carrying this mutation 
at the heterozygous state14, degradation of mutant mRNA and/or protein is likely. 
Accordingly, Western blot analysis did not reveal any truncated MYBPC3 protein in 




FIGURE 4. Tubulin expression and post-translational modifications in patients with hypertrophic 
cardiomyopathy (HCM). Protein levels of α-tubulin (A), its tyrosinated (B) and detyrosinated forms 
(C) and desmin (D), all normalized to GAPDH, in tissue of patients with HCM. Kruskal-Wallis 
test with Dunn multiple comparisons test, ****P<0.0001, ***P=0.0003 in (B), ***P=0.0009 in 
(D), **P=0.0074, *P=0.0437 in (A), *P=0.0499 in (B) and *P=0.0357 in (D). Average of the control 
group is set to 1. n(nonfailing interventricular septum [NFIVS]/HCMSMP/HCMSMN)=6/38/11 for (A), 
8/36/11 for (B and C), 8/37/11 for (D). SMN indicates sarcomere mutation-negative; and SMP, 
sarcomere mutation-positive.
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FIGURE 5. Tubulin composition in MYBPC32373insG and MYBPC3772G>A mouse models. Quanti-
fication and representative western blot images of (A) α-tubulin, (B) tyrosinated tubulin, (C) 
detyrosinated tubulin and (D) desmin in MYBPC32373insG mice and (E) α-tubulin, (F) tyrosinated 
tubulin and (G) detyrosinated tubulin in MYBPC3772G>A mice, respectively. (A) is normalized to 
total protein stain (TPS, image provided in Figure XVD), (B-G) are normalized to GAPDH. Lanes 
in (A) were run on the same gel but were noncontiguous. n(WT/MYBPC32373insG/772G>A)=6/6 (4 
females, 2 males/3 females, 3 males of 20-27 weeks for MYBPC32373insG and the corresponding 
WT; 2 females, 4 males for of 55-59 weeks for MYBPC3772G>A and the corresponding WT) for (A, 
C, E-G), 6/5 (4 females, 2 males/3 females, 2 males; 20-27 weeks) for (B) and 5/5 (3 females, 2 
males/2 females, 3 males; 20-27 weeks) for (D), unpaired two-tailed t-test, *** p=0.0001 in (C) 
and p=0.009 in (D), ** p=0.0014.
Levels of total and tyrosinated α-tubulin did not differ between the groups, whereas 
the detyrosinated tubulin and desmin levels were markedly higher in MYBPC32373insG 
than in wildtype (WT) mice (Figures 5A-D, loading control to panel A shown in Figure 
XVD). To evaluate whether these findings were specific to this model, we assessed 
the levels of total and detyrosinated tubulin in a second HCM mouse model carrying 
a different MYBPC3 mutation25. Homozygous MYBPC3772G>A mice showed a strong 
accumulation of α-tubulin and no difference in tyrosinated tubulin compared to their 
WT littermates. In addition, a trend to higher levels of detyrosinated tubulin was 
observed (Figures 5E-G). Overall, these mouse models consistently show tubulin 




FIGURE 6. Morphometric and phenotypic analysis of MYBPC32373insG mice and contractile func-
tion of isolated MYBPC32373insG cardiomyocytes upon inhibition of tubulin detyrosination. Quanti-
fication of the hypertrophy parameters (A) ventricle weight (VW)/body weight (BW) ratio and (B) 
anterior wall thickness in diastole (LWADd) and (C) interventricular septum thickness in diastole 
(IVSd) measured by echocardiography. (D) and (E) show parameters of systolic function mea-
sured by ejection fraction and left ventricular internal diameter (LVID) and (F) displays diastolic 
function assessed by isovolumetric relaxation time (IVRT). n(WT/MYBPC32373insG)=9/9 (4 females, 
5 males; 20-27 weeks) for (A) and 8/7 (3 females, 5 resp. 4 males; 25-27 weeks) for (B-F), unpaired 
two-tailed t-test, **** p<0.0001, *** p=0.0001. 
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(G) displays the effect of tubulin detyrosination inhibition by PTL on the contractile parameter 
time to peak 70% and (H) on the diastolic parameter time to baseline 70%. The dotted line visu-
alizes the WT baseline level. (I) shows example force transients for each condition of the single 
cell measurements. For (G-H) N(WT mice)=4 (2 females and 2 males, 13-33 weeks) with total 
n(cells DMSO/PTL)=191/99 and N(MYBPC32373insG mice)=6 (2 females and 4 males, 13-35 weeks) 
with total n(cells DMSO/PTL)=169/123. (G) and (H) were analyzed by 2way-ANOVA, ** p<0.01, **** 
p<0.0001. (J) Levels of detyrosinated tubulin normalized to GAPDH in isolated MYBPC32373insG 
cardiomyocytes upon inhibition of tubulin detyrosination by PTL. Every PTL treated sample was 
normalized to the DMSO control condition from the same animal. N(MYBPC32373insG mice)=6 (2 
females, 4 males, 13-19 weeks); (J) was analyzed with an unpaired two-tailed t-test, *** p=0.0004.
MYBPC32373insG mice had a severe cardiac phenotype characterized by higher ventricular 
weight to body weight ratio, increased LV anterior wall diameter and interventricular 
septum thickness, lower ejection fraction, increased left ventricular internal diameter 
and longer isovolumetric relaxation time than WT mice (Figures 6A-F ). Single 
cardiomyocytes from MYBPC32373insG hearts showed contractile deficits compared to 
WT as shown by an increase in time to peak of contraction and an impaired relaxation 
shown by an increase in time to baseline (Figures 6G-H). Inhibition of detyrosination 
by treatment with parthenolide (PTL) reduced levels of detyrosinated tubulin by 36% 
(Figure 6J) and normalized the contraction and relaxation times in MYBPC32373insG mice 
to baseline WT levels (Figures 6G-H), whereas it had no effect on calcium release and 
reuptake time in MYBPC32373insG mice (Figure XVIIA-B), indicating a direct effect on 
myofilament function.
DISCUSSION
In this study we compared the protein profile of cardiac tissue from HCM patients with 
different disease-causing gene mutations to identify common HCM disease changes as well 
as genotype-specific protein changes at the time of myectomy. The majority of detected 
protein changes were common for all HCM samples and independent of the underlying 
gene mutation. Our approach revealed different protein profiles in the presence or absence 
of a sarcomere gene mutation. While hypertrophic remodeling in HCMSMP is characterized 
by an increase in the levels of proteins involved in microtubule cytoskeleton organization, 
HCMSMN samples show reduced levels of proteins involved in protein translation.
Deregulated energy metabolism proteome
Our analysis revealed that the majority of deregulated proteins are related to 
energy metabolism and show a consistent lower expression of proteins involved in 
oxidative phosphorylation, glycolysis and fatty acid oxidation. Especially subunits of 
mitochondrial respiratory chain complex I, that are part of cluster 1 in Figure 2A, are 
consistently lower expressed. This is in line with another recent proteomics study of 
HCM tissue samples in which reduced levels of energy metabolism proteins was one 




models39 and human studies40, 41. Energy deficiency has been proposed as the primary 
mutation-induced pathomechanism leading to compensatory hypertrophy42, which is 
supported by the fact that even asymptomatic mutation carriers without hypertrophy 
display reduced cardiac energetic status9, 41. The reduced cardiac efficiency was 
larger in MYH7 mutation carriers compared to MYBPC3 mutation carriers pointing 
towards genotype-specific functional differences9. Our proteomic analyses did not 
show gene-dependent differences in proteins involved in cardiac energy metabolism. 
This indicates that the deregulated energy metabolism proteome is a secondary 
consequence due to cellular stress that is similar in patients with advanced HCM.
Protein homeostasis differs between HCMSMP and HCMSMN
Interestingly, proteins involved in protein translation are less abundant, particularly in 
HCMSMN patient tissue when compared to NFIVS, implying that the protein translation 
system is either more impaired or differently regulated in HCMSMN. Among the more 
abundant proteins, we observed a protein cluster related to protein folding. Protein 
folding proteins (chaperones) are needed for correct folding of de novo synthesized 
proteins as well as for refolding of misfolded mutant or damaged proteins. Since our 
data show downregulation of protein translation, it is unlikely that protein folding 
proteins are upregulated for folding of newly synthesized proteins. Instead, we 
speculate that their expression is upregulated to repair or remove misfolded (mutant) 
proteins43. This is in line with recent data describing an upregulation of protein folding 
proteins specifically in HCMSMP samples
44. Protein folding proteins represent potential 
treatment targets since boosting their expression has already shown beneficial effects 
in animal models of other cardiac diseases and in cardiomyopathies45-47.
Impact of increased tubulin network on cardiomyocyte function in HCM
A striking observation was the specific upregulation of microtubule subunits and 
post-translational modification detyrosination in HCMSMP compared to HCMSMN, when 
comparing both to NFIVS. Previous studies indicated important regulatory roles of 
microtubules in cardiomyocyte function48. Recent reports showed that the translation 
of the sarcomere proteins is localized to the myofilaments which points to a role 
of microtubules in the transportation of mRNA to the myofilament49, 50. Increased 
expression of tubulin subunits strengthens the microtubule network and facilitates the 
transportation of mRNAs to the sarcomere and concomitant increasing cardiomyocyte 
stability. In addition to tubulins, desmin protein level was significantly higher in HCMSMP 
than in HCMSMN. In the healthy heart, desmin is localized at the Z-discs forming a 
striated pattern and playing a central role in cardiomyocyte mechanical stability51. 
Overall, these protein changes suggest a compensatory mechanism of the cell to 
ensure sarcomere stability in the presence of a sarcomere gene mutation.
Furthermore, microtubules and their post-translational modifications play an important 
role in cardiomyocyte mechanics, especially in regulating cardiomyocyte stiffness52, 53. 
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Detyrosinated tubulin stabilizes microtubules by inhibiting disassembly54 and can anchor 
microtubules to the Z-discs of the sarcomere, most likely via desmin, and enhance stability 
and stiffness of the myofilaments and the microtubular network52. The TUBA4A transcript 
is directly synthesized in it is detyrosinated form and an upregulation could at least partly 
explain the increase in detyrosinated tubulin. In our RNA sequencing data, the TUBA4A 
transcript is however significantly downregulated when comparing HCM with NFIVS 
and it is not differentially expressed in the direct comparison of HCMSMP and HCMSMN.
Tubulin detyrosination is enzymatically regulated by the tubulin tyrosine ligase (TTL) 
and tubulin carboxypeptidases (TCPs) that have detyrosinating activity and also the 
TUBA4A transcript can undergo these reactions55. Recently, vasohibins have been 
identified as the first tubulin detyrosinating enzymes56, 57, and act in complex with 
small vasohibin-binding protein (SVBP). In accordance with findings by Robison et 
al. in explanted hearts of heart failure and cardiomyopathy patients12, we observed 
a specific upregulation of tubulins and enhanced detyrosination in our genetically 
well-characterized HCM myectomy samples. Notably, we found the increase in tubulin 
detyrosination specific for HCMSMP samples. Although levels of detyrosinated tubulin 
are equal between HCMSMP and HCMSMN when normalized to total levels of α-tubulin, 
the absolute levels of α-tubulin and detyrosinated tubulin are much higher in HCMSMP 
and thereby have a much greater impact on contractile function in these patients. 
Chen et al. have already demonstrated the reversibility of tubulin detyrosination in 
isolated cardiomyocytes from explanted HCM hearts associated with an improvement 
of contractile function13, 58. Here we performed proof-of-concept studies in HCM mouse 
models to define the impact of tubulin detyrosination in the presence of a sarcomere 
mutation. Homozygous MYBPC32373insG mice replicated the tubulin detyrosination 
without an increase in total α-tubulin levels, whereas homozygous MYBPC3772G>A mice 
display an increase in total α-tubulin with a trend to increased tubulin detyrosination. 
Considering the age difference of the mice with the MYBPC3772G>A mice being much 
older than the MYBPC32373insG mice at the time of analysis, we speculate that the 
increase in tubulin detyrosination is an early disease change together with an increase 
in desmin protein levels, which is followed by an increase of total α-tubulin during 
disease progression and ageing. In MYBPC32373insG mice we showed that the increase in 
tubulin detyrosination is accompanied by reduced contraction and relaxation kinetics 
in isolated intact cardiomyocytes. Inhibition of tubulin detyrosination by PTL restored 
contraction and relaxation kinetics to WT levels in MYBPC32373insG cardiomyocytes. 
The used concentration of PTL has already been proven to be sufficient to reduce 
detyrosination of tubulin12, 59 and Chen et al. and Robison et al. have demonstrated 
that the PTL-induced effects on kinetics of contraction are the same as obtained 
by overexpression of TTL12, 13, which specifically lowers tubulin detyrosination. The 
positive effect of PTL on cardiomyocyte function of MYBPC32373insG cardiomyocytes is 





Overall, our findings in a European HCM patient cohort strengthens the evidence that 
increased detyrosination of microtubules contributes to cardiomyocyte stiffness and 
dysfunction in HCM. Importantly, we show that this is especially true in the presence 
of a sarcomere mutation.
STUDY LIMITATIONS AND CLINICAL IMPLICATIONS
We sex- and age-matched our experimental groups as good as the availability of 
human samples allowed us. As seen in Table 1, sex and age, as well as most clinical 
parameters, are not statistically different between groups. We cannot exclude that 
differences in disease progression, as displayed by the difference in IVS thickness, E/e’ 
ratio and LVOTg between HCMSMP and HCMSMN, may influence the results. However, 
collection of patient heart tissue is only possible at the time of myectomy. Therefore, 
all our samples have the same clinical endpoint, i.e. time of myectomy. This is likely the 
cause for the low number of genotype-specific protein changes and we cannot exclude 
that genotype-specific differences might have occurred at earlier disease stages. Due 
to unavailability of myocardial biopsies from asymptomatic mutation carriers, animal 
models and human-derived cardiomyocyte muscle models should provide insight into 
gene-specific pathomechanisms at early disease stages.
Most of the patients in this study have been on drug therapy, therefore we cannot 
exclude that some of the proteomic changes are caused by medication. However, 
some of the main findings, e.g. energy deficiency, have also been observed in animal 
models39, and the number of patients on the most commonly used drugs does not 
differ between HCMSMP and HCMSMN (Table 1). Therefore it is more likely that the 
observed changes are driven by disease rather than medication.
Although we detected and quantified a large number of proteins in this study, we do 
not reach full coverage of the proteome as this method only reliably quantifies the 
more abundant proteins. Therefore, our list of differentially expressed proteins is not 
comprehensive. Also, we did not assess post-translational modifications in the proteomics 
study which have important regulatory functions. The changes at the protein level 
reflect whole tissue alterations and cannot be solely assigned to the mutation-carrying 
cardiomyocytes but might also arise from other cell types. However, cardiomyocytes are 
responsible for most of the tissue volume and therefore drive most of the protein changes.
Homozygous MYBPC32373insG mice do not fully resemble human HCM patients, 
since patients typically carry heterozygous mutations. Whilst both patients and the 
homozygous MYBPC32373insG mouse model show hypertrophy and diastolic dysfunction, 
the prominent LV systolic dysfunction as observed in the homozygous MYBPC32373insG 
151
DETYROSINATED TUBULIN AS TREATMENT TARGET IN HCM
mice is not seen in most HCM patients. But due to the lack of phenotype in heterozygous 
mice they provide a suitable genetic model of loss of MYBPC3 protein levels.
In our proteomic screen in a large set of human HCM samples we identified reduced 
levels of proteins involved in metabolic pathways as the most prominent derailment. 
This finding supports recent and ongoing clinical trials investigating the therapeutic 
effect of targeting the metabolism in HCM. Based on the proteomic data and 
functional studies in a novel HCM mouse model, we propose that an increase in 
detyrosinated tubulin contributes to the clinical and cellular differences that we see 
between HCMSMP and HCMSMN samples (Figure 7). Detyrosinated microtubules may 
represent a target for therapeutic intervention in genetic heart disease because 
reducing detyrosination improves contractile function in isolated cardiomyocytes. 
Since the increase in detyrosinated tubulin is largest in HCMSMP, this treatment strategy 
is proposed to be most beneficial in mutation-positive HCM patients. A specific 
inhibitor of detyrosination needs to be developed due to the known off-target effects 
of PTL. As sarcomere mutation carriers are identified before disease onset, targeting 
the microtubules may represent a preventive treatment option.
FIGURE 7. Schematic representation of genotype-independent changes in HCM and geno-
type-specific differences in the microtubular system. Our analysis shows that all HCM patients 
display downregulation of metabolic pathways (electron transport chain (ETC), tricarboxylic 
acid (TCA) cycle, β-oxidation (β-oxid)) and ribosomal proteins (Translation), as well as an upreg-
ulation of protein folding proteins (heat shock proteins, HSPs) and extracellular matrix (ECM) 
proteins. HCMSMP patients have a large increase in microtubules and levels of its detyrosinated 
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CHAPTER 5
Since the first reported series of patients with cardiac hypertrophy of unknown 
cause in 1944,1 insights into the primary pathogenesis and secondary consequences 
of hypertrophic cardiomyopathy (HCM) have advanced considerably. Beyond 
recognition that HCM is the most common genetic heart disease, there has been 
progress in elucidating the genetic origins of HCM, including a predominance of 
sarcomere protein mutations and typical autosomal dominant inheritance with variable 
penetrance. In a sizable subset of patients with HCM, there has been recognition that 
hypercontractility, due to increased myofilament calcium sensitivity, conspires with 
anatomic remodeling to produce dynamic left ventricular outflow tract obstruction 
(LVOTO). These insights inspired effective utilization of negative inotropic agents 
(β-blockers, calcium-channel blockers, and disopyramide) that often provide significant 
symptomatic relief in patients with LVOTO. When the anatomic features of HCM and 
LVOTO prove refractory to negative inotropes, alcohol septal ablation and surgical 
myectomy are highly effective at improving symptoms.2 Recently, more sophisticated 
targeting of the subcellular basis for hypercontractility has allowed development of 
direct myosin inhibitors that are highly effective at mitigating hypercontractility and 
LVOTO with a more favorable tolerability profile than previously used agents. These 
recent successes, coupled with the ability to identify the specific pathogenic mutation 
in about half of patients with HCM, have inspired consideration of even more precise 
disease targeting and perhaps even genotype-specific therapeutics.
In this context, the article by Schuldt et al3 in this issue of Circulation: Heart Failure 
reports the results of a proteomic analysis of myocardial tissue from a cohort of 
patients with HCM who had undergone septal myectomy for symptomatic LVOTO. The 
full cohort of patients with HCM was subdivided into 39 subjects who had an identified 
pathogenic sarcomere protein mutation and 11 in whom no pathogenic mutation 
was identified. The proteomic profiling revealed that many of the abnormalities in 
myocardial expression of metabolic, extracellular matrix, and muscle-related proteins 
in patients with HCM are similar among those with and without an identified sarcomere 
protein mutation. However, notable exceptions were abnormalities in cytoskeletal 
proteins and particularly the abundance of detyrosinated α-tubulin, which was much 
greater among patients with HCM, and a known sarcomere gene mutation than in 
those without an identified mutation. This particular finding is notable because recent 
studies have shown that this specific posttranslational modification—detyrosination 
of α-tubulin—has significant effects on the stability and density of the cardiomyocyte 
cytoskeleton and cell biomechanics. Specifically, increased detyrosination and 
associated changes to the cardiomyocyte microtubule network are causally linked 
to increased stiffness and viscoelasticity that reduce contractility and slow both 
contraction and relaxation.4–8 To better define the functional significance of increased 
tubulin detyrosination in genotype-positive patients, Schuldt et al performed studies 
using a murine model designed to mimic the most severely affected genotype in 
the HCM patient cohort: MYBPC32373insG. In these studies, mice homozygous for this 
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mutation exhibited particularly severe hypertrophy, a reduced ejection fraction, 
and severe relaxation abnormalities. Moreover, hearts from mice with this analogue 
of the human mutation had markedly increased levels of detyrosinated tubulin 
compared with wild-type controls, and cardiomyocytes from these mice demonstrated 
slowed contraction and relaxation. Importantly, administration of parthenolide—
an agent known to reduce the proportion of detyrosinated tubulin—normalized 
the cardiomyocyte contraction and relaxation times, suggesting that increased 
detyrosination contributes to the contractility and relaxation defects in mice (and 
humans) carrying the MYBPC32373insG mutation. Compared with a second mouse strain 
with a different Mybpc3 mutation, less severe increases in tubulin detyrosination, 
and slower progression of hypertrophy and contractile defects, the mice carrying 
the MYBPC32373insG mutation developed severe remodeling at a much earlier age. 
Though parthenolide has actions that are independent of decreased detyrosination,9 
the authors conclude that increased detyrosination of microtubules contributes to 
cardiomyocyte stiffness and dysfunction with a greater impact in the presence of a 
pathogenic sarcomere protein mutation. To a large extent, the findings by Schuldt 
et al confirm and complement previous reports demonstrating increased tubulin 
detyrosination in hearts obtained from patients with advanced HCM requiring heart 
transplantation.4,5 In those studies, parthenolide or genetic manipulation of the 
enzymes of the detyrosination/tyrosination cycle improved contractility and relaxation 
velocities in intact human cardiomyocytes isolated from patients with HCM.5,6 In 
this context, the studies by Schuldt et al using myectomy samples suggest that the 
development of functionally significant tubulin detyrosination in HCM may occur 
long before end-stage heart disease requiring transplantation. The interpretation of 
the findings in the smaller subset of HCM patients without a pathogenic mutation, 
who exhibited more modest increases in tubulin detyrosination, is less clear. While 
Schuldt et al conclude that the presence or absence of a demonstrable sarcomeric 
mutation determines the pathogenic contribution of tubulin detyrosination, the 
significant differences in the absolute degree of hypertrophy in the HCM groups 
with and without sarcomere protein mutations represents a potential confounding 
factor because the patients without a sarcomere protein mutation had significantly 
less hypertrophy than those with an identified mutation. Specifically, among patients 
without an identified mutation, none had a septal thickness over 20 mm. In contrast, 
19 of 39 patients with a pathogenic mutation had a septal thickness >20 mm, and 
17 of 18 patients of those with a MYBPC3 mutation had a septal thickness ≥20 mm. 
Thus, it could be the degree of pathological hypertrophy that drives the magnitude 
of α-tubulin detyrosination among patients with HCM, irrespective of mutation 
status. Indeed, the aforementioned studies using hearts from transplant recipients4,5 
demonstrate that patients with advanced dilated cardiomyopathy also demonstrated 
substantially increased degrees of tubulin detyrosination, which was not observed in 
nonfailing hearts with compensated hypertrophy. The temporal progression of this 




establishment, and progression of hypertrophy requires further inquiry in controlled 
research models. The imperfect modeling of human HCM with mouse models is 
another shortcoming worth noting. In contrast with the heterozygous MYBPC3 
mutations in the patients classified as genotype positive by Schuldt et al, the murine 
models used for their longitudinal and isolated myocyte studies are homozygous. This 
is an important difference that likely exacerbates and accelerates the progression of 
HCM in mice and could affect the magnitude of downstream changes including tubulin 
detyrosination. Nevertheless, the current studies further advance the concept that the 
myocardial adaptations downstream of primary genetic defects may be opportunities 
for therapeutic targeting. In particular, microtubule-dependent cardiomyocyte 
stiffening, as a consequence of reversible, post-transcriptional detyrosination of 
α-tubulin, is a promising therapeutic target that is supported by both the human 
proteomics and mouse studies in the article by Schuldt et al. In addition to clearer 
elucidation of the degree to which specific pathogenic mutations drive tubulin 
detyrosination, independent of hypertrophy magnitude, further studies should 
examine whether in vivo targeting of tubulin detyrosination improves contractile 
and relaxation defects at the organ level or alters the progression of HCM and its 
associated morbidity.
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Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the 
cardiac muscle, frequently caused by mutations in MYBPC3. However, little is known 
about the upstream pathways and key regulators causing the disease. Therefore, we 
employed a multi-omics approach to study the pathomechanisms underlying HCM 
comparing patient hearts harboring MYBPC3 mutations to control hearts.
Results
Using H3K27ac ChIP-seq and RNA-seq we obtained 9,310 differentially acetylated 
regions and 2,033 differentially expressed genes, respectively, between 13 HCM 
and 10 control hearts. We obtained 441 differentially expressed proteins between 
11 HCM and 8 control hearts using proteomics. By integrating multi-omics datasets, 
we identified a set of DNA regions and genes that differentiate HCM from control 
hearts and 53 protein-coding genes as the major contributors. This comprehensive 
analysis consistently points towards altered extracellular matrix formation, muscle 
contraction, and metabolism. Therefore, we studied enriched transcription factor 
(TF) binding motifs and identified 9 motif-encoded TFs, including KLF15, ETV4, AR, 
CLOCK, ETS2, GATA5, MEIS1, RXRA, and ZFX. Selected candidates were examined in 
stem cell derived-cardiomyocytes with and without mutated MYBPC3. Furthermore, 
we observed an abundance of acetylation signals and transcripts derived from 
cardiomyocytes compared to non-myocyte populations.
Conclusions
By integrating histone acetylome, transcriptome, and proteome profiles, we identified 
major effector genes and protein networks that drive the pathological changes in HCM 
with mutated MYBPC3. Our work identifies 38 highly affected protein-coding genes 
as potential plasma HCM biomarkers and 9 TFs as potential upstream regulators of 
these pathomechanisms that may serve as possible therapeutic targets.
167
MULTI-OMICS INTEGRATION IDENTIFIES KEY REGULATORS OF HCM
INTRODUCTION
Hypertrophic cardiomyopathy (HCM), characterized by thickening of the myocardium 
that is not explained by abnormal loading conditions, is the most common inherited 
cardiac disease [1]. More than 1,500 associated mutations, primarily in genes encoding 
parts of the sarcomere, such as MYBPC3, MYH7, and TNNT2, have been identified. The 
remodeled myocardium is characterized by cardiomyocyte hypertrophy and disarray, 
extensive fibrosis, and reduced capillary density [2]. HCM is a heterogeneous disease 
as the onset, the disease phenotype, and the severity of the clinical presentations 
differ greatly among mutation carriers [3]. Additionally, different mutated genes 
exhibit distinct biological impact on cellular contractility, energy metabolism, and 
sarcomeric protein expression in HCM hearts [4]. However, the driving pathological 
mechanisms underlying the heterogenous HCM remains largely unknown.
Next-generation sequencing technologies (NGS) are instrumental in understanding 
disease etiology, delivering a clinical diagnosis, and discovering new treatment 
options. Multiple studies employed NGS to reveal the epigenetic modifications in 
heart failure, including DNA methylation and histone (de-)acetylation, which provided 
insights and identification of the driving mechanism underlying the disease [5,6]. We 
previously showed the influence of histone acetylation changes on QRS complex-
related GWAS loci in HCM [7,8]. Additionally, studies from our group and others have 
shown that H3K27ac corresponds to the gene expression in human cardiac tissues as 
well as human cardiomyocytes [9,10], highlighting it as a promising epigenetic mark for 
predicting gene expression. Studies also employed RNA sequencing to identify the 
affected transcription factor-mediated upstream regulatory events and the distinct 
gene expressions that define heart failure [9,10]. Furthermore, data-piling studies are 
now connecting proteomics to NGS to get comprehensive information on the disease 
biology for precision medicine [11].
In this study, we aim to understand the pathomechanisms driving HCM by employing 
a multi-omics approach, including chromatin immunoprecipitation sequencing (ChIP-
seq), RNA sequencing (RNA-seq), and proteomics, using myocardial tissue obtained 
from clinically well-phenotyped HCM patients with truncating MYBPC3 mutations 
and compared these with non-failing donor hearts. We revealed altered histone 
acetylome, transcriptome, and proteome profiles in HCM versus control hearts and 
studied affected biological functions. Besides, we identified key factors that may play 
a critical role in regulating the pathomechanisms underlying HCM. We also evaluated 
the contribution of histone acetylation and transcription signals in 11 cell types in the 
heart. Combined, this multi-omics study gives insight into the underlying disease 





Pairwise comparison between HCM and control hearts reveals distinct histone 
acetylome profiles
H3K27ac ChIP-seq was used to capture acetylated DNA regions in each sample and 
to compare the acetylation levels between 13 HCM (n=13) and 10 control hearts 
(Figure 1A and Supplementary Table 1) using DESeq2. In total, we identified 4,226 
regions presented higher acetylation levels (hyperacetylated regions) and 5,084 
regions presented lower acetylation levels (hypoacetylated regions) in HCM versus 
control hearts (Padj<0.05, Figure 1B, Supplementary Table 2A). Examples of hyper- 
and hypoacetylated regions are shown in Supplementary Figure 1. Region-to-gene 
annotation using either a 5kb or 50kb window from the transcription start site 
(TSS) revealed genes in the hyperacetylated regions are mostly involved in muscle 
contraction and extracellular matrix (ECM) development-related processes, whereas 
genes in the hypoacetylated regions are mostly involved in metabolic processes 
(Supplementary Table 2B-2E).
Pairwise comparison between HCM and control hearts reveals distinct transcriptome 
profiles
Following RNA-seq of the same biopsies, the transcriptional profiles between 13 HCM 
(n=13) and 10 control hearts were compared using DESeq2. In total, we identified 936 
up-regulated genes and 1,097 down-regulated genes in HCM hearts compared to 
controls (Padj<0.05, Figure 1C, Supplementary Table 3A). The top biological processes 
enriched by up-regulated genes are involved in the muscle system process and energy 
production. The top biological processes enriched by down-regulated genes are 
involved in lipid metabolism and cell adhesion (Supplementary Table 3B and 3C).
Pairwise comparison between HCM and control hearts reveals distinct proteome 
profiles
We also performed proteomics in 11 HCM samples and compared their protein 
expression levels to another control group (n=8) using DESeq2. In total, we identified 
216 up-regulated proteins and 225 down-regulated proteins in HCM hearts compared 
to controls (P<0.05, Figure 1D, Supplementary Table 4A). The top enriched biological 
processes by up-regulated proteins are involved in muscular and ECM development. 
The top enriched biological processes by down-regulated proteins are involved in 
metabolism (Supplementary Figure 2, Supplementary Table 4B, and 4C).
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FIGURE 1. Pairwise analyses using DESeq2 and integrative analyses using unsupervised O2PLS 
in all samples. (A) An overview of the study design. (B) Upper plot: MA (ratio intensity) plot show-
ing the hyper- and hypoacetylation regions in HCM samples compared to controls using DESeq2; 
Bottom plot: principal component analysis (PCA) plot showing the separation between HCM and 
control samples based on the top differentially acetylated regions using DESeq2. Mean values of 
normalized counts in all samples are depicted on the x-axis and fold changes (log2) on the y-axis. 
(C) Upper plot: PCA plot showing the separation between HCM and control samples based on 
the top differentially expressed genes using DESeq2; Bottom plot: MA plot showing the up-reg-
ulated and down-regulated genes in HCM samples compared to controls using DESeq2. (D) 
Upper plot: PCA plot showing the separation between HCM and control samples based on the 
top differentially expressed proteins using DESeq2; Bottom plot: MA plot showing the up-reg-
ulated and down-regulated proteins in HCM samples compared to controls using DESeq2. (E) 
Score plot of the first joint component of the H3K27ac ChIP-seq data showing the separation 
of HCM hearts from controls. (F) Score plot of the first joint component of the RNA-seq data 
discriminating HCM hearts from controls. (G) Venn diagram showing the overlapping targets be-
tween the top 2,000 genes obtained using the integrative approach (O2PLS) and differentially ex-
pressed genes obtained using the pairwise comparison (DESeq2). (H) Enrichment analyses using 




Integrating histone acetylome, transcriptome, and proteome changes in HCM
We also integrated H3K27ac ChIP-seq and RNA-seq data in an unsupervised manner 
using O2PLS. Notably, without predefining the patient and the control groups, the first 
joint component of both ChIP-seq and RNA-seq plots discriminated HCM from control 
hearts (Figure 1E and 1F). DNA regions and genes that contributed to the separation 
between HCM and control hearts are shown in Supplementary Table 5. Next, we aimed 
to identify key genes that underlie the separation between two groups and show 
altered expression levels in HCM hearts versus controls. Therefore, we overlapped 
2,000 genes that discriminate HCM hearts and controls from the integrative analysis 
(O2PLS) with the differentially expressed genes from the pairwise comparison with the 
top and obtained 618 up-regulated genes and 308 down-regulated genes (Figure 1G 
and Supplementary Table 6A). These overlapping genes are enriched for biological 
processes in the circulatory system and muscle contraction and pathways involved 
in the ECM formation and complement system (Figure 1H, Supplementary Table 6B).
Since only 11 out of 13 HCM samples were included in the proteomics experiment 
and a different set of control samples was used in comparison with the HCM group, 
we could not apply O2PLS to integrate the proteomic data with either H3K27ac ChIP-
seq or RNA-seq data. We, therefore, overlapped differentially expressed genes 
supported by DESeq2 and O2PLS analyses with proteomic data and identified 36 
up-regulated protein-coding genes and 17 down-regulated protein-coding genes in 
HCM versus control hearts (Table 1). Notably, the protein levels of 38 protein-coding 
genes are detectable in the plasma and 5 out of them were consistently changed in 
the same direction in HCM versus control hearts at DNA (5kb from TSS), RNA, and 
protein levels, including the up-regulation of ASPN, FMOD, MCAM, and NPPA and the 
down-regulation of AASS, highlighting them as promising candidates for biomarker 
discovery in HCM (Table 1).
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FIGURE 2. Gene set enrichment analysis showing the correlation of the gene set, which are 
established in extracellular matrix organization (A), cardiac muscle contraction (B), and fatty acid 
metabolism (C), in annotated genes from differentially acetylated regions (histone acetylome), 
differentially expressed genes (transcriptome), and genes encoding differentially expressed 
proteins (proteome), respectively. Differentially expressed genes were ranked by their fold 
changes and shown on the x-axis. The running correlation throughout the gene set is shown 
by the curve (green) and the running enrichment score (ES) is shown on the y-axis. Enrichment 
score normalized for gene set size (NES), Familywise-error rate p-value (FWER), and the false 
discovery rate (FDR) are shown per enrichment plot.
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Combined omics analyses identify ECM, muscle contraction, and metabolism as 
the main mechanisms altered in HCM
Genes annotated to differentially acetylated regions in the histone acetylome data, 
differentially expressed genes in the transcriptome data, and differentially expressed 
proteins in the proteome data consistently pointed to biological functions involved 
in enhancement of ECM, enhancement of muscle contraction, and suppression 
of metabolism in HCM versus control hearts. To further evaluate these biological 
functions, we collected gene sets that are known to regulate ECM remodeling, 
muscle contraction, and metabolism, and performed GSEA to study whether they are 
primarily found in the up-regulated or down-regulated data sets in our study or they 
are randomly distributed. We observed that genes involved in ECM and cardiac muscle 
contraction were positively correlated with genes annotated to the hyperacetylated 
regions in the ChIP-seq data, the up-regulated genes in the RNA-seq data, and genes 
encoding the up-regulated proteins in the proteomics data (Figure 2A and 2B). Genes 
that are related to fatty acid metabolism were significantly correlated with genes 
annotated to the hypoacetylated regions in the ChIP-seq data, the down-regulated 
genes in the RNA-seq data, and genes encoding the down-regulated proteins in the 
proteomics data (Figure 2C, Supplementary Figure 3). Combined, we confirmed that 
pathways involved in ECM, muscle contraction, and metabolism were affected in HCM.
Consistently, protein-coding genes (36 up-regulated and 17 down-regulated ones) 
were enriched for comparable biological processes and pathways as shown in previous 
analyses, such as ECM and muscle contraction (Supplementary Table 6C). We also 
studied protein networks among them and observed that ECM and muscle contraction 
were the most enriched pathways by the up-regulated protein-coding genes and 
metabolism was the most enriched pathway by the down-regulated protein-coding 
genes (Figure 3A and 3B).
Enriched transcription factor binding motifs in differentially acetylated regions
To define the actual factors that regulate altered RNA/protein expression in HCM 
hearts, we studied the putative transcription factors (TFs) encoded by enriched 
transcription factor binding motifs (TFBMs) in differentially acetylated regions 
by scanning through the HOCOMOCO motif database of 769 human primary and 
alternative binding models. We obtained 125 TFBMs in the hyperacetylated regions 
and 115 TFs were predicted to bind to them. In the hypoacetylated regions, 120 TFBMs 
were enriched and they encoded for 111 TFs. Out of those, 68 annotated TFs were 




FIGURE 3. (A) An overview of protein-protein interactions of up-regulated proteins in HCM 
versus control hearts. Each node represents an individual protein. Nodes highlighted in red 
are involved in the top enriched pathway in extracellular matrix organization (ECM). Nodes 
highlighted in blue are involved in the top enriched pathway in muscle contraction. (B) An over-
view of protein-protein interactions of down-regulated proteins in HCM versus control hearts. 
Each node represents an individual protein. Nodes highlighted in green are involved in the top 
enriched pathway in metabolism. (C) Transcription factors enriched in differentially acetylated 
chromatin regions and their corresponding p-values (Fisher test) are shown on the left, and their 
mRNA expression levels among all samples are shown in the heatmap on the right. RPKM: reads 
per kilobase million. (D) Western blot data showing the protein levels of KLF15 and RXRA were 
comparable between HCM and control hearts. (E) A schematic overview showing all analysis 
steps in histone acetylome, transcriptome, and proteome data used in this study.
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Notably, 2 TFs (KLF15 and ETV4) that were encoded by enriched TFBMs in the 
hyperacetylated regions showed higher mRNA levels in HCM hearts than controls, 
and 7 TFs (AR, CLOCK, ETS2, GATA5, MEIS1, RXRA, and ZFX ) that were encoded by 
enriched TFBMs in the hypoacetylated regions showed lower mRNA levels in HCM 
hearts than controls (Figure 3C). These TFs are enriched for biological functions 
involved in muscle hypertrophy and lipid metabolism (Supplementary Table 7), 
suggesting their potential roles in regulating the upstream signaling in HCM. Next, 
we examined their expressions in cardiomyocytes using the public single-nuclear RNA-
seq data from adult human hearts [12]. We observed that they were all expressed in 
ventricular cardiomyocytes (Supplementary Figure 7). Interestingly, KLF15, AR, CLOCK, 
MEIS1, and ZFX were more abundantly expressed than ETV4, ETS2, GATA5, and RXRA. 
We also examined their mRNA expressions in genome-engineered cardiomyocytes 
with mutated MYBPC3 compared to the control cardiomyocytes from a published 
study using RNA-seq (Supplementary Table 10), which provided insights into the early 
biological changes due to mutated MYBPC3 in cardiomyocytes [13]. Interestingly, in 
line with our findings obtained from the bulk level at the severe stage, the mRNA 
level of ETV4 was significantly increased (P-value=9.56E-9) in mutant cardiomyocytes 
compared to the controls, whereas the mRNA level of RXRA was significantly decreased 
(P-value=0.001) in mutant versus control cardiomyocytes. However, they showed 
comparable expression levels between HCM and control hearts in the proteome data. 
We further examined their protein expressions using western blot and confirmed that 
they were not significantly changed in HCM versus control hearts (Figure 3D). We 
performed additional immunofluorescence staining and examined the expression 
of KLF15 in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-
cardiomyocytes) with and without mutated MYBPC3. We observed the expression 
of KLF15 in hiPSC-cardiomyocytes (Figure 6A), however, more cell lines derived from 
different patients and healthy individuals are needed to study whether the KLF15 
signal differs between diseased and control cardiomyocytes.
A schematic overview of all analysis steps is shown in Figure 3E.
Genes discriminating HCM from controls show consistent changes on various levels
We further selected an example of one down-regulated and one up-regulated gene 
and examined them in more detail to demonstrate the strength of our integrative omic 
analysis. ATP2A2, one protein-coding gene from the overlapping candidates, encodes 
the sarcoplasmic reticulum Ca2+-ATPase pump SERCA2a and plays a critical role in 
the regulation of calcium handling [14]. We identified ATP2A2 as one of the major 
candidates in discriminating HCM hearts from controls in our integrated H3K27ac 
ChIP-seq and RNA-seq analysis (Figure 4A). Besides, its mRNA and protein levels were 
significantly lower in HCM versus control hearts in the pairwise comparison, and the 




FIGURE 4. Changes of ATP2A/SERCA2a and HSPA2 at the mRNA and protein levels in HCM 
versus control hearts. (A) A plot of the joint component loadings of RNA-seq data showed 
ATP2A2 and HSPA2 were two major players in discriminating HCM hearts from controls. The 
dashed lines on both positive and negative sides indicate the cutoff threshold, with genes with a 
large contribution to the joint component falling outside of the dash lines. (B) ATP2A2 mRNA and 
protein levels in HCM and control samples at the mRNA and protein levels. (C) HSPA2 mRNA and 
protein levels expression in HCM and control samples. **: P<0.01, ***: P<0.001, ****: P<0.0001. 
(D) Representative immunohistochemistry staining showing higher HSPA2 staining intensity in 
HCM heart as compared to control. Scale bar=400µm (control sample) and 800µm (HCM sample). 
(E) Representative immunofluorescence staining showing HSPA2 aggregates in an HCM heart 
(indicated by the arrow), whereas the control shows diffuse staining of the cytoplasm without 
aggregates. WGA-AF488 appears in grey to visualize the cell membrane and DAPI appears in 
blue to visualize the nuclei. Scale bar=16µm.
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HSPA2, another protein-coding gene from the overlapping candidates, is involved in 
protein quality control [15]. We demonstrated that HSPA2 acts as another key player 
in discriminating HCM hearts from controls (Figure 4A). Its mRNA and protein levels 
were significantly higher in HCM versus control hearts in the pairwise comparison, 
and the enhanced protein level was also validated using western blot (Figure 4C). The 
upstream regulatory region of HSPA2 also showed a higher acetylation level in HCM 
versus control hearts (Table 1). Moreover, we showed a profound HSPA2 intensity 
in HCM compared to the control heart using the immunohistochemistry staining at 
low magnification (Figure 4D). Next, we employed immunofluorescence staining at 
high magnification and observed occasional HSPA2 aggregates in cardiomyocytes 
from the HCM heart, whereas no HSPA2 aggregates were shown in the control heart 
(Figure 4E).
Allelic imbalance of MYBPC3 in HCM hearts is observed at both DNA and RNA 
levels
To further explore the potential of the produced data, we investigated the contribution 
of both MYBPC3 alleles in the sequencing datasets. In the patient cohort, three 
heterozygous truncating mutations were present in MYBPC3, namely c.2373dupG 
(n=5), c.2827C>T (n=6), and c.927-2A>G (n=2). We observed that the average 
acetylation ratio of MYBPC3 with c.2373dupG, c.2827C>T, and c.927-2A>G mutation 
to wildtype allele was 50%, 25%, and 66.6% respectively (Supplementary Figure 5A). 
The average mRNA expression ratio of MYBPC3 with c.2373dupG, c.2827C>T, and 
c.927-2A>G mutation to wildtype allele was 6.7%, 19.7%, and 43.4% respectively 
(Supplementary Figure 5B). The acetylation and mRNA levels of three mutations were 
not observed in control hearts (Supplementary Figure 5C and 5D). It has to be noted 
that it is not possible to effectively distinguish between wildtype and mutant alleles 
in the proteomics data.
Cellular fraction sub-analysis of bulk cardiac tissue transcriptome indicates cardio-
myocyte enrichment in a cellular-specific response in HCM
Since there are multiple cell types present in the heart samples, we collected cell-
type-specific markers for cardiomyocytes and 11 non-myocyte cell types as revealed 
by recent single-cell studies in the heart [16,17], ranging from 8 to 19 markers per cell 
type (Supplementary Table 9), and we examined their expression levels in our bulk 
sequencing data. Cardiomyocyte-specific markers showed higher histone acetylation 
and mRNA levels than markers of 11 non-myocyte cell types (Figure 5A and 5B), 
regardless of health and disease. The mRNA expression of several cell-type-specific 
markers was significantly different between HCM and control hearts (Figure 5C). The 
upstream regulatory region of three cardiomyocyte-specific markers and one T-cell-
specific marker also showed significantly higher acetylation activities in HCM hearts 




FIGURE 5. The expression of cell-type-specific markers in 12 cell populations. (A) The histone 
acetylation levels of 11 cell-type-specific markers. Each dot represents the average acetylation 
value of each marker for all samples, or only control or HCM samples. One-way ANOVA was used 
to compare the mean of cardiomyocyte-specific markers with the mean of non-myocyte markers 
separately: ns (not significant), *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (B) The mRNA 
expression levels of 11 cell-type-specific markers. Each dot represents the average expression 
value of each marker for all samples, or only control or HCM samples. One-way ANOVA was 
used to compare the mean of cardiomyocyte-specific markers with the mean of non-myocyte 
markers separately: ns (not significant), *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (C) Heat-
map showing cell-type-specific markers with significantly changed mRNA expression levels in 
HCM hearts compared to controls. Fold changes of these markers are depicted. Positive fold 
changes (red) and negative fold changes (blue) represent up-regulation and down-regulation 
in HCM versus control hearts respectively. (D) Histone acetylation levels at the upstream (50 
kb) of three cardiomyocytes-specific markers (red) and one T cells-specific marker (violet) were 
significantly changed between HCM and control hearts. Tracks of one HCM and one control 
heart were scaled in the UCSC genome browser (ln(x+1): 0-10). Significantly changed upstream 
regions are indicated by the black bar above. The transcription start and end site of each marker 
are indicated by the blue arrow below.
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Identified candidates supported by multi-omics data in human induced pluripotent 
stem cells derived cardiomyocytes (hiPSC-cardiomyocytes)
We further evaluated the presence of obtained candidates, which were supported 
by the acetylome, transcriptome, and/or proteome data (Table 1), using hiPSC-
cardiomyocytes with and without mutated MYBPC3. We first employed the 
transcriptome profile comparing the genome-engineered cardiomyocytes harboring 
mutated MYBPC3 with the controls (Supplementary Table 10) from a published study 
[13]. Out of 53 candidates, 18 protein-coding genes (34%) from our bulk data also showed 
significantly affected mRNA levels between diseased and control cardiomyocytes 
(Table 1). Next, we examined the expression levels of several candidates between 
hiPSC-cardiomyocytes with and without mutated MYBPC3 using immunofluorescence 
staining, including ACTN2 and ATP2A2. Consistent with the suppressed mRNA and 
protein levels of ACTN2 in HCM versus control hearts, we observed that unlike the 
well-aligned cytoskeleton structure in control cardiomyocytes, HCM cardiomyocytes 
seemed to have a disrupted cytoskeleton as revealed by ACTN2 staining (Figure 6B). 
Besides, we again observed the inhibited expression of ATP2A2/SERCA2a in HCM 
cardiomyocytes when compared with the controls (Figure 6C). Combined, we showed 
that candidates screened by multi-omics approaches from the cardiac tissues also 




FIGURE 6. Immunofluorescence (IF) staining of selected candidates in control and HCM 
hiPS-cardiomyocytes. The same amount of control and HCM hiPS-cardiomyocytes (20,000 cells 
per well) were seeded to the plate and cultured for 27 days prior to the staining. (A) Represen-
tative IF staining showing the expression of KLF15 in HCM and control cardiomyocytes (KLF15: 
red; ACTN2: green; blue: cell nuclei). (B) Representative IF staining showing disrupted ACTN2 
in HCM cardiomyocytes compared to controls (ACTN2: green; blue: cell nuclei). (C) Represen-
tative IF staining showing suppressed ATP2A2 in HCM cardiomyocytes compared to controls 
(ATP2A2: red; blue: cell nuclei). Nuclei were stained by Hoechst. All overview images were taken 
at 20x magnification, scale bar = 100 µm. All zoomed regions were taken under Zoom Factor=1.5.
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DISCUSSION
In the present study, we studied changes in histone acetylome, transcriptome, and 
proteome between HCM and control hearts. Integrating these multi-omics data, we 
present for the first time a set of DNA regions and genes that differentiate HCM from 
control hearts and identified 53 protein-coding genes as the major contributors. Since 
these comprehensive datasets consistently indicated altered biological functions 
involved in ECM, muscle contraction, and metabolism, we further studied and 
identified the upstream TFs that could play a critical regulatory role. We also observed 
an abundance of acetylation signals and transcripts signals from cardiomyocyte-
specific markers compared to markers of 11 non-myocyte populations in the heart.
By integrating ChIP-seq, RNA-seq, and proteomics data we identified a list of deciding 
elements in discriminating HCM hearts from controls. Among these, ATP2A2/
SERCA2a, the cardiomyocyte-specific marker, transports cytosolic calcium into the 
sarcoplasmic reticulum and subsequently regulates the contraction and relaxation 
of cardiomyocytes [18]. Suppressed ATP2A2/SERCA2a expression is associated with 
impaired relaxation in cardiomyocytes and contributes to diastolic dysfunction in 
HCM [14,19]. Consistent with previous findings, we also showed lower mRNA and 
protein levels in HCM hearts compared to controls. Additionally, we employed iPSC-
derived cardiomyocytes and confirmed the suppressed ATP2A2/SERCA2a in HCM 
versus control cardiomyocytes.
Another element HSPA2 (heat shock-related 70 kDa protein 2), which protects cardiac 
integrity by correcting misfolded proteins upon stress [20], showed higher upstream 
acetylation level, mRNA level, and protein level in HCM hearts versus controls. Up-
regulated HSPA2 protein level has been observed at both the initial stage of diseased 
cardiomyocytes and at the end stage of diseased heart with diastolic dysfunction 
[21,22]. We previously also showed elevated HSPA2 protein level in HCM with 
mutations in different sarcomeric proteins when compared to controls and it was 
negatively correlated with MYBPC3 peptide counts [15]. Here we further demonstrated 
a cardiomyocyte-specific elevation of HSPA2 accompanied by the occasional HSPA2 
aggregates in the HCM heart, which may contribute to the disease progression by 
hampering the protein quality control system.
Interestingly, both ATP2A2/Serca2a- and HSPA2-mediated activities are ATP-
dependent, highlighting the strength of our sequencing data that align with 
previous observations showing energy deficiency as a key pathomechanism in HCM 
development. A reduced myocardial external efficiency, the ratio between cardiac 
work and oxygen consumption, in asymptomatic MYBPC3 mutation carriers compared 
to the control hearts [23]. More details on the metabolic changes in HCM hearts 




MYBPC3 mutations showed a reduced super-relax state, which may result in an 
increased sarcomere energy utilization [25]. Likewise, hiPSC-derived cardiomyocytes 
with mutated MYH7, another sarcomeric gene that is often mutated in HCM patients, 
also showed a reduced super-relax state, increased contractility, and a greater basal 
oxygen consumption rate when compared to the controls, suggesting an impaired 
energetics [26]. Taken together, previous studies show mutation-mediated contractile 
dysfunction with associated disturbed energetics. Here, besides the enriched 
metabolism using the ChIP-seq, RNA-seq, and proteomic data, we also identified 
several TFs as potential key upstream factors in regulating metabolisms in HCM hearts, 
such as KLF15, AR, and RXRA [27–29]. Furthermore, we confirmed the expression of 
KLF15, a key regulator in cardiac metabolism [30], in hiPSC-cardiomyocytes using 
immunofluorescence staining, highlighting the potential involvement of KLF15 in 
diseased cardiomyocytes. Drugs targeting energy metabolism, such as trimetazidine, 
have been investigated in the clinical trial in HCM patients [31]. Combined, identified 
TFs could be potential therapeutic targets in restoring metabolic homeostasis in HCM 
patients, and future studies in hiPSC-cardiomyocyte models are warranted to define 
the mutation-mediated sequence in mitochondrial function and cellular metabolism.
Although those identified TFs showed the same changing direction at the acetylation 
and mRNA levels in HCM versus control hearts, their protein levels were comparable 
between HCM and control hearts. Similarly, some of those identified key protein-
coding genes, which changed in the same direction at the mRNA and protein levels, 
showed comparable acetylation levels between HCM and control hearts. These 
findings indicate that the central dogma of cellular information transition from DNA, 
RNA, to protein is oversimplified [32]. Numerous factors, such as the post-translational 
modifications on gene expression and TF activity, mRNA degradation, and protein 
degradation [33–36], could lead to a poor correlation between DNA, mRNA, and 
protein expressions. Additionally, both H3K27ac ChIP-seq and RNA-seq data were 
generated from the same 13 HCM and 10 control samples. Whereas, only 11 out 
of 13 HCM samples were included in the proteomics analysis in comparison with 
8 different control samples. Thus, different donor samples and group sizes might 
obscure the integrative analysis of the multi-omics data. Therefore, it is important 
to find an optimal way to integrate multi-omics data rather than a simple correlative. 
The discovery of new types of machinery beyond the central dogma is also needed 
in future studies.
Previous studies from our group and others showed around a 30% ratio of mutant to 
wildtype MYH7- and MYBPC3-alleles in HCM patients at the mRNA and the protein 
levels, respectively [37,38]. In this study, we present the imbalanced mRNA expression 
of three truncating mutations in MYBPC3. Notably, we showed for the first time the 
presence of such an imbalance at the DNA level by evaluating allele-specific histone 
acetylation signals. The mutant/wildtype expression ratio differs between truncating 
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mutations and between DNA and mRNA levels, suggesting mutation-specific 
imbalance and additional machinery between DNA and mRNA. It is important to 
point out that H3K27ac ChIP-seq is sensitive in capturing upstream regulatory regions 
of a gene and is restored in covering the core gene body [39], the allelic expression 
based on the histone acetylation level could be limited by the nature of the technique. 
Nevertheless, this finding highlights another utilization of omics data in detecting 
allelic imbalance for genetic diseases.
As the cell composition changes in diseased hearts, we investigated cell-type-specific 
signals from cardiomyocytes and 11 non-myocyte cell types and observed more ChIP-
seq signals and transcripts in cardiomyocyte-specific markers than all non-myocyte 
markers, suggesting a considerable portion of cardiomyocytes-derived signals in the 
bulk sequencing data. Gene set enrichment analysis showed enriched pathways in 
ECM, which is in line with previous reports indicating fibrosis as a hallmark of HCM [40]. 
Apart from fibroblasts, cardiomyocytes also express ECM-related genes, including 
two fibroblast-specific markers (DKK3 and ABI3BP) [41]. Because cell-type-specific 
markers might also be expressed by other cell types and the limitation of capturing 
pure cell populations from snap-frozen tissues without damaging the DNA and RNA 
integrity, we can only speculate that the majority of the signals were likely obtained 
from cardiomyocytes and it remains a challenge to separate them in bulk sequencing. 
Additionally, we used cell-type-specific markers obtained from the murine models 
[16,17], which may not translate one-to-one across species. Therefore, future studies 
are required to validate the cellular-specific response in HCM by isolating single-cell 
populations from human cardiac tissues.
In conclusion, our study presents detailed information in HCM hearts with truncating 
MYBPC3 mutations. These data showed altered ECM, muscle contraction, and 
metabolism in HCM. Integrative analyses further identified a subset of protein-coding 
genes and upstream TFs that could drive these pathophysiological mechanisms 
and serve as promising diagnostic and/or therapeutic targets. We also showed a 
considerable amount of cardiomyocyte-derived signals compared to non-myocyte 




The study protocol was approved by the local medical ethics review committees, 
including the Biobank Research Ethics Committee of University Medical Center Utrecht 
(protocol number 12/387), the local ethics committee of the Erasmus MC (2010-




Review Board), and the Sydney Heart Bank (HREC Univ. Sydney 2012/030). Since septal 
thickening is a typical feature of HCM, septal myectomy is commonly performed to 
relieve left ventricular outflow tract obstruction in HCM patients [2,42,43]. Therefore, 
we collected cardiac tissue of the interventricular septum of 13 HCM patients. Genetic 
analyses of all patients revealed three truncating pathogenic heterozygous mutations 
in MYBPC3, namely c.2373dupG in 5 HCM patients, c.2827C>T in 6 patients, and 
c927-2A>G in 2 HCM patients. Control tissues of 18 non-failing donors were obtained 
from the Biobank of University Medical Center Utrecht, the Washington University 
School of Medicine, and the Sydney Heart Bank. Informed consent was obtained from 
each patient prior to surgery or was waived by the ethics committee when acquiring 
informed consent was not possible due to the death of the donor. Samples were 
collected and snap-frozen in liquid nitrogen and stored at -80˚C up until analysis. 
Detailed clinical characteristics are shown in Supplementary Table 1 and an overview 
of samples included in the following experiments is shown in Figure 1A.
H3K27ac chromatin immunoprecipitation and sequencing (ChIP-seq)
We performed chromatin immunoprecipitation and sequencing (ChIP-seq) using the 
H3K27ac mark to study the differences of the histone acetylome between patient 
and control samples as previously described [10]. To study the differences of the 
histone acetylome between patient and control samples, we performed chromatin 
immunoprecipitation and sequencing (ChIP-seq) using the H3K27ac mark. Briefly, all 
cardiac samples were sectioned at a thickness of 10µm, and chromatin was isolated 
using the MAGnifyᵀᴹ Chromatin Immunoprecipitation System kit (Life Technologies) 
according to the manufacturer's instructions. The anti-histone H3K27ac antibody 
(ab4729, Abcam) was used for immunoprecipitation. Captured DNA was purified using 
the ChIP DNA Clean & Concentrator kit (Zymo Research). Libraries were prepared 
using the NEXTflex™ Rapid DNA Sequencing Kit (Bioo Scientific). Samples were PCR 
amplified, checked for the proper size range and absence of adaptor dimers on a 2% 
agarose gel, and barcoded libraries were sequenced 75 bp single-end on an Illumina 
NextSeq500 sequencer. Sequencing reads were mapped against the reference 
genome (hg19 assembly, NCBI37) using the BWA package (mem –t 7 –c 100 –M –R)1. 
Multiple reads mapping to the same location and strand were collapsed to a single 
read and only uniquely placed reads were used for peak-calling. Peaks/regions were 
called using Cisgenome 2.02 (–e 150 -maxgap 200 –minlen 200). Region coordinates 
from all samples were stretched to at least 2000 base pairs and collapsed into a 
single common list. Overlapping regions were merged based on their coordinates. 
Only regions supported by at least 2 independent datasets were further analyzed. 
Autosomal sequencing reads from each ChIP-seq library were overlapped back with 
the common region list to set the H3K27ac occupancy for every region-sample pair. 
Differentially acetylated regions between HCM and control hearts were identified 
using DESeq2 under the default setting in the Galaxy environment [44].
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Annotating genes in the vicinity of differentially acetylated regions
Region-to-gene annotation was performed to study potentially affected genes in the 
vicinity of DNA regions with altered acetylation levels in HCM hearts when compared 
with controls. Differentially acetylated regions located within either +/-5 kb or +/-50 
kb window from the transcription start site (TSS) of all genes were obtained, and the 
nearest genes of these regions were collected.
Predicting transcription factor binding motifs in differentially acetylated regions
To study the putative upstream signaling, we studied the enriched transcription 
factor binding motifs (TFBMs) by differentially acetylated regions and motifs-encoded 
transcription factors (TFs). DNAse I hypersensitivity regions in human cardiac samples, 
which play a key role in transcription factor footprinting [45], were collected from the 
ENCODE project and overlapped with differentially acetylated regions in this study [46]. 
Overlapping DNA sequences between differentially acetylated regions and DNAse 
I hypersensitivity regions were used to studying the enriched transcription factor 
binding motifs and motifs-encoded TFs using MEME Suite AME tool (HOCOMOCO 
Human v11 Full, average odds scoring method, and Fisher’s exact test) [47].
RNA sequencing
We also performed RNA sequencing (RNA-seq) and obtained the transcriptome 
landscapes in all samples. Briefly, RNA was isolated using the RNeasy Micro Kit (Qiagen) 
or ISOLATE II RNA Mini Kit (Bioline) according to the manufacturer’s instructions. 
Sample quality was assessed using the 2100 Bioanalyzer with an RNA 6000 Pico Kit 
(Agilent), and sample quantity was measured using Qubit Fluorometer with an HS RNA 
Assay (Thermo Fisher). Afterward, libraries were prepared using the NEXTflexTM Rapid 
RNA-seq Kit (Bioo Scientific) and sequenced by the Nextseq500 platform (Illumina). 
Sequenced reads were aligned to the human reference genome GRCh37 using STAR 
v2.4.2a [48]. Reads per kilobase million reads sequenced (RPKMs) were calculated 
with edgeR’s RPKM function [49]. To identify a list of differentially expressed genes 
between HCM and control hearts at Padj<0.05, we employed d DESeq2 to process all 
the raw counts per sample per group in the Galaxy environment [44].
Allele-specific expression of MYBPC3 in ChIP-seq and RNA-seq data
RNA-seq and ChIP-seq reads were processed with TrimGalore (version 0.6.5) to 
detect and clip off adaptor sequences, reads with a remaining length of 20 or more 
nucleotides, and an average read quality q>20 were selected. The reads were aligned 
to the human genome (GRCh37) with transcript annotation from Ensembl (version 
74) using the STAR aligner (version 2.7.1a). To facilitate the equal alignment of reads 
from wildtype and mutant alleles, alignments were made without clipping off end 
sequences (STAR option alignEndsType set to EndToEnd), and only best scoring 
alignments were selected (STAR option outSAMprimaryFlag set to AllBestScore). 




python (version 2.7.10) script [50]. Reads that aligned to the same genomic interval 
and that aligned with identical bases to the two non-indel MYBPC3 SNPs (rs397516082 
and rs387907267) of interest, were considered duplicates. ChIP-seq reads matching 
to one of the three SNPs of interest were assigned to the wildtype or mutant allele 
based on the following rules: for the single base polymorphic SNPs (rs397516082 
and rs387907267), based on having the wildtype or mutant nucleotide aligned to the 
SNP position; for the indel SNP (rs397515963) based on having the exact wildtype or 
mutant sequence of the SNP with 10 surrounding bases in a read aligned to the SNP. 
In addition, ChIP-seq reads with wildtype or mutant assignment were required to 
have >90% of the bases aligned to the genome. For RNA-seq reads, the assignment 
to be wildtype or mutant allele derived was complicated by changed splice patterns 
for two of the three SNPs. For rs387907267 (c.2827C>T) that has no changed splice 
patterns, reads were classified based on having the wildtype or mutant nucleotide 
aligned to the SNP position. For rs397515963 (c.2373dupG) that disrupts the correct 
splicing of intron 23, reads covering the splice-junction with the correct intron spliced 
out were counted as wildtype reads, whereas reads using either the correct intron 
donor or acceptor site, but not both, were counted as mutant reads. For rs397516082 
(c.927-2A>G) that disrupts the correct splicing of intron 11, reads covering the splice-
junction with the correct intron spliced out were counted as wildtype reads, whereas 
reads that were running through the intron 11 - exon 12 splice site and into the SNP 
position were counted as wildtype or mutant based on having the wildtype or mutant 
nucleotide aligned to the SNP position.
Integrating ChIP-seq and RNA-seq data with Two-way Orthogonal Partial Least 
Squares
To find common parts between RNA-seq and ChIP-seq data simultaneously across 
all genes and regions, a data integration approach is considered using Two-way 
Orthogonal Partial Least Squares (O2PLS) [51]. O2PLS decomposes both RNA-seq 
and ChIP-seq datasets into joint, omic-specific, and residual parts. The joint subspaces 
contain variations that are correlated to one another. The Joint Principal Components 
(JPCs) that span the joint subspaces are obtained by finding linear combinations of 
genes and regions that maximize the covariation. Omic-specific subspaces capture 
variation unrelated to another omics dataset, enabling JPCs to better estimate 
the underlying system. Here, the rows of the ChIP-seq and RNA-seq data should 
represent the same samples. Note that O2PLS uses all genes and regions in the 
datasets, and does not rely on prior information about the position or function of 
these features. Furthermore, O2PLS is unsupervised, and its algorithm is implemented 
in the OmicsPLS R package and freely available from CRAN [52]. Prior to the analysis, 
genes with expression lower than 10 counts in at least 22 samples were removed. 
Samples in both datasets were matched and 23 overlapping samples were retained. 
The expression data is normalized. Both datasets were log-transformed, and quantile 
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normalized across samples. The dimensionality of the preprocessed datasets is 23 by 
15,882 (RNA-seq) and 23 by 33,642 (ChIP-seq).
Proteomics
We performed proteomics using cardiac samples from the same patients (n=11) and 8 
non-failing donor samples from the Sydney heart bank (Supplementary Table 1). Briefly, 
proteins were loaded to a 4-12% NuPAGE Novex Bis-Tris 1.5 mm mini gel (Invitrogen) 
for separation, followed by fixation (50% ethanol and 3% phosphoric acid) and staining 
using 0.1% Coomassie brilliant blue G-250 solution. In-gel digestion was performed 
and the samples were concentrated in a vacuum centrifuge as described previously 
[53]. Nano-LC-MS/MS was performed as described previously [54]. Briefly, separated 
peptides were separated using an Ultimate 3000 Nano LC-MS/MS system (Dionex LC-
Packings, Amsterdam, The Netherlands) and trapped. Eluting peptides were ionized into 
a Q Exactive mass spectrometer (Thermo Fisher, Bremen, Germany), and intact masses 
were measured in the orbitrap. Among all, the top 10 peptide signals were selected 
and analyzed using the MS/MS. MS/MS spectra were searched against a Uniprot 
human reference proteome FASTA file (Swissprot_2017_03_human_canonical_and_
isoform.fasta, 42161 entries) using MaxQuant version 1.5.4.1. Differentially expressed 
proteins between HCM and control hearts at P<0.05 were identified using DESeq2 [44].
Functional enrichment analysis
Gene Ontology (GO) enrichment analysis: To study the enriched biological functions, 
GO enrichment analysis was performed using the ToppFun ToppGene Suite under 
the default settings (FDR correction, p-value cutoff of 0.05, and gene limits between 
1 and 2,000) [55].
Gene set enrichment analysis (GSEA): Established gene sets involved in the most 
enriched biological functions in HCM versus control hearts were collected from 
Molecular Signature Database v7.1 (Supplementary Table 8) [56,57]. Each gene set 
per biological function was studied for its positive or negative correlation with genes 
annotated from the altered acetylated levels in the ChIP-seq data, genes with altered 
mRNA levels in the RNA-seq data, and protein-coding genes with altered protein 
levels in the proteomic data in this study under the following setting: Number of 
permutations: 1,000; Phenotype labels: up_versus_down; Collapses dataset to gene 
symbols: false; Permutation type: gene_set; Enrichment statistics: weighted; Metric for 
ranking genes: Signal2Noise; Gene list sorting mode: real; Gene list ordering mode: 
descending; Max size: 500; Min size: 1.
Protein-protein interaction (PPI) networks: Protein networks were performed using 
the STRING Version 11.0 under the following settings: the meaning of network edges: 




Human induced pluripotent stem cells derived cardiomyocytes (hiPSC-cardiomyocytes)
Clones from one control hiPSC line and one hiPSC line derived from an HCM patient 
with mutated MYBPC3 were differentiated to cardiomyocytes as previously described 
[59]. The contractile function of differentiated control and HCM cardiomyocytes were 
examined as previously described [60]. Cells were seeded at the density of 20,000 
cells per well to the 96-well plate. After culturing for 27 days, cardiomyocytes were 
fixed and stained for interested proteins.
Western blot
Western blot was performed as described previously [15]. Primary antibodies, including 
mouse anti-HSPA2 (heat shock-related 70 kDa protein 2, 66291-1, Proteintech Group), 
mouse anti-GAPDH (10R-G109a, Fitzgerald Industries International), anti-ATP2A2 
(sarcoplasmic reticulum Ca2+-ATPase 2, also known as SERCA2), anti-KLF15 (AV32587, 
Sigma Aldrich), anti-RXRA (ab125001, Abcam), and anti-β-actin, were used.
Immunohistochemistry and immunofluorescence (IF) staining
Tissue sections were thawed and left at RT for 20 min inside a closed box. Then 
the sections were treated with peroxidase blocking solution (3% H2O2 in MeOH) 
and blocked with 1% BSA. HSPA2 (Anti-HSPA2 rabbit-Polyclonal antibody Prestige 
Antibodies HPA000798) primary antibodies were incubated for 1 hour at RT (1:100 
for IF and 1:200 for IHC). Sections were washed and incubated with the secondary 
antibodies for 30 min. Vector Vectastain Universal Elite ABC Kit (PK-6200) was used 
to enhance the brightfield staining (IHC) and WGA (for cell membranes) and DAPI 
(nuclei) were added to counterstain fluorescence staining. The brightfield slides were 
washed, treated with DAB, counterstained with Mayers Hematoxylin, dehydrated, and 
mounted with DPX. Fluorescence staining was mounted with Mowiol. Images were 
acquired with the Vectra Polaris Scanner (brightfield/IHC) or Confocal Nikon A1 (IF). 
The analysis was performed with QuPath, Fiji, and NIS Nikon software.
HiPSC-cardiomyocytes were fixed using 4% paraformaldehyde solution for 10 mins 
at room temperature and incubated overnight with the primary antibodies, including 
ACTN2 (A7811, Sigma Aldrich) and ATP2A2 (MA3-910, Thermo Fisher Scientific). 
Afterward, cells were washed three times with PBS and incubated for 1 hr with Hoechst 
33342 and the secondary antibodies (Invitrogen), including Alexa Fluor 488 and Alexa 
Fluor 568. Images were taken by Leica confocal microscope at 20x magnification.
Availability of data and materials
All relevant data are available within the article and the supplementary files. Because 
of the sensitive nature of the data collected for this study (13 patient samples and 
10 control samples), requests to access the raw sequencing dataset from qualified 
researchers trained in human subject confidentiality protocols may be sent to 
the corresponding authors. It is important to note that processed RNA-seq and 
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H3K27ac ChIP-seq data of 11 patient samples and 7 control samples are published 
in a GWAS study [7] and available in Supplementary Table 3 and Supplementary 
Table 5, respectively. Raw proteomics data within the article can be found at the 
ProteomeXchange Consortium via the PRIDE partner repository with the dataset 
identifier PXD012467 [61]. Currently, the paper is accepted by Circulation: Heart Failure 
and will become publicly available soon.
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Sex-differences in clinical presentation contribute to the phenotypic heterogeneity 
of hypertrophic cardiomyopathy (HCM) patients. While disease prevalence is higher 
in men, women present with more severe diastolic dysfunction and worse survival. 
Until today, little is known about the cellular differences underlying sex-differences 
in clinical presentation.
Methods
To define sex-differences at the protein level, we performed a proteomic analysis in 
cardiac tissue obtained during myectomy surgery to relieve left ventricular outflow tract 
obstruction of age-matched female and male HCM patients harboring a sarcomere 
mutation (n=13 in both groups). Furthermore, these samples were compared to 8 non-
failing controls. Women presented with more severe diastolic dysfunction.
Results
Out of 2099 quantified proteins, direct comparison of male and female HCM samples 
revealed only 46 significantly differentially expressed proteins. Increased levels of 
tubulin and heat shock proteins were observed in female compared to male HCM 
patients. Western blot analyses confirmed higher levels of tubulin in female HCM 
samples. In addition, proteins involved in carbohydrate metabolism were significantly 
lower in female compared to male samples. Furthermore, we found lower levels of 
translational proteins specifically in male HCM samples. The disease-specificity of 
these changes were confirmed by a second analysis in which we compared female 
and male samples separately to non-failing control samples. Transcription factor 
analysis showed that sex hormone-dependent transcription factors may contribute 
to differential protein expression, but do not explain the majority of protein changes 
observed between male and female HCM samples.
Conclusion
In conclusion, based on our proteomics analyses we propose that increased levels of 
tubulin partly underlie more severe diastolic dysfunction in women compared to men. 
Since heat shock proteins have cardioprotective effects, elevated levels of heat shock 
proteins in females may contribute to later disease onset in woman, while reduced 
protein turnover in men may lead to the accumulation of damaged proteins which in 
turn affects proper cellular function.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease with 
a prevalence of 1:200-500 (1, 2). Clinically, it is characterized by unexplained asymmetric 
left ventricular hypertrophy and diastolic dysfunction (3, 4). A pathogenic mutation is 
identified in about 50–60% of all patients (5). Both genetic and clinical heterogeneity 
is large, with more than 1,500 identified gene mutations, and mutation carriers who 
are asymptomatic, die of acute cardiac arrest or show end-stage heart failure (6).
Sex-differences in clinical presentation contribute to the phenotypic heterogeneity 
of HCM. Several large cohort studies observed a higher disease prevalence in men 
representing 55–65% of the total HCM population (7–11). At HCM diagnosis, women are 
on average 9 years older than men (7, 12), and at the time of myectomy surgery women are 
on average 7 years older than men (13). While women display less ventricular remodeling 
(14, 15), several studies have demonstrated more severe diastolic dysfunction (13, 16–18) 
and worse survival compared to men (19). Based on recent studies, our group put forward 
the hypothesis that disease severity in female patients with HCM is underestimated 
because females have smaller hearts than men, and the diagnostic criterion of ≥15mm 
wall thickness does not take into account a correction by body surface area (BSA) (20). 
Consequently, womenmay be diagnosed at a later disease stage, since it takes more time 
for them to reach the diagnostic threshold of 15mm wall thickness. This is supported by 
the observation that differences in wall thickness between genotype-positive men and 
women, that presented for cardiac screening, aremitigated after correction for BSA (21).
Recently, efforts have been made to understand the sexspecific phenotypical differences 
on a cellular level. Single cardiomyocyte studies did not observe sex-specific changes 
in passive stiffness compared to non-failing controls, and the HCMrelated increase in 
myofilament Ca2+-sensitivity was similar in male and female HCM patients, implying 
that the sex-difference in diastolic dysfunction is not explained by sarcomere function 
itself (13). However, women had more fibrosis compared to men, expressed more 
compliant titin and showed reduced levels of calcium-handling proteins (13). These 
findings are first indications of differences between males and females on a cellular 
level. To further investigate cellular alterations that may underlie the sex-differences 
in HCM, we analyzed protein expression data of males and females in a proteomics 
data set of septal myocardial tissue that was collected during myectomy surgery.
By direct comparison of male and female samples we found higher levels of tubulin 
subunits and heat shock proteins in females. The levels of a-tubulin, determined by 
Western blot analysis, correlate with diastolic function displayed as E/e’ and may 
therefore at least partly underlie the sex-difference in diastolic dysfunction. The 
increased levels of heat shock proteins in females are proposed to be cardioprotective 






The proteomics data in this study is a new analysis of a subset of the samples that were 
included of the study from Schuldt et al. (24), where we identified HCM-specific protein 
changes compared to non-failing controls. We here focus on sex-specific protein 
changes in HCM by comparing cardiac samples from age-matched female and male 
genotype-positive HCM patients. In addition, a comparison was made between the 
proteomics data from the female and the male group, and the proteomic data from 
the non-failing control group. HCM patient tissue from the interventricular septum 
(IVS) of HCM patients was obtained during myectomy surgery to relieve left ventricular 
outflow tract obstruction (LVOTO). The study protocol for the human tissue samples 
was approved by the local medical ethics review committees and written informed 
consent was obtained from each patient prior to surgery.
For the analysis of sex-differences age-matched sarcomere mutation-positive (SMP) 
female (n = 13) and male (n = 13) samples were compared in a group-wise comparison 
using the beta binomial test as described previously (24, 25). Furthermore, the male 
and female SMP samples were compared to 8 nonfailing healthy controls (NFIVS; 
5 females and 3 males) obtained fromthe SydneyHeart Bank (HREC Univ Sydney 
2012/030). The non-failing controls have no history of cardiac disease and do not take 
anymedication. The clinical characteristics of the groups are summarized in Table 1, 
individual patient characteristics are displayed in Supplementary Table 1.
Tissue Homogenization
Pulverized frozen tissue was homogenized in 40 μl/mg tissue 1x reducing sample buffer 
(106 mM Tris-HCl, 141 mM Tris-base, 2% lithium dodecyl sulfate (LDS), 10% glycerol, 
0.51 mM EDTA, 0.22 mM SERVA Blue G250, 0.18 mM Phenol Red, 100 mM DTT) using a 
glass tissue grinder. Proteins were denatured by heating to 99°C for 5 min, after which 
samples were sonicated and heated again. Debris was removed by centrifugation at 
maximum speed for 10 min in a microcentrifuge (Sigma, 1-15K).
Protein Fractionation
Proteins were separated using 1D SDS-PAGE. Samples from each group were 
loaded alternating on the gels to avoid bias. Equal volumes of sample (30 μl protein 
homogenate per sample, containing approximately 20-30 μg of protein) were loaded 
on a precast 4-12% NuPAGE Novex Bis-Tris 1.5 mm mini gel (Invitrogen). Electrophoresis 
was performed at 200V in NuPAGE MES SDS running buffer until the dye front reached 
the bottom of the gel. Gels were fixed in a solution of 50% ethanol and 3% phosphoric 
acid, and stained with 0.1% (w/v) Coomassie brilliant blue G-250 solution (containing 
34% (v/v) methanol, 3% (v/v) phosphoric acid and 15% (w/v) ammonium sulfate).
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In-Gel-Digestion
In-gel digestion was performed as described previously (26). The proteins were in-gel 
reduced with 10 mM DTT and alkylated with 54 mM iodoacetamide. Each gel lane 
was cut into 5 pieces which were subsequently sliced into 1 mm³ cubes. Proteins were 
digested in-gel with 6.3 ng/ml trypsin. Peptides were extracted from gel slices with 
1% formic acid and 5% formic acid/50% acetonitrile and concentrated in a vacuum 
centrifuge prior to nano-LC-MS/MS measurement. Samples were measured by LC-MS 
per gel band starting at the high molecular weight (MW) fraction for all samples, 
before continuing with the next gel band until the last (low MW fraction) band was 
measured. Injections alternated between all different group samples to minimize 
experimental bias between groups.
Nano-LC-MS/MS
Analysis of the experiment was performed as described in Piersma et al (27). Peptides 
were separated using an Ultimate 3000 Nano LC-MS/MS system (Dionex LC-Packings, 
Amsterdam, The Netherlands) equipped with a 40 cm x 75 μm ID fused silica 
column custom packed with 1.9 μm ,120 Å ReproSil Pur C18 aqua (Dr Maisch GMBH, 
Ammerbuch-Entringen, Germany). After injection, peptides were trapped at 6 μl/min 
on a 10 mm × 100 μm ID trap column packed with 5 μm, 120 Å ReproSil Pur C18aqua 
at 2% buffer B (buffer A: 0.5% acetic acid (Fischer Scientific), buffer B: 80% acetonitrile, 
0.5% acetic acid) and separated at 300 nl/min in a 10–40% buffer B gradient in 60 
minutes (90 min inject-to-inject). Eluting peptides were ionized at a potential of + 2 
kV into a Q Exactive mass spectrometer (Thermo Fisher, Bremen, Germany). Intact 
masses were measured at resolution 70,000 (at m/z 200) in the orbitrap using an 
automatic gain control (AGC) target value of 3x106 charges. The top 10 peptide signals 
(charge-states 2+ and higher) were submitted to MS/MS in the HCD (higher-energy 
collision) cell using 1.6 amu isolation width and 25% normalized collision energy. MS/
MS spectra were acquired at resolution 17,500 (at m/z 200) in the orbitrap using an 
AGC target value of 1x106 charges, a maxIT of 60 ms and an underfill ratio of 0.1%. 
Dynamic exclusion was applied with a repeat count of 1 and an exclusion time of 30 s.
Data Analysis
MS/MS spectra were searched against a Uniprot human reference proteome FASTA 
file (Swissprot_2017_03_human_canonical_and_isoform.fasta, 42161 entries) using 
MaxQuant version 1.5.4.1. Enzyme specificity was set to trypsin and up to two 
missed cleavages were allowed. Cysteine carboxamidomethylation was treated as 
fixed modification, and methionine oxidation and N-terminal acetylation as variable 
modifications. Peptide precursor ions were searched with a maximum mass deviation of 
4.5 parts per million (ppm) and fragment ions with a maximum mass deviation of 20 ppm. 
Peptide and protein identifications were filtered at a false discovery rate (FDR) of 1% 
using the decoy database strategy. The minimal peptide length was 7 amino acids, the 




was 6. Proteins that could not be differentiated based on MS/MS spectra alone were 
grouped to protein groups (default MaxQuant settings). Searches were performed with 
the label-free quantification option selected. The mass spectrometry proteomics data 
have been deposited to the ProteomeXchange Consortium via the PRIDE (28) partner 
repository with the dataset identifier PXD012467. Beta-binominal statistics were used to 
assess differential protein expression between groups, after normalization on the sum 
of the counts for each sample (25). Proteins with a p value below 0.05 were considered 
significantly differentially expressed. Proteins which were present in less than 25% of the 
samples or had an average normalized count of less than 1.4 were excluded from further 
functional analysis. Principal component analysis was performed in R. Therefore quantile 
normalization and log2 transformation was performed on the normalized counts. The 95th 
Percentile was taken, the data median centered and the principal components calculated. 
Hierarchical clustering was performed after a statistical multi-group comparison. 
Protein networks were generated utilizing the STRING database (Search Tool for the 
Retrieval of Interacting Genes/Proteins) and visualized with Cytoscape software (29). 
Protein interaction networks were generated with ClusterONE and gene ontology 
(GO) analysis was performed using the BiNGO application in cytoscape (30, 31). Venn 
diagrams were created with InteractiVenn tool (32) and the layout modified if needed.
Transcription Factor Analysis
The ToppFun tool from the ToppGene Suite was used to identify transcription factors 
of significantly different proteins between HCMfemale and HCMmale (33). All significantly 
different proteins between HCMfemale and HCMmale were used as input.
Western Blot
For analysis of protein levels by Western blot, whole tissue lysates were used from 
either the proteomic analysis or were prepared as described previously (34). Proteins 
were separated on precast SDS-PAGE 4-12% criterion gels (Bio-Rad) and transferred 
to polyvinylidene difluoride or nitrocellulose membranes. Site-specific antibodies 
directed to acetylated a-tubulin (Sigma, T7451), HSPA1 (Enzo Life Sciences, ADI-
SPA-810), HSPA2 (Proteintech group, 66291-1), HSPB1 (Enzo Life Sciences, ADISPA-800), 
HSPB5 (Enzo Life Sciences, ADI-SPA-223), HSPB7 (abcam, ab150390), HSPD1 (Enzo Life 
Sciences, ADI-SPA-805), HSPA4 (Cell Signaling, 3303S), HSP90 (Cell Signaling, 4874S), 
a-tubulin (Sigma, T9026), tyrosinated tubulin (Sigma, T9028), detyrosinated tubulin 
(abcam, ab48389), and GAPDH (Cell Signaling, 2118S; Fitzgerald, 10R-G109a) were used 
to detect the proteins which were visualized with an enhanced chemiluminescence 
detection kit (Amersham) and scanned with Amersham Imager 600. Protein levels were 
determined by densitometric analysis and normalized to GAPDH.
Statistics
Graphpad Prism v8 software was used for statistical analysis. Normally distributed 
data (except proteomics data) were statistically analyzed with the Student’s t-test 
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when comparing 2 groups and with one-way ANOVA when comparing more than 2 
groups. Non-normally distributed data were analyzed with Mann-Whitney test. Linear 
regression was statistically tested with Pearson correlation. Data are presented as 
means ± standard errors of the mean, clinical characteristics are presented as mean ± 
standard deviation or median with interquartile range when appropriate. Categorical 
data was statistically analyzed using Fisher’s exact test and presented as frequencies. 
A p-value ≤0.05 was considered as significantly different.
RESULTS
To define sex-specific protein changes in HCM, we compared the protein expression 
profile of male and female HCM samples. We performed a new analysis on a subset 
of patients from our proteomics data set (24). We compared age-matched samples 
from 13 male and 13 female sarcomere mutation-positive (SMP) HCM patients. The 
genotype distribution of both groups is depicted in Figure 1 and shows that the 
majority of mutations in both groups are located in the thick filament genes MYBPC3 
and MYH7. Clinical characteristics of the groups are summarized in Table 1. Both male 
and female patients had obstructive HCM. While male patients presented with a larger 
LV end-systolic diameter (ESD), females displayed more severe diastolic dysfunction, 
indicated by a higher E/e’ ratio compared to male patients, and more females with 
diastolic dysfunction stage 2 (35, 36).
FIGURE 1. Genotypes in female and male HCM patient groups. The pie charts indicate the 
number of patients with a mutation in MYBPC3, MYH7, TNNT2, TNNI3 and MYL2 for the female 




TABLE 1. Clinical characteristics. Table displays clinical characteristics of female and male HCM 
patient group with testing for statistical differences. Abbreviations: LVOTg, left ventricular outflow 
tract gradient; LAD, left atrial diameter; IVS, interventricular septum; IVSi, indexed interventricular 
septum thickness corrected for body surface area (BSA); EDD, end-diastolic diameter; ESD, end-






Age at myectomy (years) 48.5 ± 17.7 49.8 ± 15.5 0.85
LVOTg (mmHg) 60.4 ± 31.8 55.6 ± 32.2 0.72
LV parameters
LAD (mm) 45.5 ± 4.3 48.4 ± 7.3 0.25
IVS (mm) 21.0 [20.0-23.0] 21.0 [18.3-23.0] 0.80
IVSi 12.5 [10.0-13.8] 10.0 [8.3-10.8] 0.07
EDD (mm) 41.5 [39.3-42.8] 43.5 [40.0-46.5] 0.39
ESD (mm) 16.7 ± 1.2 24.9 ± 4.7 *0.02
Systolic parameter
FS (%) 56.7 ± 2.5 44.4 ± 12.3 0.13
Diastolic parameters
E/A ratio 1.20 [0.79-2.17] 0.87 [0.74-1.40] 0.34
E/e’ ratio 20.3 [17.9-32.7] 13.9 [12.6-16.0] ***0.0003
TR velocity (cm/s) 2.6 [2.1-2.9] 2.3 [2.2-2.4] 0.20
Grade of diastolic dysfunction
1 11.1% (1) 75.0% (9) **0.008
2 55.6% (5) 8.3% (1) *0.046
3 33.3% (3) 16.7% (2) 0.61
Medication
beta blocker 84.6% (11) 84.6% (11) >0.9999
calcium channel blocker 46.2% (6) 23.1% (3) 0.41
statins 15.4% (2) 23.1% (3) >0.9999
Although there is no difference between women and men in absolute IVS thickness, 
the women included in this study showed a higher IVS thickness when corrected for 
BSA compared to males (25% increase, p=0.07; Table 1). This is in line with a previous 
study showing significant differences in IVS thickness between women and men when 
corrected for BSA (13).
Females Express More Tubulin and Heat Shock Proteins
Out of 2099 quantified proteins, only 46 proteins were significantly differentially 
expressed in the direct comparison of the female and male group. Two functional 
protein interaction clusters were identified for both the 14 downregulated and the 32 
upregulated proteins in females compared to males. The functional protein clusters 
that were less expressed in females compared to males were related to muscle filament 
sliding and carbohydrate catabolic process (Figure 2A). The functional protein clusters 
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of proteins that are more expressed in females compared to males are chaperone-
mediated protein complex assembly and action potential (Figure 2B). Chaperone-
mediated complex assembly is, based on the number of proteins in this cluster (18, 
39% of the differentially expressed proteins), the dominating protein cluster in the 
comparison of female and male SMP HCM samples. Interestingly, this cluster contains 
mainly heat shock proteins (HSPs) and tubulin subunits. HSPs and tubulin have already 
been investigated before by our group in the context of SMP and sarcomere-mutation 
negative HCM samples (24, 34). Therefore, we now further determined if there are 
any sex-differences at the protein levels of tubulin and a selection of HSPs that were 
assessed by western blot. While we did not observe significant sex-differences in 
the levels of HSPA1, HSPA2, HSPB5, HSPB7, HSPA4 and HSP90, we found a trend 
to higher levels of HSPD1 (p = 0.0957) and HSPB1 (p=0.0850) in female compared 
to male samples [Figure 3, reanalyzed from the dataset from Dorsch et al. (34)]. 
Although the HSPs assessed by western blot do not show significant differences 
between females and males, the data are in line with the small fold changes found 
in the proteomics data and point toward higher levels of HSPs in female compared 
to male HCM tissue. Likewise, we analyzed the sex-differences in our tubulin data 
set (Figure 4), re-analyzed from the datasets from Dorsch et al. and Schuldt et al. 
(24, 34). In line with the proteomics data, levels of a-tubulin were significantly higher 
in females compared to males, whereas we did not find any sex-differences in the 
posttranslational modifications acetylation, tyrosination and detyrosination. To 
determine if elevated levels of tubulin may correlate with diastolic dysfunction, we 
plotted levels of a-tubulin with the clinical parameter E/e’ for male and female patients 
separately (Figure 4E). Female patients have higher levels of a-tubulin in combination 
with more severe diastolic dysfunction, as indicated by increased E/e’, compared to 




FIGURE 2. Functional protein cluster of the direct comparison of HCMfemale and HCMmale. (A) 
illustrates the functional protein cluster of the proteins that are significantly lower expressed 
in females compared to males. (B) shows the functional protein cluster of the proteins that are 
significantly higher expressed in females compared to males. For each protein cluster the most 
significant biological process is given. Proteins with a p-value <0.05 were used for the analysis.
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FIGURE 3. Protein levels of heat shock proteins determined by western blot. (A–C) Show repre-
sentative western blot images. (D–K) Display quantified protein levels for HSPA1, HSPA2, HSPD1, 
HSPB1, HSPB5, HSPB7, HSPA4, and HSP90, respectively. Data were statistically analyzed by un-
paired two-tailed t-test. Dashed line indicates protein levels in the NFIVS. Western blot dataset 
is partly derived from Dorsch et al. and re-analyzed for the age-matched samples included in 




FIGURE 4. Protein levels of α-tubulin and its posttranslational modifications determined by 
western blot. Panels (A-D) show protein levels of α-tubulin (A), acetylated tubulin (B), tyrosinat-
ed tubulin (C) and detyrosinated tubulin (D) with representative images. Data were statistically 
analyzed by unpaired two-tailed t-test, #p=0.0407. Dashed line indicates protein levels in the 
NFIVS.Western blot dataset is new analysis of a subset of samples from Dorsch et al. and Schuldt 
et al. (24, 34). (E) shows correlation of α-tubulin levels with E/e’ ratio.
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Proteins Involved in Translation Are Specifically Downregulated in Male HCM 
Patients Compared to Non-failing Control Myocardium
As an additional approach, we compared protein expression of both the male and 
the female group to NFIVS to look at specific sex-related protein changes compared 
to non-failing myocardium, thereby identifying proteins that are not only sex but also 
disease-specific. We have identified 236 proteins that are less expressed and 214 
proteins that are more expressed in the female HCM patients versus NFIVS. In the male 
HCM patients we identified 251 lower expressed proteins and 156 more abundant 
proteins compared to NFIVS. The top 10 functional protein interaction clusters of the 
females compared to NFIVS are listed in Table 2 and the top 10 protein clusters of the 
male samples compared to NFIVS are displayed in Table 3. The complete set of protein 
interaction clusters resulting from this analysis is shown in Supplementary Figures 1-4. 
To identify differences between female and male HCM using this analysis approach, we 
created Venn diagrams of the significantly different proteins from the female vs NFIVS 
and the male vs NFIVS comparison to look at overlapping proteins that are shared by 
both comparisons, and proteins that are unique for either males or females compared 
to NFIVS (Figures 5, 6, Venn diagrams).
Of the proteins that are downregulated compared to NFIVS we identified 181 proteins 
that are overlapping between males and females. These proteins belong mainly to 
metabolic pathways (Supplementary Figure 5), and can be considered as general 
HCM-specific protein changes. Fifty five of the downregulated proteins are only 
significantly different for the females. The functional protein clusters of these proteins 
are related to respiratory electron transport chain, cellular lipid catabolic process, 
response to activity, small molecule catabolic process, neutrophil degranulation, 
energy deprivation by oxidation of organic compounds and response to aldosterone 
(Figure 5A). Seventy downregulated proteins are only significantly different in the 
male group and cluster analysis revealed that the biggest protein cluster is related 
to the biological process translation. It contains many ribosomal proteins that have a 
consistently high fold-change compared no NFIVS. Other clusters are related to amide 
biosynthetic process and several processes related to energy metabolism like ketone 
body biosynthetic process, electron transport chain and tricarboxylic acid metabolic 
process. Furthermore, we obtained protein clusters related to pyridoxal phosphate 
biosynthetic process, cellular water homeostasis, glutathione metabolic process and 




TABLE 2. Top 10 differentially regulated pathways in HCMfemale vs NFIVS.
Downregulated proteins Upregulated proteins
Pathway (GO ID) nodes p-value Pathway (GO ID) nodes p-value
Cellular respiration 
(45333)









22 2.3313E-25 Post-translational protein 
modification (43687)
17 1.4103E-11
Organic acid catabolic 
process (16054)



























9 6.5002E-10 Cellular carbohydrate 
metabolic process (44262)
8 2.0038E-9
Cardiac muscle tissue 
development (48738)
8 9.5592E-12 Membrane organization 
(61024)
8 4.7889E-6
Table lists the top 10 functional protein cluster (based on size) of the down- and upregulated 
proteins for the comparison of HCMfemale with NFIVS. Displayed are the most significant biological 
process (gene ontology), the number of nodes in the cluster and the p-value.
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TABLE 3. Top 10 differentially regulated pathways in HCMmale vs NFIVS.
Downregulated proteins Upregulated proteins
Pathway (GO ID) nodes p-value Pathway (GO ID) nodes p-value
Cellular respiration 
(45333)
62 9.9733E-62 Extracellular matrix 
organization (30198)
47 9.0957E-40
Small molecule metabolic 
process (44281)





27 2.6386E-19 Striated muscle cell 
development (55002)
12 4.8955E-11
Carboxylic acid catabolic 
process (46395)














Protein folding (6457) 15 1.9000E-7 Response to muscle 
inactivity involved in 
regulation of muscle 
adaptation (14877)
8 8.5753E-6
Organic acid catabolic 
process (16054)










12 3.2195E-12 Regulation of podosome 
assembly (71801)
6 9.2900E-6
Table lists the top 10 functional protein cluster (based on size) of the down- and upregulated 
proteins for the comparison of HCMmale with NFIVS. Displayed are the most significant biological 




FIGURE 5. Functional protein cluster of the downregulated proteins that are unique for either 
HCMfemale or HCMmale when compared separately to NFIVS. A Venn diagram was created with 
the significantly lower expressed proteins between HCMfemale and NFIVS and HCMmale and NFIVS, 
to identify the downregulated proteins that are unique for either males or females, or shared 
by both groups. Panel (A) illustrates the functional protein cluster of the proteins that are only 
significantly lower expressed in females when compared to NFIVS, whereas (B) shows the func-
tional protein cluster of the proteins that are only significantly lower expressed in males when 
compared to NFIVS. For each protein cluster the most significant biological process is given. 
Proteins with a p-value <0.05 were used for the analysis.
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Microtubular and Heat Shock Proteins Are Specifically Upregulated in Female HCM 
Patients When Compared to Controls
For the upregulated proteins, 140 proteins are significantly more expressed in both 
females vs NFIVS and males vs NFIVS. The functional protein interaction clusters are 
illustrated in Supplementary Figure 6. The 74 proteins that are significantly higher in 
females compared to controls result in clusters related to response to unfolded protein, 
chylomicron assembly, membrane organization, regulation of cell migration, negative 
regulation of microtubule polymerization or depolymerization, positive regulation of 
cellular component organization, sarcomere organization, glycophagy, muscle organ 
development and carboxylic acid biosynthetic process (Figure 6A). With the cluster 
response to unfolded protein and negative regulation of microtubule polymerization 
or depolymerization the results of this approach are in line with the direct comparison 
of female and male HCM samples in which these proteins were represented by the 
cluster chaperone-mediated protein complex assembly. 8 of the 74 proteins that are 
significantly higher expressed only in females (CRK, HSPA4, TUBB6, ALDH1B1, DMD, 
LMOD2, HNRNPA3 and TFRC) overlap with the 46 proteins significantly different in 
the direct male and female comparison and may represent important candidates to 
define the female group (Figure 7).
The 16 proteins that are only significantly higher in HCM males compared to NFIVS did 
not form any functional protein cluster. Of these proteins, only the protein SLC27A6 
(solute carrier family 27 member 6/long chain fatty acid transport protein 6) overlaps 
with the 46 proteins that are significantly different in the direct comparison of females 
and males. As being significantly higher expressed compared to both NFIVS and 
females, SLC27A6, involved in long chain fatty acid uptake, may be an important 




FIGURE 6. Functional protein cluster of the upregulated proteins that are unique for either 
HCMfemale or HCMmale when compared separately to NFIVS. A venn diagram was created with the 
significantly higher expressed proteins between HCMfemale and NFIVS and HCMmale and NFIVS, to 
identify the upregulated proteins that are unique for either males or females or shared by both 
groups. Panel (A) illustrates the functional protein cluster of the proteins that are only signifi-
cantly higher expressed in females when compared to NFIVS. The proteins only significant for 
HCMmale did not give any functional protein cluster. For each protein cluster the most significant 
biological process is given. Proteins with a p-value <0.05 were used for the analysis.
Transcriptional Regulation of Significantly Different Proteins Between HCMfemale 
and HCMmale Is Not Dominated by Sex Hormones
Since sex hormones also act as transcription factors, we analyzed if sex-hormone-
related transcription factors can be responsible for the 46 significantly differentially 
expressed proteins of the direct comparison between female and male HCM samples 
(Figure 2). Possible transcription factor bindings sites were analyzed with the ToppFun 
database. Three hundred Seventy two transcription factors were identified that 
have binding-sites in the 46 proteins that are significantly different between female 
and male HCM patient samples. The 10 most significant transcription factors are 
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shown in Supplementary Table 2. Of these we found 7 to be sex-hormone related 
(Supplementary Table 3). These 7 transcription factors are involved in the regulation of 
5 significantly different proteins between male and female HCM myocardium: HSPD1, 
PYGM, DMD, ENO3 and TFRC. Of these, DMD, ENO3 and TFRC are also significantly 
different when comparing females with NFIVS (Figures 5, 6). With PYGM and ENO3 
involved in carbohydrate metabolism, DMD involved in muscle organization and 
HSPD1 as a member of the PQC, we thereby identified candidate proteins that may be 
regulated by sex hormone-related transcription factors. However, the bioinformatical 
analysis revealed that the 5 proteins also have binding sites for another 258 of the 372 
identified transcription factors. Based on this we can conclude that the differences 
found between female and male samples may be partly due to transcriptional 
regulation by sex hormones but that this is not the dominant mechanism driving sex-
dependent differential protein expression.
FIGURE 7. Normalized counts of proteins that are significantly upregulated in HCMfemale com-
pared to HCMmale and are uniquely upregulated in females when compared to NFIVS. (A) CRK, (B) 
HSPA4), (C) TUBB6, (D) ALDH1B1, (E) DMD, (F) LMOD2, (G) HNRNPA3 and (H) TFRC. #p<0.05, 





In this study we analyzed sex-differences at the protein level in proteomics data of 
HCM patient tissue to define sex-specific protein expression which may explain the 
difference in clinical presentation. The direct comparison of the male and female 
patient groups resulted in only a small number of significantly different proteins. 
Compared to males, female HCM patients display lower levels of myofilament proteins 
related to the biological process muscle filament sliding and have elevated levels 
of tubulin and HSPs. Consistently, by subtracting the baseline differences using an 
additional non-failing control group, we observed a more profound elevation of HSPs 
and the microtubule processes in female HCM patients.
Set of 8 Proteins Consistently Defines the Female HCM Patients
A study investigating sex-differences in gene expression at the mRNA level in 
idiopathic cardiomyopathy patients found 1837 differently expressed genes between 
male and female patients, of which the large majority of 1377 genes had a fold change 
<1.2 (37). Considering these low fold changes on a gene expression level, little changes 
at the protein level are to be expected. We found expression levels of 8 proteins 
significantly higher in females when directly compared to males, and also uniquely 
significant for females when compared to NFIVS (Figure 7). Thereby, these proteins 
are disease-specific and may play an important role in defining the female patient 
group. One of these proteins is CRK, which is an adaptor protein with SH2 and SH3 
domains but no catalytic region. It functions in signal transduction processes and 
has been shown to be involved in cardiac development (38). HSPA4 is a heat shock 
protein that acts as nucleotide exchange factor for HSP70 chaperones. Its expression 
is upregulated in response to pressure overload and in human heart failure, which is 
thought to be a beneficial response as it helps degrading misfolded proteins (39). 
TUBB6 is a b-tubulin subtype that forms microtubules together with a-tubulin. Elevated 
levels of tubulin have been observed in heart failure (40). ALDH1B1 is an aldehyde 
dehydrogenase that is involved in alcoholmetabolism and has been shown to function 
in glucose metabolism (41). DMD encodes for dystrophin and connects the actin 
cytoskeleton with the extracellular matrix. As actin crosslinker, it plays an important 
role for the mechanical properties of the cardiomyocyte. Elevated levels in females 
may be explained by its gene location on the X-chromosome. Mutations in DMD have 
been associated with muscular dystrophies and Xlinked dilated cardiomyopathy (42). 
LMOD2 is the cardiac isoform of leiomodin, an actin-binding protein involved in thin 
filament assembly. Studies in adult mice have shown that LMOD2 has an essential role 
in maintaining proper cardiac thin filament length and coinciding force generation (43). 
HNRNPA3 is a heterogeneous nuclear ribonucleoprotein that binds to single-stranded 
telomeric repeats to stabilize them (44), and TFRC encodes for the transferrin receptor 
that promotes iron uptake (45).
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Elevated Levels of HSPs and Tubulin Are in Line With a More Severe Phenotype
The most prominent difference in our study were higher levels of tubulin and HSPs 
in female compared to male HCM patient samples taken at the time of myectomy. 
Interestingly, sex-differences in the expression of HSPs have been observed before. 
Higher levels of HSPA1A have been measured in healthy female rat hearts compared 
to male, and these increased levels were estrogen dependent (46). We also found 
by bio-informatical analysis that HSPD1, which is elevated in female compared to 
male HCM myocardium, can be regulated by the estrogen-related receptor α. It 
may be speculated that the estrogen-dependent HSP induction, that is known to be 
cardioprotective (47), has also beneficial effects in HCM, leading to lower disease 
penetrance and later disease onset in women. Indeed, HSP activation has been shown 
to have beneficial effects on heart function in a mouse model of desmin-related 
cardiomyopathy in which HSP expression was induced by geranylgeranylacetone (48). 
In our study we observed increased protein expression of HSPs in tissue samples 
from symptomatic stage II HCM patients, which raises the question if the optimal 
therapeutic window for HSP induction might already be at an earlier preclinical stage 
of the disease. This warrants further studies in iPSC-derived human heart models and 
other cardiomyopathy animal models.
Cytoskeletal proteins like tubulin and desmin are known to be elevated in heart failure 
(40). Our group has previously shown that tubulin protein levels are increased in HCM 
myectomy tissue compared to NFIVS (24, 34). Interestingly, tubulin and desmin protein 
content has been shown to correlate well with left ventricular end-diastolic pressure 
(LVEDP) in heart failure (40). As increased LVEDP indicates diastolic dysfunction, 
cytoskeletal protein levels correlate directly with diastolic dysfunction. Furthermore, 
tubulin has in combination with its posttranslational modifications a direct effect on 
contractile function, as detyrosinated tubulin binds to desmin and causes a stiffening 
of the myofilament (49-51). As increased levels of tubulin in females compared to 
males correlate with more severe diastolic dysfunction (13), proof-of-concept studies 
in model systems have to show whether this is a causal relationship during HCM 
development.
Male Samples Display Lower Levels of Translational Proteins
Ribosomal and protein synthesis-related proteins, which form the cluster “translation”, 
were significantly downregulated in male HCM patients compared to NFIVS. 
Interestingly, it was recently shown that cMyBP-C protein synthesis and degradation 
rates were slowed down in induced pluripotent stem cell-derived cardiomyocytes 
harboring a heterozygous MYBPC3 mutation (52). The authors proposed that cells 
harboring a MYBPC3 truncating mutation may have the capacity to attain normal levels 
of cMyBP-C protein and thereby preserve cardiomyocyte function. On the other hand, 
protein turnover is needed to replace aged/damaged proteins. Thus, while reduced 




function, it may lead to accumulation of damaged proteins in the sarcomere. Our 
data are in line with the study of Helms and colleagues, and imply reduced protein 
turnover in particular in male HCM hearts at the time of myectomy. Increasing protein 
translation rate to maintain proper protein turnover represents an attractive avenue 
to further explore.
Sex-Specific Difference in Carbohydrate Metabolism
Downregulation of metabolic pathways is a general HCM disease hall mark (24, 53) and 
accordingly we did not find major differences in these pathways between males and 
females. However, females showed lower levels of proteins related to carbohydrate 
catabolic process (Figure 2A), including muscle associated glycogen phosphorylase 
(PYGM) and β-enolase (ENO3). Mutations in both of these genes have been associated 
with glycogen metabolism disorders (54). Consequently, reduced levels of PYGM 
and ENO3 impair glycogen metabolism in women. Our transcription factor analysis 
showed that both PYGM and ENO3 can be regulated by sex hormone transcription 
factors. The findings indicate that women may be less metabolically flexible to adapt 
to altered metabolic demand, at least during disease development. Imaging studies 
have shown that reduced cardiac efficiency occurs already at the early disease stage 
in asymptomatic male and female mutation carriers (55, 56) and may indicate that 
metabolic changes may be present in the very early stages before the onset of cardiac 
remodeling.
More Fibrosis in Female Patients Is Not Reflected at Protein Level
It has been observed that female HCM patient samples show more fibrosis compared 
to male samples (13). Interestingly, this difference is not reflected at protein level. 
Neither in the direct comparison of female and male HCM samples, nor in the analysis 
compared to NFIVS, we observed a specific increase in extracellular matrix proteins 
for females. In the current proteomics analysis, increased expression of extracellular 
matrix proteins was a general disease hallmark, and common for both female and 
male group. The methodological difference between quantifying proteins involved 
in extracellular matrix organization in this proteomics analysis and measuring the 
actual fibrotic area in tissue sections as performed by Nijenkamp et al. may underlie 
the divergent findings.
STUDY LIMITATIONS
The findings in this study are observational and provide a starting point for further 
validation in an independent cohort and proof-of-concept studies in disease models. 
Due to the limited availability of non-failing heart tissues, the male control samples 
used in this study are not age-matched with the male HCM samples, whichmay 
contribute to observed differences in protein expression. Furthermore, the group 
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size of only female or male non-failing samples is too small to perform comparisons 
of HCM and controls of the same sex. Therefore, follow-up studies would benefit from 
age-matched and increased numbers of nonfailing controls to differentiate between 
sex- and disease-specific differences in protein expression. As our findings point 
toward a possible role of sex hormone regulation, information about the hormonal 
state of the female subjects should be collected for future studies.
CONCLUSION
This proteomic analysis of female and male SMP HCM tissue highlights that elevated 
protein levels of tubulin correlate with more severe diastolic dysfunction in females. 
Another aspect which warrants further research is reduced protein turnover, in 
particular in male HCM, which may represent an adaptive mechanism to maintain 
protein stoichiometry, though may also have a negative impact and result in “aged” 
sarcomeres. Further research in experimental model systems is needed to determine 
if targeting tubulin and protein quality control at an early disease stage prevent the 
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archive/projects/PXD012467.
ETHICS STATEMENT
The studies involving human participants were reviewed and approved by Local 
medical ethics review committee of the Erasmus Medical Center, Rotterdam, 
Netherlands. Written informed consent to participate in this study was provided by 
the participants’ legal guardian/next of kin.
AUTHOR CONTRIBUTIONS
MS, DK, and JV conceived, designed, and coordinated the study and wrote the 
manuscript. MS, LD, JK, TP, TS, and SP performed and/or analyzed the experiments. 
CR and MM were involved in patient data andmaterial acquisition. CJ provided 
supervision for proteomics experiments. All authors proof-read the manuscript and 
gave valuable input.
FUNDING
We acknowledge the support from the Netherlands Cardiovascular Research Initiative: 
An initiative with support of the Dutch Heart Foundation, CVON2014-40 DOSIS and 
NWO (NWO-ZonMW; 91818602 VICI Grant to JV).
CONFLICT OF INTEREST
The authors declare that the research was conducted in the absence of any commercial 
or financial relationships that could be construed as a potential conflict of interest.
223
PROTEOMIC SEX DIFFERENCES IN HCM
REFERENCES
1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, BildDE. Prevalence of hypertrophic 
cardiomyopathy in a general population of young adults: echocardiographic analysis of 
4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. 
Circulation. (1995) 92:785–9. doi: 10.1161/01.CIR.92.4.785
2. Semsarian C, Jodie I, Martin Maron S, Barry JM. New perspectives on the prevalence of 
hypertrophic cardiomyopathy. J Am College Cardiol. (2015) 65:1249–54. doi: 10.1016/j.
jacc.2015.01.019
3. Michels M, Olivotto I, Asselbergs F, van der Velden WJ. Life-long tailoring of management 
for patients with hypertrophic cardiomyopathy: awareness and decision-making in changing 
scenarios. Neth Heart J. (2017) 25:186–99. doi: 10.1007/s12471-016-0943-2
4. Authors/Task Force, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 
ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task 
force for the diagnosis and management of hypertrophic cardiomyopathy of the european 
society of cardiology (ESC). Eur Heart J. (2014) 35:2733–79. doi: 10.1093/eurheartj/ehu284
5. Ho CY, Charron P, Richard P, Girolami F, Van Spaendonck-Zwarts KY, Pinto Y. Genetic 
advances in sarcomeric cardiomyopathies: state of the art. Cardiovasc Res. (2015) 105:397–
408. do: 10.1093/cvr/cvv025
6. Ingles J, Burns C, Barratt A, Semsarian C. Application of genetic testing in hypertrophic 
cardiomyopathy for preclinical disease detection. Circ Cardiovasc Genet. (2015) 8:852–9. 
doi: 10.1161/CIRCGENETICS.115.001093
7. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, et al. Gender-related 
differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J 
Am Coll Cardiol. (2005) 46:480–7. doi: 10.1016/j.jacc.2005.04.043
8. Kubo T, Kitaoka H, OkawaM, Hirota T, Hayato K, Yamasaki N, et al. Gender-specific 
differences in the clinical features of hypertrophic cardiomyopathy in a community-based 
Japanese population: results from Kochi RYOMA study. J Cardiol. (2010) 56:314–9. doi: 
10.1016/j.jjcc.2010.07.004
9. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of 
hypertrophic cardiomyopathy in a regional United States cohort. JAMA. (1999) 281:650–5. 
doi: 10.1001/jama.281.7.650
10. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, et al. Epidemiology of 
hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient 
population. Circulation. (2000) 102:858–64. doi: 10.1161/01.CIR.102.8.858
11. Marstrand P, Han L, Day SM, Olivotto I, Ashley EA, Michels M, et al. Hypertrophic 
cardiomyopathy with left ventricular systolic dysfunction: insights from the share registry. 
Circulation. (2020) 141:1371–83. doi: 10.1161/CIRCULATIONAHA.119.044366
12. Bos JM, Theis JL, Tajik AJ, Gersh BJ, Ommen SR, Ackerman MJ. Relationship between sex, 
shape, and substrate in hypertrophic cardiomyopathy. Am Heart J. (2008) 155:1128–34. doi: 
10.1016/j.ahj.2008.01.005
13. Nijenkamp L, Bollen IAE, van Velzen HG, Regan JA, van Slegtenhorst M. Sex differences at 





14. Schulz-Menger J, Abdel-Aty H, Rudolph A, Elgeti T, Messroghli D, Utz W, et al. 
Gender-specific differences in left ventricular remodelling and fibrosis in hypertrophic 
cardiomyopathy: insights from cardiovascular magnetic resonance. Eur J Heart Fail. (2008) 
10:850–4. doi: 10.1016/j.ejheart.2008.06.021
15. Leinwand LA. Sex is a potent modifier of the cardiovascular system. J Clin Invest. (2003) 
112:302–7. doi: 10.1172/JCI200319429
16. Chen YZ, Qiao SB, Hu FH, Yuan JS, Yang WX, Cui JG, et al. Left ventricular remodeling 
and fibrosis: sex differences and relationship with diastolic function in hypertrophic 
cardiomyopathy. Eur J Radiol. (2015) 84:1487–92. doi: 10.1016/j.ejrad.2015.04.026
17. Borlaug BA, Redfield MM, Melenovsky V, Kane GC, Karon BL, Jacobsen SJ, et al. Longitudinal 
changes in left ventricular stiffness: a community-based study. Circ Heart Fail. (2013) 6:944–
52. doi: 10.1161/CIRCHEARTFAILURE.113.000383
18. van Velzen HG, Schinkel AFL, Baart SJ R, Huurman, van Slegtenhorst MA, Kardys I, et 
al. Effect of gender and genetic mutations on outcomes in patients with hypertrophic 
cardiomyopathy. Am J Cardiol. (2018) 122:1947–54. doi: 10.1016/j.amjcard.2018.08.040
19. Geske JB, Ong KC, Siontis KC, Hebl VB, Ackerman MJ, Hodge DO, et al. Women with 
hypertrophic cardiomyopathy have worse survival. Eur Heart J. (2017) 38:3434–40.doi: 
10.1093/eurheartj/ehx527
20. van Driel B, Nijenkamp L, Huurman RM, van der Velden MJ. Sex differences in hypertrophic 
cardiomyopathy: new insights. Curr Opin Cardiol. (2019) 34:254–9. doi: 10.1097/
HCO.0000000000000612
21. Huurman R, Schinkel AFL, van der Velde N, Bowen DJ, Menting ME. Effect of body surface 
area and gender on wall thickness thresholds in hypertrophic cardiomyopathy. Neth Heart 
J. (2020) 28:37–43. doi: 10.1007/s12471-019-01349-1
22. Latchman DS. Heat shock proteins and cardiac protection. Cardiovasc Res. (2001) 51:637–46. 
doi: 10.1016/S0008-6363(01)00354-6
23. Golenhofen N, Perng MD, Quinlan RA, Drenckhahn D. Comparison of the small heat shock 
proteins alphaB-crystallin, MKBP. HSP25, HSP20, and cvHSP in heart and skeletal muscle. 
Histochem Cell Biol. (2004) 122:415–25. doi: 10.1007/s00418-004-0711-z
24. Schuldt M, Pei J, Harakalova M, Dorsch LM, Schlossarek S, Mokry M, et al. Proteomic 
and functional studies reveal detyrosinated tubulin as treatment target in sarcomere 
mutationinduced hypertrophic cardiomyopathy. Circ Heart Fail. (2021) 26:139–40. doi: 
10.1161/CIRCHEARTFAILURE.120.007022
25. Pham TV, Piersma SR, Warmoes M, Jimenez CR. On the betabinomial model for analysis 
of spectral count data in label-free tandem mass spectrometry-based proteomics. 
Bioinformatics. (2010) 26:363–9. doi: 10.1093/bioinformatics/btp677
26. Warmoes M, Jaspers JE, Pham TV, Piersma SR, Oudgenoeg G, Massink MP, et al. Proteomics 
of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential 
diagnostic and prognostic value in human breast cancer. Mol Cell Proteomics. (2012) 
11:M111013334. doi: 10.1074/mcp.M111.013334
27. Piersma SR, Broxterman HJM, Kapci, de Haas RR, Hoekman K, VerheulHM, et al. Proteomics 
of the TRAP-induced platelet releasate. J Proteom. (2009) 72:91–109. doi: 10.1016/j.
jprot.2008.10.009
28. Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, et al. 
The PRIDE database and related tools and resources in 2019: improving support for 
quantification data. Nucleic Acids Res. (2019) 47: D442–D50. doi: 10.1093/nar/gky1106
225
PROTEOMIC SEX DIFFERENCES IN HCM
29. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software 
environment for integrated models of biomolecular interaction networks. Genome Res. 
(2003) 13:2498–504. doi: 10.1101/gr.1239303
30. Maere S, Heymans K, Kuiper M. BiNGO: a cytoscape plugin to assess overrepresentation 
of gene ontology categories in biological networks. Bioinformatics. (2005) 21:3448–49. doi: 
10.1093/bioinformatics/bti551
31. Nepusz T, Yu H, Paccanaro A. Detecting overlapping protein complexes in protein-protein 
interaction networks. Nat Methods. (2012) 9:471–2. doi: 10.1038/nmeth.1938
32. Heberle H, Meirelles GV, da Silva FR, Telles GP, Minghim R. InteractiVenn: a web-based tool 
for the analysis of sets through Venn diagrams. BMC Bioinform. (2015) 16:169. doi: 10.1186/
s12859-015-0611-3
33. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene suite for gene list enrichment analysis 
and candidate gene prioritization. Nucleic Acids Res. (2009) 37:W305–11. doi: 10.1093/nar/
gkp427
34. Dorsch LM M, Schuldt, dos Remedios CG, Schinkel AFL, de Jong PL, Michels M, et al. 
(2019). Protein quality control activation and microtubule remodeling in hypertrophic 
cardiomyopathy. Cells. 8:741. doi: 10.3390/cells8070741
35. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. 
Recommendations for chamber quantification: a report from the American Society 
of Echocardiography’s Guidelines and Standards Committee and the Chamber 
Quantification Writing Group, developed in conjunction with the European Association of 
Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 
(2005) 18:1440–63. doi: 10.1016/j.echo.2005.10.005
36. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. 
Recommendations for the evaluation of left ventricular diastolic function by 
echocardiography. J Am Soc Echocardiogr. (2009) 22:107–33. doi: 10.1016/j.echo.2008.11.023
37. Fermin DR, Barac A, Lee S, Polster SP, Hannenhalli S, Bergemann TL, et al. Sex and age 
dimorphism of myocardial gene expression in nonischemic human heart failure. Circ 
Cardiovasc Genet. (2008) 1:117–25. doi: 10.1161/CIRCGENETICS.108.802652
38. Park TJ, Boyd K, Curran T. Cardiovascular and craniofacial defects in Crk-null mice. Mol Cell 
Biol. (2006) 26:6272–82. doi: 10.1128/MCB.00472-06
39. Mohamed BA, Barakat AZ, Zimmermann WH, Bittner RE, Muhlfeld C, Hunlich M, et al. 
Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis. J Mol Cell 
Cardiol/. (2012) 53:459–68. doi: 10.1016/j.yjmcc.2012.07.014
40. Heling A, Zimmermann R, Kostin S, Maeno Y, Hein S, Devaux B, et al. Increased expression 
of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ Res. 
(2000) 86:846–53. doi: 10.1161/01.RES.86.8.846
41. Singh S, Chen Y, Matsumoto A, Orlicky DJ, Dong H, Thompson DC, et al. ALDH1B1 links 
alcohol consumption and diabetes. Biochem Biophys Res Commun. (2015) 463:768–73. doi: 
10.1016/j.bbrc.2015. 06.011
42. Pecorari I, Mestroni L, Sbaizero O. Current understanding of the role of cytoskeletal cross-
linkers in the onset and development of cardiomyopathies. Int J Mol Sci. (2020) 21:16. doi: 
10.3390/ijms21165865
43. Pappas CT, Farman GP, Mayfield RM, Konhilas JP, Gregorio CC. Cardiacspecific knockout 
of Lmod2 results in a severe reduction in myofilament force production and rapid cardiac 




44. Tanaka E, Fukuda H, Nakashima K, Tsuchiya N, Seimiya H, Nakagama H. HnRNP A3 binds to 
and protects mammalian telomeric repeats in vitro. Biochem Biophys Res Commun. (2007) 
358:608–14. doi: 10.1016/j.bbrc.2007.04.177
45. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of 
mammalian iron metabolism. Cell. (2004) 117:285–97. doi: 10.1016/S0092-8674(04)00343-5
46. Voss MR, Stallone JN, Li M, Cornelussen RN, Knuefermann P, Knowlton AA. Gender 
differences in the expression of heat shock proteins: the effect of estrogen. Am J Physiol 
Heart Circ Physiol. (2003) 285:H687–92. doi: 10.1152/ajpheart.01000.2002
47. Knowlton AA, Korzick DH. Estrogen and the female heart. Mol Cell Endocrinol. (2014) 
389:31–9. doi: 10.1016/j.mce.2014.01.002
48. Sanbe A, Daicho T, Mizutani R, Endo T, Miyauchi N, Yamauchi J, et al. Protective effect 
of geranylgeranylacetone via enhancement of HSPB8 induction in desmin-related 
cardiomyopathy. PLoS ONE. (2009) 4:e5351. doi: 10.1371/journal.pone.0005351
49. Robison P, Caporizzo MA, Ahmadzadeh H, Bogush AI, Chen CY, Margulies KB, et al. 
Detyrosinated microtubules buckle and bear load in contracting cardiomyocytes. Science. 
(2016) 352:aaf0659. doi: 10.1126/science.aaf0659
50. Chen CY, Caporizzo MA, Bedi K, Vite A, Bogush AI, Robison P, et al. Suppression of 
detyrosinated microtubules improves cardiomyocyte function in human heart failure. Nat 
Med. (2018) 24:1225–33. doi: 10.1038/s41591-018-0046-2
51. Caporizzo MA, Chen CY, Bedi K, Margulies KB, Prosser BL. Microtubules increase diastolic 
stiffness in failing human cardiomyocytes and myocardium. Circulation. (2020) 141:902–15. 
doi: 10.1161/CIRCULATIONAHA.119.043930
52. Helms AS, Tang VT, O’Leary TS, Friedline S, Wauchope M, Arora A, et al. Effects of MYBPC3 
loss-of-function mutations preceding hypertrophic cardiomyopathy. JCI Insight. (2020) 
5:e133782. doi: 10.1172/jci.insight.133782
53. Coats CJ, Heywood WE, Virasami A, Ashrafi N, Syrris P, Dos Remedios C, et al. Proteomic 
analysis of the myocardium in hypertrophic obstructive cardiomyopathy. Circ Genom Precis 
Med. (2018) 11:e001974. doi: 10.1161/CIRCGENETICS.117.001974
54. Tarnopolsky MA. Myopathies related to glycogen metabolism disorders. Neurotherapeutics. 
(2018) 15:915–27. doi: 10.1007/s13311-018-00684-2
55. Guclu A, Knaapen P, Harms HJ, Parbhudayal RY, Michels M, Lammertsma AA, et al. Disease 
stage-dependent changes in cardiac contractile performance and oxygen utilization 
underlie reduced myocardial efficiency in human inherited hypertrophic cardiomyopathy. 
Circ Cardiovasc Imaging. (2017) 10:1249–54. doi: 10.1161/CIRCIMAGING.116.005604
56. Timmer SA, Germans T, Brouwer WP, Lubberink MJ, van der Velden AA. Carriers of the 
hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial 
efficiency in the absence of hypertrophy and microvascular dysfunction. Eur J Heart Fail. 
(2011) 13:1283–9. doi: 10.1093/eurjhf/hfr135
227
PROTEOMIC SEX DIFFERENCES IN HCM






METABOLOMIC SIGNATURES IN PRECLINICAL 
AND ADVANCED DISEASE STAGES OF 
HYPERTROPHIC CARDIOMYOPATHY
Maike Schuldt, Beau van Driel, Sila Algul, Rahana Y. Parbhudayal, Daniela QCM. 
Barge-Schaapveld, Ahmet Güçlü, Mark Jansen, Annette F. Baas, Mark A. van de Wiel, 






To define if disturbed myocardial energetics are reflected in the serum metabolome in 
the preclinical stage of HCM with the potential to serve as biomarkers, we performed 
a metabolomics screen in serum of asymptomatic carriers in comparison to healthy 
controls and patients with obstructive HCM (HOCM).
Background
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease but 
risk prediction is still poor due to incomplete penetrance and lack of clear genotype-
phenotype correlations. Advanced imaging techniques have shown altered myocardial 
energetics already in preclinical mutation carriers.
Methods
We performed non-quantitative direct-infusion high-resolution mass spectrometry-
based metabolomics on serum from fasted asymptomatic mutation carriers, 
symptomatic HOCM patients and healthy controls (n= 31, 14 and 9, respectively). 
We performed multivariate modelling with multiple gradient boosting classifiers to 
identify biomarker panels that discriminate the groups.
Results
For all 3 group-wise comparisons, we identified a panel of 30 serum metabolites that 
discriminate the groups. These metabolite panels perform equally good as advanced 
imaging techniques in distinguishing the groups.
Conclusions
This study reveals unique metabolic signatures in serum of preclinical Carriers and 
HOCM patients, which may be used for risk stratification and precision therapeutics.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease 
with a prevalence ranging from 1:500 to 1:200 (1,2) and identification of a pathogenic 
gene variant in~50-60% of all patients. Genetic family screening enables to identify 
gene variant carriers (carriers) early in life, who are at risk to develop cardiac disease. 
However, risk prediction is still poor due to incomplete penetrance and lack of clear 
genotype-phenotype correlations (3). Based on current guidelines of the European 
Society of Cardiology, HCM is defined by a wall thickness ≥13 mm in first-degree 
family members (i.e. preclinical carriers) in one or more left ventricular (LV) myocardial 
segments (2). To diagnose cardiac hypertrophy and dysfunction, the American College 
of Cardiology Foundation/American Heart Association recommends long-term clinical 
evaluations (echocardiography and electrocardiography) every 12–18 months from the 
age of 12 to 18–21 years, and at least every 5 years at the age of >21 years, while the 
ESC does not recommend a specific interval.
Efforts have been made to find prognostic markers that can identify asymptomatic 
preclinical carriers who are at risk to develop overt HCM. The first study that identified 
a possible early disease marker in blood was done by Ho et al. who provided evidence 
for a pro-fibrotic response in carriers without hypertrophy illustrated by significantly 
elevated levels of the C-terminal pro-peptide of type I procollagen (4). Furthermore, 
elevated levels of NT-proBNP have been linked with heart failure-related death and 
transplantation (5). Identification of markers at preclinical disease stage may allow 
early treatment to prevent and/or delay disease.
Here we performed a metabolic analyses in blood samples from carriers based on 
studies showing altered energetic state of the heart at preclinical HCM disease stage. 
Phosphorus-31 magnetic resonance spectroscopy showed an abnormal cardiac 
energetic state, evident from a decrease in the phosphocreatine to adenosine 
triphosphate ratio (PCr/ATP), in carriers independent of the presence of hypertrophy 
(6). In accordance, analysis of in vivo myocardial external efficiency by combined 
11C-acetate positron emission tomography (PET) and cardiovascular magnetic 
resonance (CMR) imaging showed increased myocardial oxygen consumption (MVO2) 
and decreased myocardial efficiency in preclinical carriers compared to healthy 
controls (7,8). At a cellular level, studies in human cardiac HCM samples showed 
that pathogenic gene variants increase myofilament calcium sensitivity, kinetics, and 
tension cost and alter myosin sequestration (9-14), which may alter cardiomyocyte 
energetics and underlie the increase in MVO2. In patients with obstructive HCM 
(HOCM), a decrease in MVO2 is observed compared to controls and carriers (15), which 
may be explained by secondary changes in metabolism and mitochondrial function in 
the hypertrophied myocardium. Indeed, proteomic analyses recently revealed lower 




(16,17). Overall, these studies show that metabolic changes (i.e. energetic state of the 
heart) are central in the early (preclinical) and advanced disease stages of HCM, and 
may be used as biomarker for disease stage-dependent diagnosis and the design of 
treatment strategies.
While advanced in vivo tools to monitor energy status and metabolism of the heart are 
available, such imaging modalities are expensive and limited to specialized medical 
centers. There is an urgent need to find easily accessible serum biomarkers for better risk 
prediction that can be tested in standard diagnostic laboratories. To define if changes 
in the metabolic serum profile are already evident at a preclinical stage of HCM, we 
performed a metabolomics screen in serum of asymptomatic carriers in comparison to 
healthy controls. To establish if the metabolic serum profile is altered at the advanced 
disease stage, a comparison was made between carriers and individuals with HOCM.
METHODS
Study population
The study protocol was in agreement with the principles outlined in the Declaration 
of Helsinki. Inclusion of individuals was part of the Engine study (18), and approval 
for this study was given by the local Medical Ethics Review Committees. Written 
informed consent was obtained from each individual prior to inclusion in this study. 
The study population consisted of 31 asymptomatic carriers without hypertrophy 
(carrier). Maximal wall thickness for the carrier group was based on the ESC criterion 
of LV thickness of ≥13 mm in first-degree family members. In addition, 14 patients with 
symptomatic HOCM. Criteria of exclusion were: aortic regurgitation more than grade 
1, presence of coronary artery disease (coronary artery stenosis >30%), previous septal 
reduction therapy, poor LV function (ejection fraction <50%), a history of diabetes 
mellitus or hypertension (defined as a systemic blood pressure ≥140/90 mm Hg), and 
significant renal dysfunction defined as an estimated glomerular filtration rate <30 
mL/min per 1.73∙m2 (15). Table S1 provides an overview of the specific mutations of 
both preclinical carriers and HOCM patients. Nine healthy related and mutation-
negative participants served as control group (Ctrl). PET-CMR data for these groups 
have been published previously (7,18). Clinical parameters of the different groups are 
shown in Table 1.
Blood serum preparation
Patients fasted overnight prior to collection of blood samples. The samples were 
collected by venous puncture and allowed to clot for 1 hour at 37°C. Following this 
incubation period, clotted samples were left to contract for at least 30 minutes at 4°C. 
The serum was centrifuged (4000 rpm, 20 minutes, 4°C) and separated. Sodium azide 
(0.01%) was added to the supernatant. All samples were stored at -20°C until use.
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Age (years) 38 ± 14* 50 ± 13# 51 ± 8
Male sex (no. (%))$ 7 (22.6) 10 (71.4) 6 (66.7)
LVM (g) 70.3 ± 16.8 193.7 ± 68.7*
,# 102.5 ± 17.8
LVMi 38.6 ± 7.3 95.4 ± 33.0*
,# 49.5 ± 6.1
LVEF (%) 67 ± 5 71 ± 10* 61 ± 6
Systolic BP (mmHg) 111 ± 14 118 ± 17 124 ± 13
Diastolic (mmHg) 66 ± 9 69 ± 13 69 ± 4
MAP (mmHg) 81 ± 10 85 ± 14 88 ± 5
HR (bpm) 61 ± 8 60 ± 4 66 ± 9
NT-proBNP (pg/l) 77 ± 55 1533 ± 2976 # 54 ± 55
1Values are given as mean ± SD. Abbreviations: HOCM, hypertrophic obstructive cardiomyopathy; 
Ctrl, control; LVM, left ventricular mass; LVMi, LVM indexed for body surface area; LVEF, left 
ventricular ejection fraction; BP; blood pressure; MAP, mean arterial pressure; HR, heart rate. 
*p<0.05 compared to Ctrl; #p<0.05 compared to Carrier, one-way ANOVA with Tukey’s multiple 
comparisons test. $p<0.05 Chi-square test.
Metabolomics profiling
Analysis of the metabolites was conducted as previously described (19). Briefly, 
a non-quantitative direct-infusion high-resolution mass spectrometry (DI-
HRMS) based metabolomics method was applied in combination with a nano-
electrospray ionization source. The mean peak intensities of the technical 
triplicates were calculated and annotated by matching the m/z of these mass 
peaks with a range of two parts per million to metabolite masses that are found 
in the Human Metabolome Database (20). Accordingly, mass peaks were identified.
Data analysis and modelling
We identified panels of metabolic biomarkers in order to discriminate between the 
following groups of subjects: Carrier vs Ctrl, Carrier vs HOCM and HOCM vs Ctrl. 
In brief, we used a combination of multiple gradient boosting classifiers (21,22) to 
improve prediction accuracy. To avoid over-fitting, we used a 5-fold stratified cross-
validation over the training partition of the data (80%), while the remaining data (20%) 
was used as the test dataset. We conducted a rigorous stability selection procedure 
(22) to ensure the reliability and robustness of the biomarker signatures. This was 
repeated 10 times and Receiver-Operating-Characteristics Area-Under-Curve (ROC 
AUC) scores were computed each time and averaged for the final test ROC AUC. A 
permutation (randomization test) (23) was used to evaluate statistical validity of the 
results. In the permutation test, the outcome variable (e.g. Carrier vs HOCM) was 
randomly reshuffled 1000 times while the corresponding -omics profiles were kept 
intact. We used Python v. 3.8 (www.python.org), with packages Numpy, Scipy and 





The prediction model combining MEE and MVO2.beat is a standard logistic regression 
model as fit with R’s glm() function. As this is a low-dimensional model, predictions 
were simply obtained from the model fit. These probabilistic predictions define the 
possible cut-offs for a positive test. Sensitivity and specificity are determined for 
these cut-offs, and then visualized by the receiver operating characteristic (ROC) 
curve. Area-under-the-ROC-curve (AUC) is determined as well. ROC and AUC were 
computed using R’s pROC package.
Correlation analysis
Pearson correlation with Benjamini-Hochberg correction was performed to check if 
top 30 metabolites correlate with clinical parameters.
Analysis of metabolite-protein links
For identification of functional links between metabolites and significantly different 
expressed proteins in HCM, the directly interacting enzymes of the top 30 metabolites 
of each pairwise comparison were identified using MetaBridge v1.2 based on the 
KEGG database. Consequently, proteins were overlapped with significantly different 
proteins in HCM compared to control, derived from a proteomics study of our group 
(17). Additionally, we identified metabolite-protein links by manual literature search.
Statistics
Graphpad Prism v8 software was used for statistical analysis of clinical data. Data were 
statistically analyzed using one-way ANOVA with Tukey’s multiple comparisons post 
hoc test or Chi-square test if appropriate. All values are shown as mean ± standard 
error of the mean. A p-value ≤0.05 was considered as significantly different.
RESULTS
Characteristics of study population
Metabolomic serum profiling was performed in 31 Carriers, 14 HOCM patients and 
9 Ctrl. Gene variants in the Carriers were present in MYH7, MYBPC3 and troponins 
(Figure 1A; Table S1), whereas HOCM patients displayed a mixed genetic background 
and 28.6% of patients were sarcomere mutation negative (Figure 1B). Figure 1A-B 
shows an overview of the affected genes in our study groups. Figure S1 highlights 
the location of all gene variants in this study. Patient characteristics are summarized 
in Table 1. The Carrier group was on average approximately 10 years younger than 
the HOCM and Ctrl group and is dominated by females, whereas HOCM and Ctrls 
have more males. The HOCM group showed significantly higher LV mass, a slightly 
increased LV ejection fraction and highly elevated NT-proBNP levels compared to 
Carriers and Ctrls, which is characteristic for the obstructive nature of the disease. 
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Changes in energetic status of the heart of included individuals, measured by PET-
CMR imaging (8,15), are illustrated in Figure 1. Compared to Ctrls, Carriers showed 
increased MVO2 and both Carriers and HOCM showed reduced myocardial external 
efficiency (MEE) (Figure 1C-D).
FIGURE 1. Distribution of affected genes in the (A) Carrier and (B) HOCM group. (C) Myocardial 
external efficiency (MEE) and (D) myocardial oxygen consumption normalized to tissue weight 
(MVO2) in Ctrls, Carriers and HOCM patients (data have been published in Guclu et al. and Par-
bhudayal et al. (8,15). ****p<0.0001, **p<0.01 compared to Ctrls, ##p<0.01 compared to HOCM, 
one-way ANOVA with Tukey’s multiple comparisons test.
Multivariate modeling reveals altered metabolic profile in preclinical stage of HCM
Multivariate modelling was performed for the Carrier vs Ctrl group, the Carrier vs 
HOCM group and the HOCM vs Ctrl group to determine if the serum metabolome 
profiles could distinguish the groups. Principal component analysis (PCA) (Figure S2A) 
and partial least squares-discriminant analysis (PLS-DA) (Figure 2A) indeed showed 
distinct patterns in all group comparisons. Notably, the Carrier group clusters more 
tightly than the control and HOCM group, indicating less variability within the Carrier 




group comparisons are presented with their relative importance in Figure 2B, and their 
corresponding –log10(p) values are presented in Figure S2C. Some metabolites cannot 
be uniquely identified because they share the same mass with other metabolites. 
The possible identifications of these metabolites are listed in Table S2. The radar 
plots in Figure 2C show the 15 most important metabolites that differentiate the 
two respective groups, and illustrate the differential serum metabolite profile in the 
different group comparisons. With this analysis we established metabolic signatures 
that define the three groups.
FIGURE 2. Multivariate modelling. (A) Partial least square-discriminant analysis plots for the 
three group-wise comparisons Carrier vs Ctrls, Carrier vs HOCM and HOCM vs Ctrls. (B) Top 30 
most predictive metabolites sorted based on their relative importance in distinguishing the two 
groups. (C) Radar plots of the top 15 most predictive metabolites, illustrating the differences in 
the serum metabolite profile between the groups.
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Distinct metabolic signatures at preclinical and symptomatic stage of HCM
We listed and grouped the 30 most predictive metabolites of each comparison into 
different subgroups based on their chemical taxonomy super class (Table 2). The bar 
graphs with the individual data points are provided in Figure S3A-C for Carrier vs 
Ctrl, in Figure S4A-C for Carrier vs HOCM and in Figure S5A-C for HOCM vs Ctrl (data 
from the third group is included in all comparisons). The number of metabolites per 
subgroup are shown in Table 2, and illustrate that the majority of changes are in the 




TABLE 2. Top 30 most important metabolites of the three pairwise comparisons categorized based 
on their chemical taxonomy super class2.
Carrier vs Ctrl Carrier vs HOCM HOCM vs Ctrl
Benzenoids
2 1 2











Metabolite 3 Metabolite 3
Metabolite 5 Metabolite 5
8-[(Aminomethyl)sulfanyl]-
6-sulfanyloctanoic acid




Metabolite 1 Glutarylcarnitine Metabolite 28
Metabolite 6 Metabolite 15 Metabolite 30
Metabolite 7 Metabolite 16 Metabolite 34
Metabolite 14 Metabolite 18 Metabolite 39
Perillic acid Metabolite 22 Metabolite 40
Tetracosanoic acid Metabolite 25 Metabolite 41
Metabolite 26 Stearic acid
Metabolite 27 Stigmastanol
Palmitoyl glucuronide
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TABLE 2. Continued.
Carrier vs Ctrl Carrier vs HOCM HOCM vs Ctrl





Metabolite 17 Cytidine 2’,3’-cyclic phosphate
Indoleacetyl glutamine Metabolite 19 Dityrosine
Metabolite 4 Metabolite 20 Gamma Glutamylglutamic acid
Metabolite 9 Metabolite 21 Metabolite 29
Metabolite 11 Metabolite 24 Metabolite 31
Metabolite 12 N-Acetylaspartylglutamic acid Metabolite 32





Metabolite 8 Epinephrine glucoronide Metabolite 33


















2The numbers indicate the number of metabolites in the different metabolite categories. 




Most metabolites that belong to the category “organic acids and derivatives” in 
all three comparisons are dipeptides. The dipeptides differ between the different 
comparisons but represent a common finding. Lipids and lipid-like molecules are also 
among the top 30 metabolites of all three comparisons. Among these metabolites are 
fatty acids and conjugates, indicating changes in the fatty acid metabolism, but also 
eicosanoids that represent metabolites involved in the inflammatory response. The 
number of metabolites belonging to the category “lipids and lipid-like molecules” is 
largest in the comparisons with the HOCM group, suggesting that changes in lipid 
metabolism are predominant in the advanced disease stage.
Notably, 7 of the 30 most important metabolites are predictive in two different 
comparisons (Figure 3). Pentadecanoylglycine and Metabolite 5 are amongst the 
30 most important metabolites in the Carrier vs Ctrl comparison and the Carrier vs 
HOCM comparison. This indicates that a decrease in these two metabolites may be an 
early change defining the Carrier group (Figure 3A). Levels of 11beta,20-Dihydroxy-3-
oxopregn-4-en-21-oic acid and 13’-Hydroxy-alpha-tocotrienol are higher in the HOCM 
group and may therefore define an advanced disease stage (Figure 3B). Among the 30 
most important metabolites in the Carrier vs Ctrl and the HOCM vs Ctrl comparison 
are SAICAR, Metabolite 2 and Metabolite 3. These metabolites show lower levels in 
both the Carrier and the HOCM group compared to Control and may characterize 
myocardial disease from early to late stages (Figure 3C).
Taken together, the 7 metabolites that are predictive in two different comparisons 
may play an important role in defining the disease stage.
Metabolic signature versus in vivo energetic status of the heart
To define if the top metabolites reflect energetic changes in the heart, a correlation 
was made between metabolites and MEE and MVO2. Correlation analyses showed 
that 15 metabolites of all three sets of top 30 metabolites significantly correlated 
with MEE, and 20 metabolites correlated with MVO2, but this correlation was not 
significant after correcting for multiple testing (p values are included in Table S2). 
This indicates that one single metabolite alone is not powerful enough as a predictive 
biomarker. To evaluate if the complete metabolic signature could be used to identify 
preclinical Carriers that show already an altered energetic status of the heart, we 
compared the performance of the imaging parameters MEE and MVO2 with the 
metabolite signature in sensitivity and specificity curves (Figure 4). In all three group-
wise comparisons the metabolite profile as well as the imaging parameters perform 
equally well in distinguishing the groups. As this analysis is driven by the 30 most 
important metabolites from our multivariate analysis, a biomarker panel derived from 
a selection of the 30 metabolites could potentially represent a suitable tool for clinical 
practice and has to be validated in an independent cohort.
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FIGURE 3. Metabolites that are among the 30 most important metabolites in distinguishing 
the groups in the (A) Carrier vs Ctrl and Carrier vs HOCM comparison, (B) Carrier vs HOCM and 
HOCM vs Ctrl comparison and (C) Carrier vs Ctrl and HOCM vs Ctrl comparison.
FIGURE 4. Sensitivity and specificity curves comparing the performance of the metabolomics 





In this study we investigated the ability of serum metabolites to discriminate preclinical 
carriers from healthy controls and HOCM patients. For each comparison we obtained 
a set of 30 metabolites that are together most predictive in distinguishing these 
groups. Based on the number of metabolites per category in each comparison (Table 
2) we can hypothesize that changes in organic compounds are an early event in HCM 
pathogenesis and already present in asymptomatic carriers, while changes in lipid 
metabolism are pronounced at the advanced disease stage. Our study reveals unique 
metabolic signatures in serum of preclinical Carriers and HOCM patients, which may 
have potential for risk stratification and precision therapeutics.
Altered inflammatory signature at preclinical disease stage
Several inflammatory metabolites show a different expression pattern in the 
serum of preclinical carriers compared to controls or HOCM. Metabolite 2 
(p-Ethylacetophenone; Anethole), which has lower levels in the carriers and HOCM, 
has anti-inflammatory properties that are mediated by either inhibition of production 
and/or release of inflammatory mediators like tumor necrosis factor (TNF), nitric oxide, 
prostaglandins, interleukin-1, and interleukin-17 (24,25). The anti-inflammatory effects 
of Mesoporphyrin, which is lower in carriers compared to HOCM, are suggested to be 
mediated by inhibition of cytokine production like interferon-gamma and interleukin 
6 (26). Leukotrienes and prostaglandins, that can be summarized as eicosanoids, 
are more difficult to interpret since they can have pro-inflammatory as well as anti-
inflammatory functions, which are dependent on the particular immunological context 
(27,28). Metabolite 6 has Leukotriene A4 as a possible metabolite identification and 
shows reduced levels in carriers vs controls and intermediate levels in HOCM. Overall, 
the preclinical carriers show an altered inflammatory blood signature.
Altered metabolic blood profile reflects changes in the HOCM heart
The metabolic signatures in serum from Carriers and HOCM may reflect disease 
mechanisms in the heart, the signature in Carriers may especially reflect early disease 
changes. To validate the biological relevance of the identified metabolites in the 
context of HCM, we looked for common pathways and direct links of the top 30 
metabolites and significantly changed proteins of our recent proteomics study in 
myectomy tissue of HCM patients (17). Indeed, several top metabolites could be linked 
to altered changes in the heart of HOCM patients. Our recent proteomics analysis of 
50 HOCM samples showed significantly lower levels of Leukotriene A4 hydrolase, the 
enzyme that converts Leukotriene A4 to Leukotriene B4 (17). The catalytic reaction 
inactivates the enzyme which is notable by a change in molecular weight. Therefore, 
reduced levels of Leukotriene A4 and the Leukotriene A4 hydrolase could indicate 
increased conversion to Leukotriene B4 which is implicated in inflammatory conditions 
(29). Asymmetric dimethylarginine is directly linked to the enzyme dimethylarginine 
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dimethylaminohydrolase 1. This enzyme is increased in myocardial tissue of HCM 
patients and plays a role in nitric oxide generation, which is a key molecule in the 
process of inflammation (30).
Next to the inflammatory response, we also identified links between the serum 
metabolites and tissue proteins in the lipid and fatty acid metabolism. Tetracosanoic 
acid, a very long chain fatty acid, has lower serum levels in carriers and HOCM 
compared to controls. In tissue of HOCM patients we found reduced expression of 
Long-chain-fatty-acid-CoA ligase 1 (17) which catalyzes a step in the fatty acid beta-
oxidation. Increased tissue protein levels of the long chain fatty acid transport protein 
6 (17), that translocates long-chain fatty acids across the plasma membrane (31), are in 
line with elevated serum levels of stearic acid in HOCM compared to Ctrls. Reduced 
Monoacylglycerol (Metabolite 18 and 34) serum levels in HOCM compared to Ctrls with 
intermediate levels in Carriers are in line with lower protein levels of monoglyceride 
lipase in heart tissue of HOCM patients (17), which is the enzyme that can hydrolyze the 
reaction to fatty acids and glycerol. The metabolite Glycerylphosphorylethanolamine 
is directly linked to Lysophospholipase 1, which hydrolyzes fatty acids, and is 
decreased in the tissue of HCM patients. The top 30 metabolites Indoleacetic acid and 
5-Hydroxyindoleacetaldehyde from the HOCM vs Ctrl comparison have the aldehyde 
dehydrogenases ALDH9A1, ALDH3A2 and ALDH7A1 as directly interacting enzymes, 
of which ALDH3A2 is increased in HCM tissue, whereas ALDH9A1 and ALDH7A1 have 
lower levels in HCM. Since ALDH3A2 catalyzes the oxidation of medium and long 
chain aliphatic aldehydes to fatty acids, also this finding points towards an altered 
fatty acid metabolism.
As we can identify direct links of serum metabolites with protein changes in the 
heart, mainly regarding fatty acid metabolism, the top serum metabolites may reflect 
pathologic changes in the heart underlining their biological relevance.
Disease stage-dependent changes in metabolic signatures
A shift from fatty acids to glucose as substrate for mitochondrial oxidation is reported 
in acquired forms of cardiac hypertrophy and disease (32,33). Accordingly, changes in 
serum levels of fatty acids may derive from substrate changes in the heart. One of the 
fatty acids elevated in the HOCM group compared to the carrier is glutarylcarnitine. 
It belongs to the class of acylcarnitines that play a key role in transporting fatty 
acids across the mitochondrial membrane for subsequent fatty acid beta-oxidation 
(34). Lower acylcarnitine levels have been observed in the serum of asymptomatic 
or mildly symptomatic idiopathic HCM patients compared to controls in a study by 
Nakamura (35). Since our HOCM patients are already in an advanced disease stage, 
levels of acylcarnitines could differ dependent on the disease stage, with lower levels 
in asymptomatic patients and higher levels in symptomatic patients. Differences in 




Carnitine palmitoyltransferase II deficiency, one of the most common inherited 
disorders of mitochondrial fatty acid oxidation, is diagnosed by calculating the 
(C16:0+C18:1)/C2 ratio in the blood (36,37). Since we found an elevated carnitine in the 
HOCM group, we calculated the (C16:0+C18:1)/C2 ratio for our samples but did not find 
differences between groups (data not shown), excluding that one of the patients 
suffered from carnitine palmitoyltransferase II deficiency.
FIGURE 5. Schematic overview of the mitochondrial electron transport chain. Some of the top 
30 metabolites (highlighted in blue) can be linked to energy metabolism, as they are involved 
in pathways that lead to essential molecules of the electron transport chain, which are high-
lighted in red.
Previous studies have shown different stages of energy deficiency in the myocardium 
of preclinical carriers and HOCM patients (15). Interestingly, when comparing the 
serum of the carrier and HOCM group, we also find alterations of metabolites that can 
be linked to energy metabolism (highlighted in Figure 5). 7-Hydroxy-6-methyl-8-ribityl 
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lumazine is an intermediate in the riboflavin metabolism which is important for building 
the enzyme cofactors flavin-adenine dinucleotide (FAD) and flavin mononucleotide 
(FMN) (38,39). 3-Polyprenyl-4,5-dihydroxybenzoate, also elevated in the HOCM 
group, is a substrate for the mitochondrial enzyme hexaprenyldihydroxybenzoate 
methyltransferase which is involved in the ubiquinone biosynthesis pathway and 
important for the electron transport chain (40). Carriers have elevated levels of 
the carbohydrate Ribose-1-arsenate compared to controls. Ribose-1-arsenate is an 
intermediate in the arsenate detoxification pathway, and is formed by the enzyme 
purine nucleoside phosphorylase (41). We also found other components of the purine 
metabolism being altered. Purine is not only a building block for the nucleotide 
bases adenosine and guanosine, but also a component of the molecules ATP, GTP, 
cyclic AMP, NADH and coenzyme A that are involved in cellular energy transmission. 
Although the metabolites are not directly involved in the electron transport chain, 
they are intermediates of pathways that lead to essential components of the electron 
transport chain (Figure 5).
Altered protein homeostasis in HCM
We found peptide alterations in both the carriers and the HOCM patients. Most of 
these peptides are dipeptides that are supposedly incomplete breakdown products 
of proteins. We can speculate that these changes are associated with the presence of 
mutant protein in carriers and HOCM patients causing increased protein degradation 
and protein synthesis to renew proteins. This would match findings of activated 
protein quality control in tissue of HOCM patients (42,43). The dipeptide Metabolite 
11 (Alanyl-Leucine), which belongs to the branched chain amino acids, is significantly 
elevated in carriers and HOCM compared to controls. This is in line with previous 
findings of increased levels of branched chain amino acids in a Finnish HCM cohort 
(44). Interestingly, the first step of branched chain amino acid catabolism occurs not 
in the liver, but in the heart (45). Hence, this may point to derailed branched chain 
amino acid catabolism in the heart at preclinical disease stage.
STUDY LIMITATIONS AND CLINICAL IMPLICATIONS
As shown in Figure 4, the serum metabolites perform as good as the advanced 
imaging modalities MEE and MVO2 in identifying preclinical Carriers and HOCM 
patients in our study cohort. Therefore, serum metabolites have the potential to serve 
as diagnostic biomarkers. As serum can be sampled repeatedly and minimal invasively 
from individuals, a metabolite panel could be used to detect energetic changes in the 
heart to monitor carriers and to determine the right time for therapeutic intervention. 
This study shows that there are serum biomarker candidates which can as a combined 
set distinguish healthy controls, preclinical carriers with an altered energetic status of 




relatively small groups and provide a starting point for the ultimate goal to define a 
set of blood biomarkers that is predictive for identifying asymptomatic gene variant 
carriers that will transition into a symptomatic state and are in need of preventive 
treatment. The top 30 metabolites that are driving our multivariate model will need 
to be validated in follow-up studies with independent data sets with the ultimate goal 
to define a clinically feasible biomarker panel of 4-6 prognostic markers.
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FIGURE S1. Overview of gene variants in this study. (A) shows the protein domains in which the 
gene variants are located. Image with permission granted by Vasco Sequeira. (B) indicates the 
location of the gene variants in the structural context. Image adapted from Sequeira et al. Circ 
Res 2013 with permission Circ Res.
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FIGURE S2. Multivariate modelling. (A) Principal component analysis (PCA) for the three group-
wise comparisons Carrier vs Ctrls, Carrier vs HOCM and HOCM vs Ctrls. (B) ROC curves of the 
three group-wise comparisons presenting the performance of the metabolomics data in distin-




FIGURE S3. Bar graphs with individual data points of the top 30 most important metabolites 
in distinguishing the Carrier vs Ctrl group. Data from the third group is included in all graphs.
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FIGURE S4. Bar graphs with individual data points of the top 30 most important metabolites in 











FIGURE S5. Bar graphs with individual data points of the top 30 most important metabolites 
in distinguishing the HOCM vs Ctrl group. Data from the third group is included in all graphs.
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TABLE S1. Gene variants of preclinical Carriers and HOCM patients including mutation type, sex 
and age of the individuals.
Gene Mutation Type Age Sex
Preclinical Carriers
MYH7 p.His576Arg missense 34 F
MYH7 p.Arg403Trp missense 35 F
MYH7 p.Val606Met missense 30 M
MYH7 p.Thr1377Met missense 58 F
MYH7 p.Thr1377Met missense 36 F
MYH7 p.Thr1377Met missense 21 M
MYH7 p.Arg403Trp missense 21 F
MYH7 p.Arg403Trp missense 65 F
MYH7 p.Thr1377Met missense 44 F
MYH7 p.Arg1712Gln missense 45 F
MYH7 p.Arg1712Gln missense 33 M
MYH7 p.Thr1377Met missense 18 F
MYH7 p.Thr1377Met missense 31 F
MYBPC3 p.Trp792ValfsX41 truncation 60 F
MYBPC3 p.Trp792ValfsX41 truncation 28 F
MYBPC3 p.Trp792ValfsX41 truncation 30 F
MYBPC3 p.Trp792ValfsX41 truncation 22 M
MYBPC3 p.Trp792ValfsX41 truncation 34 F
MYBPC3 p.Trp792ValfsX41 truncation 60 F
MYBPC3 p.Trp792ValfsX41 truncation 24 F
MYBPC3 p.Trp792ValfsX41 truncation 56 F
MYBPC3 p.Trp792ValfsX41 truncation 26 M
MYBPC3 p.Trp792ValfsX41 truncation 43 F
MYBPC3 p.Trp792ValfsX41 truncation 31 F
MYBPC3 p.Lys301fs frame shift 41 F
TNNT2 p.Arg102Trp missense 59 F
TNNT2 p.Arg102Trp missense 58 F
TNNT2 p.Arg286Cys missense 48 F
TNNT2 p.Arg144Trp missense 40 F
TNNT2 p.Arg285Cys missense 32 M





Gene Mutation Type Age Sex
HOCM patients
MYH7 p.Gln895His missense 66 M
MYBPC3 54 F
MYBPC3 p.Trp792ValfsX41 truncation 18 M
MYBPC3 p.Arg943* truncation 54 F
TNNT2 p.Arg285Cys missense 43 M
TNNT2 p.Arg102Trp missense 27 M
TNNT2 p.Arg286Cys missense 53 M
TNNT2 p.Gln279* truncation 54 M
MYL2 p.Glu134Ala missense 57 F
SCN5A 64 M
Sarcomere mutation negative 52 M
Sarcomere mutation negative 68 F
Sarcomere mutation negative 46 M
Sarcomere mutation negative 47 M
263























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous disease with large 
differences in disease penetrance and severity between patients [1]. This is partly due to 
the presence of 2 major patient populations, the one with an identified gene mutation 
(sarcomere mutation-positive, SMP) and the one in which a pathogenic gene mutation 
is not identified (sarcomere mutation-negative, SMN) [2]. But also within these groups 
variation is large. The variability between the SMP patients is not only explained by 
the large number and variety of identified pathogenic gene variants termed mutations 
[2], as even patients with the exact same mutation can have a very different disease 
course and outcome [3]. Therefore, we hypothesize that a variety of disease modifiers 
can contribute and influence the clinical disease course in patients. Potential disease 
modifiers could be environmental factors, such as rural or urban residence, differences 
in lifestyle, including diet and exercise, and additional gene mutations or (epi)genetic 
modifiers. In this thesis we explored the mutant protein dose and mutation location 
and the cellular protein quality control (PQC) as potential disease modifiers. We 
further used -omics techniques to identify differences at the RNA and protein level 
between different genetic groups to identify novel disease modifiers and potential 
novel treatment targets. Additionally, we have shown with a metabolomics study 
that asymptomatic mutation carriers have a metabolic profile which is distinct from 
healthy controls, which may be used in the future to identify mutation carriers at risk.
Mutant protein dose and location
One of the proposed disease modifiers that we explored in this thesis is the mutation 
location and the mutant protein dose. Different mutation locations can be defined as 
mutations in different genes, and studies in the past aimed to establish a relationship 
between disease severity and symptoms and the different affected genes. Although some 
genes have been associated with a more or less severe phenotype, no clear genotype-
phenotype correlations were established [4-6]. In addition to gene-specific differences, he 
mutation location effect can also be assessed for mutations in different protein domains 
of the same gene. Some functional correlations have been described for mutations in 
MYH7 [7, 8], but overall this is poorly investigated. Therefore, we focused in this thesis on 
the mutation location effect in the TNNT2 gene, encoding for cardiac troponin T (cTnT).
Especially in individuals with the exact same mutation, differences in the mutant 
protein dose could contribute to the differences in clinical disease outcome. As most 
HCM-causing gene mutations are heterozygous, which means that the patient has 
one healthy and one mutant allele, a ratio of 50% wild-type and 50% mutant protein 
would be expected. However, different factors could change this expected ratio of 
healthy and mutant protein. Differences in mRNA and/or protein stability between 
the healthy and mutant mRNA or protein could alter the ratio. A less stable mutant 
protein which is prone for degradation and removal by the PQC system could result 
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in a lower percentage of mutant protein compared to the wild type form, whereas a 
more stable protein could accumulate resulting in an increased dose of mutant protein. 
Also the PQC might be an important player regulating the amount of mutant protein 
in the cell. A healthy well-working PQC might be able to keep the mutant protein dose 
low. Translating this to the clinical situation, it could imply that patients with a high 
percentage of mutant protein may present with more severe symptoms and earlier 
disease onset, whereas patients with a low dose of mutant protein may have only mild 
symptoms. Timely activation of the PQC to keep the mutant protein dose low may 
provide a new treatment option.
In HCM, the role of the mutant protein dose is poorly investigated. It is not known 
how much mutant protein is present in the myocardium of patients as this is difficult to 
determine. Only for patients with a truncating mutation in MYBPC3 it is known that the 
truncated mutant protein is not present, but that the levels of the healthy protein are 
reduced to ~70% compared to healthy controls [9], which is called haploinsufficiency.
In Chapter 2 we investigated the mutant protein dose and location effect of different 
TNNT2 mutations on cardiomyocyte function. For this we introduced different doses 
of recombinant mutant cTnT into single permeabilized cardiomyocytes from healthy 
donors by performing troponin exchange experiments. Strikingly, we observed for 
two of the mutations, I79N and R94C, that a low dose of mutant protein (<15%) is 
already sufficient for the maximal increase in myofilament Ca2+-sensitivity, while the 
effect size is determined by the mutation location. For the R278C mutation, however, 
we observed increased myofilament Ca2+-sensitivity at low and intermediate dose, 
whereas a high mutant dose led to decreased myofilament Ca2+-sensitivity. Although 
we only looked at 3 different cTnT mutations, we have evidence that the mutant 
protein dose effect is mutation location-specific and not applicable in the same way 
for every mutation. As the R278C mutation shows a mutant protein dose-dependent 
functional effect on Ca2+-sensitivity, this could indeed underlie clinical differences 
between patients. In 2 myectomy samples of HCM patients with the R278C mutation 
we determined the mutant protein content with mass spectrometry. With 28% and 
36% the amount of mutant protein was quite similar in the samples, and could not be 
directly linked to differences in function. As clinical outcome is most likely dependent 
on a combination of disease modifiers, in vitro results may not be directly reflected 
in the complex in vivo setting.
Protein quality control
The PQC, comprising heat shock proteins (HSPs), the ubiquitin-proteasome system 
(UPS) and autophagy [10], has already been investigated in a variety of cardiac diseases 
and often derailment of the PQC has been found. The PQC is crucial for cellular 
proteostasis as it maintains a healthy balance of protein synthesis and degradation 




damaged and defective proteins and ensures their degradation and is crucial for 
cardiac health [10, 11].
In HCM, a malfunctioning PQC could lead to accumulation of mutant protein which 
in turn could cause disease onset or a more severe phenotype. As the function of 
the PQC declines with age, patients may exceed a toxic mutant protein threshold 
in late adulthood explaining the average disease in the later stages of life. But a 
defective PQC may not only lead to the accumulation of the mutant protein, also the 
normal protein turnover will be hampered, so that other aged and defective proteins 
accumulate which will increase the overall cell stress.
In Chapter 3 we reviewed the current knowledge about the role of the PQC in the 
pathogenesis of inherited cardiomyopathies. In human cardiomyopathies, HSP 
expression has been poorly studied, but upregulation of HSPs has been described in 
different cardiomyopathy animal models and is generally considered as a beneficial 
compensatory effect [12, 13]. UPS derailment has already been described in human 
heart disease [14, 15] and may aggravate disease as decreased proteasome function 
leads to accumulation of toxic mutant protein. Therefore, modulating different 
components of the PQC system may provide a novel treatment strategy for inherited 
cardiomyopathies. The pharmacological induction of HSPs in an animal model of 
desmin-related cardiomyopathy provides promising evidence for its effectiveness, 
as it reduced protein aggregation and improved heart function [16].
In Chapter 4 we determined the expression levels of several PQC key players in our 
large HCM patient cohort. Compared to healthy controls, we found increased levels of 
the stabilizing HSPs HSPB1 and HSPB7 and the ATP-dependent HSPD1 and HSPA2, that 
have refolding capacity. Additionally, we observed increased levels of α-tubulin that 
correlated with its acetylation level and with the HSP expression levels. This is in line 
with previous work showing elevated levels of microtubules in failing myocardium [17], 
which is thought to increase cellular stability. In summary, we showed that HSP levels are 
indeed elevated in the myocardium of HCM patients and may act as disease modifiers.
Deregulated energy metabolism proteome
In part 2 of this thesis we performed omics-techniques to identify novel disease 
modifiers in an unbiased manner on different cellular levels. In Chapter 5 we performed 
a proteomics screen of a large number of well-characterized human myectomy 
samples. One of our main findings was reduced expression of proteins involved in 
energy metabolism. We found lower levels of proteins related to glucose metabolism 
as well as fatty acid metabolism. Also proteins of the mitochondrial respiratory chain 
were consistently lower expressed, matching observations of energy deficiency in 
patients and animal models [18-20]. As energy deficiency has been proposed as the 
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primary mutation-induced pathomechanism leading to compensatory hypertrophy 
[21], our study supports ongoing clinical trials investigating the therapeutic effect of 
targeting the metabolism in early stages of the disease [22].
Detyrosinated tubulin provides novel treatment target in HCM
In Chapter 5 we also identified increased levels of detyrosinated tubulin as the main 
difference between SMP and SMN HCM samples. In line with previous studies by 
the Prosser group [23, 24], we could show in our novel MYBPC32373insG mouse model 
that detyrosinated tubulin has a negative effect on diastolic function of isolated 
cardiomyocytes. Lowering tubulin detyrosination by treatment with parthenolide 
increased relaxation time and improved diastolic function. As our mouse model 
replicated the increase in detyrosination of tubulin, but not the increase in total 
levels of α-tubulin as we found in the human samples, we speculate that the increase 
in detyrosination may happen before the increase in levels of α-tubulin. Hence, 
detyrosinated tubulin may be an early treatment target and inhibition of detyrosination 
could potentially halt or slow disease progression.
As we found the elevated levels of detyrosinated tubulin mainly in SMP samples and 
only to a lower extent in SMN samples, targeting detyrosination is thought to be a 
promising therapeutic target only in SMP patients. As HCM is clinically heterogeneous, 
patient-specific or at least genotype-specific treatment strategies may characterize 
future therapies.
Sex differences at the protein level
As we also see differences in clinical presentation between male and female patients 
[25-33], we defined sex-specific differences in our proteomics data in Chapter 7 to 
identify differences at the protein level between male and female SMP HCM samples. 
Interestingly, we found higher levels of tubulin in females compared to males. As 
females show more severe diastolic dysfunction [29, 31, 33], we propose that this is 
(at least partly) due to elevated levels of tubulin. Furthermore, we found increased 
levels of HSPs in females compared to males. Studies have shown that the estrogen-
dependent induction of HSPs has cardio-protective effects [34]. This could explain why 
females have a later disease onset compared to males. Follow-up studies are needed 
to determine whether the female-specific increase in HSPs may be estrogen regulated.
Identification of novel candidate regulators
In Chapter 6 we integrated different layers of cellular regulation, namely the histone 
acetylome, the transcriptome and the proteome, to identify key players that drive 
pathological changes in HCM patients with a mutation in MYBPC3. We identified 36 
upregulated and 17 downregulated protein-coding genes that were changed in all 
three levels of analysis, DNA, RNA and protein. Consequently, these candidates may 




Due to the characteristics and limitations of the different methodologies, integration 
and direct translation to the clinic is challenging. As the analysis is performed on bulk 
tissue, not only the mutation-carrying cardiomyocytes are analyzed, but also other 
cell types like fibroblasts, endothelial cells and immune cells. The larger proportion 
of cells in the heart are non-cardiomyocytes. As ChIP-seq and RNA-seq is performed 
on nuclear material, these data are highly influenced by the non-cardiomyocytes. 
Proteomics on the other hand is a stronger representation of the cardiomyocytes 
as these are responsible for most of the cell volume. While ChIP-seq and RNA-
seq provide a good coverage of the whole histone acetylome and transcriptome, 
proteomics is prone to the more abundant proteins covering only a fraction of the 
proteome. Different levels of regulation at all stages further complicate the direct 
integration and translation of these findings.
Further studies are needed to validate whether the identified candidates have a 
functional effect in HCM pathogenesis. Induced pluripotent stem cell-derived 
cardiomyocytes from HCM patients carrying a pathogenic mutation can provide a 
screening platform to test the functional role of the candidate genes in overexpression 
and knock-down experiments.
Metabolic signature
For early treatment that may be able to halt or slow disease progression, it is of 
importance to identify mutation carriers at risk before the onset of symptoms and 
irreversible cardiac remodeling. Imaging studies have shown that asymptomatic 
mutation carriers show already reduced cardiac efficiency [19]. However, these 
advanced imaging techniques are not suitable for periodic screening of patients due 
to their high costs, and because they can only be performed in specialized centers. 
Since changes in metabolism may be reflected in the serum metabolite profile, we 
performed serum metabolomics on healthy controls, asymptomatic mutation carriers 
and obstructive HCM patients in Chapter 8. Interestingly, we found a very distinct 
serum metabolite profile between asymptomatic carriers and healthy controls, that 
can distinguish the two groups in our patient cohort. Our statistical model revealed 
a panel of 30 metabolites that drives the model and provides a starting point for 
further validation in a different independent cohort. If a set of these candidates can 
be validated, a simple serum biomarker panel can be developed and used for periodic 
screening. In the future, this may provide a tool to determine the correct time point for 
therapeutic intervention and identifying mutation carriers at risk to develop cardiac 
dysfunction.
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FUTURE PERSPECTIVES
The findings from the omics-studies that are described in this thesis serve as a starting 
point for follow-up studies to validate their functional relevance in HCM pathogenesis. 
Thereto, different animal models and cellular model systems are available. As many 
animal models lack some of the key characteristics of human HCM, advances have 
been made in the generation of 3D engineered heart tissues (EHTs) [35]. EHTs allow for 
the assessment of both functional and structural changes upon genetic manipulations, 
drug treatment and other interventions [36]. These EHTs can be generated from 
patient-derived induced pluripotent stem cells (ipsc), that are differentiated into 
cardiomyocytes. For the last few years, many efforts have been put into optimizing 
the differentiation protocols to improve purity, maturity and yield. Recently, Buikema et 
al. published a cardiomyocyte expansion protocol [37], that allows for the generation 
of a very large number of cardiomyocytes in a short amount of time. We could show 
that these cells are also functional in the EHT model [37]. Being able to produce a large 
amount of cardiomyocytes provides the opportunity to generate EHTs in a large scale 
for e.g. drug screening purposes. These EHTs can be used to test novel treatment 
strategies, but also to study disease modifiers, like the mutant protein dose effect, in 
a more complex cellular system. For these purposes, viral gene expression systems 
can be used to introduce the mutant gene into the EHT.
The current treatment of HCM patients is only symptomatic to relieve left ventricular 
outflow tract obstruction and heart failure symptoms. Omics-studies in well 
characterized patient cohorts and patient tissues form a basis to unravel genotype-
specific pathomechanisms that can ultimately lead to patient-specific treatment 
approaches. Identification of disease modifiers will further help to improve risk 
prediction in mutation carriers and novel biomarker panels may aid in determining 
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Hypertrophe Kardiomyopathie ist eine genetische Erkrankung des Herzmuskels, die 
zu einer asymmetrischen Verdickung des Septums führt. Während der Diastole haben 
Patienten Schwierigkeiten, die Herzkammer ausreichend mit Blut zu füllen. Zudem 
haben sie ein erhöhtes Risiko, einen plötzlichen Herztod zu erleiden. Da es zurzeit noch 
keine heilenden Therapiemöglichkeiten gibt, werden Patienten nur symptomatisch 
behandelt, um die Krankheitssymptome zu lindern.
Ein wichtiges Merkmal der hypertrophischen Kardiomyopathie ist der individuell sehr 
unterschiedliche Krankheitsverlauf, der zum Teil dadurch erklärt werden kann, dass 
es zwei verschiedene Patientenpopulationen gibt. Etwa die Hälfte aller Patienten 
hat eine Genmutation in einem der kontraktilen Proteine des Herzens, während die 
Krankheitsursache in der anderen Hälfte der Patienten unbekannt ist. Inzwischen 
sind mehr als 1500 krankheitsauslösende Mutationen bekannt, selbst Patienten mit 
einer identischen Mutation können stark variierende Krankheitsverläufe zeigen. Es 
wird vermutet, dass eine Vielzahl an Faktoren den Schweregrad der Erkrankung 
beeinflussen. Zu diesen potenziellen Faktoren zählen unter anderem äußere 
Lebenseinflüsse, wie städtischer oder ländlicher Wohnort, unterschiedliche Lebensstile 
einschließlich Ernährung und sportliche Betätigung, sowie zusätzliche Genmutationen 
oder (epi)genetische Modifikationen.
Im ersten Teil dieser Doktorarbeit wurde der Einfluss der vorhandenen Menge 
an mutiertem Protein und die Mutationsstelle im Gen auf die Funktion von 
Herzmuskelzellen untersucht, da angenommen wird, dass Patienten mit mehr 
mutiertem Protein einen schwereren Krankheitsverlauf aufweisen. Interessanterweise 
konnte für zwei Mutationen im Protein Troponin T gezeigt werden, dass schon eine 
sehr geringe Menge an mutiertem Protein ausreichend ist, um die Funktion der Zelle 
negativ zu beeinflussen. Das Ausmaß dieses Effekts war dabei von der Mutationsstelle 
abhängig. Wie genau sich diese Beobachtungen auf Patienten übertragen lassen, 
müssen weitere Studien zeigen.
In Herzgewebeproben von Patienten wurde zudem die Menge an Hitzeschockproteinen 
untersucht, um zu bestimmen, ob es Unterschiede in der Aktivität der zellulären 
Proteinqualitätskontrolle gibt. Die Proteinqualitätskontrolle ist dazu da, defekte oder 
mutierte Proteine abzubauen, um eine normale Zellfunktion zu gewährleisten. Im 
Vergleich mit Kontrollproben konnten wir erhöhte Mengen an Hitzeschockproteinen 
in den Patientenproben feststellen. Dies ist vermutlich eine Reaktion der Zelle, 
um die mutierten Proteine abzubauen und dem generellen erhöhten Zellstress 
entgegenzuwirken. Weitere Studien müssen zeigen, ob eine gezielte Aktivierung der 
Proteinqualitätskontrolle als Therapiemöglichkeit genutzt werden kann, um einen 
Abbau der mutierten und fehlerhaften Proteine zu fördern.
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Im zweiten Teil dieser Doktorarbeit wurden sogenannte omics-Techniken verwendet, 
um nach neuen krankheitsmodifizierende Faktoren auf Protein und RNA Basis zu 
suchen und neue therapeutische Angriffspunkte zu finden.
Dazu wurde das Proteom und das Transkriptom im Herzgewebe von Patienten 
untereinander und mit gesunden Kontrollproben verglichen. Alle Patientenproben 
hatten gemeinsam, dass sie weniger Proteine exprimiert haben, die für die zelluläre 
Energiegewinnung von Bedeutung sind. Diese Beobachtung stützt laufende klinische 
Studien, die zu therapeutischen Zwecken im frühen Krankheitsstadium in den 
Energiemetabolismus eingreifen.
Zudem haben die Studien ergeben, dass Patienten mit einer Genmutation, im 
Vergleich zu Patienten ohne Mutation, stark erhöhte Mengen α-Tubulin aufweisen, 
besonders von der detyrosinierten Form des Proteins. In einem Mausmodell 
mit einer krankheitsauslösenden Mutation konnte gezeigt werden, dass eine 
pharmakologische Verringerung der detyrosinierten Form dieses Proteins zu einer 
verbesserten Funktion der Herzmuskelzellen führt. Dementsprechend ergibt 
sich daraus ein vielversprechender neuer Therapieansatz für Patienten mit einer 
krankheitsverursachenden Mutation.
Ein Vergleich der Proben von Frauen und Männern hat zudem gezeigt, dass besonders 
Frauen mehr α-Tubulin sowie höhere Mengen an Hitzeschockproteinen haben.
In einem weiteren Ansatz wurden das Proteom, das Transkriptom und die 
Histonmodifikationen integriert, um neue potenzielle Regulatoren zu identifizieren, 
die einheitlich auf allen drei Ebenen verändert sind und dadurch besonders 
krankheitsrelevant sein könnten. Mehrere Kandidaten wurden identifiziert und 
weitere Studien werden zeigen, ob diese tatsächlich einen funktionellen Effekt in der 
Krankheitsentstehung haben.
Zusätzlich wurde in einer Metabolomics Studie gezeigt, dass asymptomatische 
Mutationsträger, verglichen zu gesunden Probanden, bereits ein anderes Profil an 
Metaboliten im Blutserum aufweisen. Dies könnte in der Zukunft als Biomarker genutzt 
werden, um Mutationsträger, bei denen sich der Krankheitsverlauf verschlechtert, 
zeitnah zu erkennen und rechtzeitig zu behandeln.
Die Ergebnisse dieser Doktorarbeit bestätigen, dass der Krankheitsverlauf der 
hypertrophischen Kardiomyopathie aus einem komplexen Zusammenspiel vieler 
Faktoren bestimmt wird. Die Ergebnisse dieser Studien bilden einen Ausganspunkt 
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